<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006627.pub2" GROUP_ID="SCHIZ" ID="226006090712351437" MERGED_FROM="" MODIFIED="2013-03-12 14:06:21 +0000" MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2013-03-12 14:06:21 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Ziprasidone versus other atypical antipsychotics for schizophrenia</TITLE>
<CONTACT MODIFIED="2013-03-12 14:06:21 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Komossa</LAST_NAME><POSITION>4th Year Resident (Dr. Med)</POSITION><EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychosomatische und Medizin und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München, Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Moehlstrasse 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049 (0) 89 4141/4247</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-03-12 14:06:21 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Komossa</LAST_NAME><POSITION>4th Year Resident (Dr. Med)</POSITION><EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychosomatische und Medizin und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München, Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Moehlstrasse 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049 (0) 89 4141/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Rummel-Kluge</LAST_NAME><POSITION>Fachärztin für Psychiatrie und Psychotherapie</POSITION><EMAIL_1>Christine.rummel-kluge@medizin.uni-leipzig.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Leipzig</DEPARTMENT><ORGANISATION/><ADDRESS_1>Semmelweisstr. 10</ADDRESS_1><CITY>04103 Leipzig</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-34-1972-4493</PHONE_1><FAX_1>+49-34-1972-4599</FAX_1></ADDRESS></PERSON><PERSON ID="2E84257C82E26AA201BA4B54250245B7" ROLE="AUTHOR"><FIRST_NAME>Heike</FIRST_NAME><LAST_NAME>Hunger</LAST_NAME><EMAIL_1>mailtoHeike@gmx.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+498 941 404247</PHONE_1></ADDRESS></PERSON><PERSON ID="90591E5482E26AA201AA8B42BEBB7D04" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sandra</FIRST_NAME><LAST_NAME>Schwarz</LAST_NAME><EMAIL_1>sandra.schwarz@khsweb.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049/89/4140/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="3FB53CB982E26AA20088EE03F5F8228E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Paranthaman Sethupathi</FIRST_NAME><LAST_NAME>Bhoopathi</LAST_NAME><EMAIL_1>psbhoopathi@googlemail.com</EMAIL_1><ADDRESS><ORGANISATION/><ADDRESS_1>42 Meramanai Street</ADDRESS_1><ADDRESS_2>Vettaikaranpudur, Pollachi (TK)</ADDRESS_2><CITY>Coimbatore(Dt) Tamilnadu</CITY><ZIP>PIN 642129</ZIP><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+44 914 253 282259</PHONE_1><PHONE_2>+44 919 994 967681</PHONE_2></ADDRESS></PERSON><PERSON ID="11850D1F82E26AA201DC7B3E2041CA58" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Werner</FIRST_NAME><LAST_NAME>Kissling</LAST_NAME><POSITION>Leitender Oberarzt</POSITION><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>49-89-4140-4207</PHONE_1><FAX_1>49-89-4140-4894</FAX_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaningerstrasse 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-03-12 13:55:30 +0000" MODIFIED_BY="Claire Irving">
<UP_TO_DATE>
<DATE DAY="30" MONTH="4" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="4" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="12" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2013-03-12 13:58:14 +0000" MODIFIED_BY="Claire Irving">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-03-12 13:58:14 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>), 254 citations added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-11 11:44:19 +0000" MODIFIED_BY="Claire Irving">
<DATE DAY="11" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-07-03 12:23:42 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-06 14:13:21 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Psychiatrische Klinik, Klinikum rechts der Isar, TU München, Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Bundesministerium für Bildung und Forschung, Nr FKZ: 01KG 0606,GZ:GF-GFKG01100506</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-03-12 14:00:14 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-08-06 11:27:15 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-28 19:39:25 +0000" MODIFIED_BY="[Empty name]">Ziprasidone versus other atypical antipsychotics for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2009-08-06 11:27:15 +0100" MODIFIED_BY="[Empty name]">
<P>Ziprasidone is one of a group of new 'atypical' antipsychotics used for treating schizophrenia. This review wanted to find out if there was evidence to support that there is any difference between ziprasidone and the other atypical medications. Because of the large number of people that dropped out of the studies it is difficult to draw any firm conclusions, however, people taking ziprasidone did not do as well regarding their symptoms, as those taking olanzapine and risperidone and perhaps amisulpride, but they were less likely to gain weight.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-03-12 13:58:01 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-03-06 14:53:30 +0000" MODIFIED_BY="[Empty name]">
<P>In many countries of the industrialised world second generation ('atypical') antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether, and if so how much, the effects of the various new generation antipsychotics differ is a matter of debate. In this review we examined how the efficacy and tolerability of ziprasidone differs from that of other second generation antipsychotics.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-08-06 11:24:36 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects of ziprasidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-03-12 13:58:01 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group Specialised Register (April 2007) and references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information.</P>
<P>This search was updated July 2012, 254 citations added to awaiting classification section.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-08-06 11:24:55 +0100" MODIFIED_BY="[Empty name]">
<P>We included all randomised, at least single-blind, controlled trials comparing oral ziprasidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone or zotepine in people with schizophrenia or schizophrenia-like psychoses.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-08-06 14:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>We extracted data independently. For continuous data, we calculated weighted mean differences (MD) for dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-03-12 13:57:40 +0000" MODIFIED_BY="[Empty name]">
<P>The review currently includes nine randomised controlled trials (RCTs) with 3361 participants. The overall rate of premature study discontinuation was very high (59.1%). Data for the comparisons of ziprasidone with amisulpride, clozapine, olanzapine, quetiapine and risperidone were available. Ziprasidone was a less acceptable treatment than olanzapine (leaving the studies early for any reason: 5 RCTs, n=1937, RR 1.26 CI 1.18 to 1.35, NNH 7 CI 5 to 10) and risperidone (3 RCTs, n=1029, RR 1.11 CI 1.02 to 1.20, NNH 14 CI 8 to 50), but not than the other second generation antipsychotic drugs. Ziprasidone was less efficacious than amisulpride (leaving the study early due to inefficacy: 1 RCT, n=123, RR 4.72 CI 1.06 to 20.98, NNH 8 CI 5 to 50) olanzapine (PANSS total score: 4 RCTs, n=1291, MD 8.32 CI 5.64 to 10.99) and risperidone (PANSS total score: 3 RCTs, n=1016, MD 3.91 CI 0.27 to 7.55). Based on limited data there were no significant differences in tolerability between ziprasidone and amisulpride or clozapine. Ziprasidone produced less weight gain than olanzapine (5 RCTs, n=1659, MD -3.82 CI -4.69 to -2.96), quetiapine (2 RCTs, n=754, RR 0.45 CI 0.28 to 0.74) or risperidone (3 RCTs, n=1063, RR 0.49 CI 0.33 to 0.74). It was associated with less cholesterol increase than olanzapine, quetiapine and risperidone. Conversely ziprasidone produced slightly more extrapyramidal side-effects than olanzapine (4 RCTs, n=1732, RR 1.43 CI 1.03 to 1.99, NNH not estimable) and more prolactin increase than quetiapine (2 RCTs, n=754, MD 4.77 CI 1.37 to 8.16), but less movement disorders (2 RCTs, n=822, RR 0.70 CI 0.51 to 0.97, NNT not estimable) and less prolactin increase (2 RCTs, n=767, MD -21.97 CI -27.34 to -16.60) than risperidone.</P>
<P>Note: the 254 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-02-12 17:27:14 +0000" MODIFIED_BY="[Empty name]">
<P>Ziprasidone may be a slightly less efficacious antipsychotic drug than amisulpride, olanzapine and risperidone. Its main advantage is the low propensity to induce weight gain and associated adverse effects. However, the high overall rate of participants leaving the studies early limits the validity of any findings. <BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-03-12 14:00:14 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-08-06 11:43:53 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-08-06 11:42:16 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is usually a chronic and disabling psychiatric disorder which afflicts approximately one per cent of the population world-wide with little gender differences. The annual incidence of schizophrenia averages 15 per 100,000, the point prevalence averages approximately 4.5 per population of 1000 and the risk of developing the illness over one's lifetime averages 0.7%. (<LINK REF="REF-Tandon-2008" TYPE="REFERENCE">Tandon 2008</LINK>). Its typical manifestations are 'positive' symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), 'negative' symptoms such as apathy and lack of drive, disorganisation of behaviour and thought and catatonic symptoms such as mannerisms and bizarre posturing (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). The degree of suffering and disability is considerable with 80 - 90% not working (<LINK REF="REF-Marvaha-2004" TYPE="REFERENCE">Marvaha 2004</LINK>) and up to 10% dying (<LINK REF="REF-Tsuang-1978" TYPE="REFERENCE">Tsuang 1978</LINK>). In the15-44 years age group, schizophrenia is among the top ten leading causes of disease-related disability in the world (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>). Conventional antipsychotic drugs such as chlorpromazine and haloperidol have traditionally been used as first line antipsychotics for people with schizophrenia (<LINK REF="REF-Kane-1993" TYPE="REFERENCE">Kane 1993</LINK>). The re-introduction of clozapine in the United States of America and a finding that clozapine was more efficacious and associated with fewer movement disorders than chlorpromazine (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>) has boosted the development of so-called 'atypical' or new (second) generation antipsychotics (NGA).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-06-08 16:17:05 +0100" MODIFIED_BY="[Empty name]">
<P>There is no good definition of what an atypical or second generation antipsychotic is, but they were initially said to differ from typical antipsychotics in that they do not cause movement disorders (catalepsy) in rats at clinically effective doses (<LINK REF="REF-Arnt-1998" TYPE="REFERENCE">Arnt 1998</LINK>). The terms 'new' or 'second generation' antipsychotics are not much better, because clozapine is a very old drug. According to treatment guidelines (<LINK REF="REF-APA-2004" TYPE="REFERENCE">APA 2004</LINK>, <LINK REF="REF-Gaebel-2006" TYPE="REFERENCE">Gaebel 2006</LINK>) second generation antipsychotics include drugs such as amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine, although it is unclear whether some old and inexpensive compounds such as sulpiride or perazine have similar properties (<LINK REF="REF-M_x00f6_ller-2000" TYPE="REFERENCE">Möller 2000</LINK>). The second generation antipsychotics raised major hopes of superior effects in a number of areas such as compliance, cognitive functioning, negative symptoms, movement disorders, quality of life and the treatment of people whose illness had been resistant to treatment.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-08-06 11:43:53 +0100" MODIFIED_BY="[Empty name]">
<P>Ziprasidone (5-[2-[4-(1, 2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-2-indolinone) has a low affinity for dopamine (D2) receptors and a much higher affinity for serotonin (5HT2) receptors; the serotonin/dopamine ratio is one of the highest among the atypicals. It has a low affinity for adrenergic (a1) and histaminergic (H1) receptors and may block noradrenaline re-uptake (explaining possible antidepressant effects). Its half life is about 4 hours after oral administration and 2.9 hours after intravenous administration and its oral bioavailability is 59% (<LINK REF="REF-Bagnall-2000" TYPE="REFERENCE">Bagnall 2000</LINK>), therefore it must be ingested with food.</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-07-22 12:34:26 +0100" MODIFIED_BY="[Empty name]">
<P>The debate as to how far the NGA improve these outcomes compared to conventional antipsychotics continues (<LINK REF="REF-Duggan-2005" TYPE="REFERENCE">Duggan 2005</LINK>, <LINK REF="REF-El_x002d_Sayeh-2006" TYPE="REFERENCE">El-Sayeh 2006</LINK>) and the results from recent studies were sobering (<LINK REF="REF-Jones-2006" TYPE="REFERENCE">Jones 2006</LINK>, <LINK REF="REF-Liebermann-2005" TYPE="REFERENCE">Liebermann 2005</LINK>). Nevertheless, in some parts of the world, especially in the highly industrialised countries, second generation antipsychotics have become the mainstay of treatment. The second generation antipsychotics also differ in terms of their costs; while amisulpride and risperidone are already generic in many countries, ziprasidone for example is still not. Therefore the question as to whether they differ from each other in their clinical effects becomes increasingly important. In this review we aim to summarise evidence from randomised controlled trials that compared ziprasidone with other second generation antipsychotics.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-06-08 16:18:52 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the clinical effects of ziprasidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-03-12 13:58:44 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-08-06 12:15:30 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-08-06 12:15:30 +0100" MODIFIED_BY="[Empty name]">
<P>We included relevant randomised controlled trials which were at least single-blind (blind raters). Where a trial was described as 'double-blind', but it was only implied that the study was randomised, we included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
<P>Randomised cross-over studies will be eligible but only data up to the point of first cross-over because of the instability of the problem behaviours and the likely carry-over effects of all treatments.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included people with schizophrenia and other types of schizophrenia-like psychosis (e.g. schizophreniform and schizoaffective disorders), irrespective of the diagnostic criteria used. There is no clear evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-03-11 13:44:57 +0000" MODIFIED_BY="[Empty name]">
<P>1. Ziprasidone: any oral form of application, any dose.<BR/>2. Other 'atypical' antipsychotic drugs: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, zotepine: any oral form of application, any dose.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-07-03 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes were grouped into the short term (up to 12 weeks), medium term (13-26 weeks) and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-07-03 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: no clinically important response as defined by the individual studies (e.g. global impression less than much improved or less than 50% reduction on a rating scale).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-06-08 16:22:00 +0100" MODIFIED_BY="[Empty name]">
<P>1. Leaving the studies early (any reason, adverse events, inefficacy of treatment)</P>
<P>2. Global state<BR/>2.1 No clinically important change in global state (as defined by individual studies)<BR/>2.2 Relapse (as defined by the individual studies)</P>
<P>3. Mental state (with particular reference to the 'positive' and 'negative' symptoms of schizophrenia)<BR/>3.1 No clinically important change in general mental state score<BR/>3.2 Average endpoint general mental state score<BR/>3.3 Average change in general mental state score<BR/>3.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia)<BR/>3.5 Average endpoint specific symptom score<BR/>3.6 Average change in specific symptom score</P>
<P>4. General functioning<BR/>4.1 No clinically important change in general functioning<BR/>4.2 Average endpoint general functioning score<BR/>4.3 Average change in general functioning score</P>
<P>5. Quality of life/satisfaction with treatment<BR/>5.1 No clinically important change in general quality of life<BR/>5.2 Average endpoint general quality of life score<BR/>5.3 Average change in general quality of life score</P>
<P>6. Cognitive functioning<BR/>6.1 No clinically important change in overall cognitive functioning<BR/>6.2 Average endpoint of overall cognitive functioning score<BR/>6.3 Average change of overall cognitive functioning score</P>
<P>7. Service use<BR/>7.1 Number of patients hospitalised</P>
<P>8. Adverse effects<BR/>8.1 Number of participants with at least one adverse effect<BR/>8.2 Clinically important specific adverse effects (cardiac effects, death, movement disorders, prolactin increase and associated effects, sedation, seizures, weight gain, effects on white blood cell count)<BR/>8.3 Average endpoint in specific adverse effects<BR/>8.4 Average change in specific adverse effects</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-03-12 13:58:44 +0000" MODIFIED_BY="[Empty name]">
<P>No language restriction was applied within the limitations of the search tools.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-03-12 13:58:44 +0000" MODIFIED_BY="[Empty name]">
<P>1. Cochrane Schizophrenia Group Trials Register</P>
<P>We searched the Cochrane Schizophrenia Group's Specialised Register (April 2007) using the phrase:</P>
<P>[((ziprasidon* AND (amisulprid* OR aripiprazol* OR clozapin* OR olanzapin* OR quetiapin* OR sertindol* OR risperidon* OR zotepin*)) in title, abstract or index terms of REFERENCE) or ((ziprasidon* AND (amisulprid* OR aripiprazol* OR clozapin* OR olanzapin* OR quetiapin* OR sertindol* OR risperidon * OR zotepin*)) in interventions of STUDY)]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). The Cochrane Schizophrenia Group Trials Register is maintained on Meerkat 1.5. This version of Meerkat stores references as studies. When an individual reference is selected through a search, all references which have been identified as the same study are also selected.</P>
<P>2. Cochrane Schizophrenia Group Trials Register</P>
<P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register (August 2012)</P>
<P>[((*ziprasidon* AND (*amisulprid* OR *aripiprazol* OR *clozapin* OR *olanzapin* OR *quetiapin* OR *sertindol* OR *risperidon* OR *zotepin*)) in title, abstract or index terms of REFERENCE) or ((*ziprasidon* AND (*amisulprid* OR *aripiprazol* OR *clozapin* OR *olanzapin* OR *quetiapin* OR *sertindol* OR *risperidon * OR *zotepin*)) in interventions of STUDY)]</P>
<P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches of relevant journals and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). Incoming trials are assigned to existing or new review titles.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-07-03 09:55:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Reference searching<BR/>We inspected the reference lists of all studies identified in the search for more trials.</P>
<P>2. Personal contact<BR/>We contacted the first author of each included study for missing information.</P>
<P>3. Drug companies<BR/>We contacted the manufacturers of all atypical antipsychotics included for additional data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-08-06 14:59:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-08-06 12:43:45 +0100" MODIFIED_BY="[Empty name]">
<P>We independently inspected all reports. We resolved any disagreement by discussion, and where there was still doubt, we acquired the full article for further inspection. Once the full articles were obtained, we independently decided whether the studies met the review criteria. If disagreement could not be resolved by discussion, we sought further information and these trials were added to the list of those awaiting assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-06-08 16:27:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Data extraction<BR/>We independently extracted data from selected trials. When disputes arose we attempted to resolve these by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added the trial to the list of those awaiting assessment.</P>
<P>2. Management<BR/>We extracted the data onto standard simple forms. Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for ziprasidone.</P>
<P>3. Rating scales<BR/>A wide range of instruments are available to measure outcomes in mental health studies. These instruments vary in quality and many are not validated, or are even ad hoc. It is accepted generally that measuring instruments should have the properties of reliability (the extent to which a test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure) (<LINK REF="REF-Rust-1989" TYPE="REFERENCE">Rust 1989</LINK>). Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore continuous data from rating scales were included only if the measuring instrument had been described in a peer-reviewed journal. In addition, the following minimum standards for instruments were set: the instrument should either be (a) a self-report or (b) completed by an independent rater or relative (not the therapist) and (c) the instrument should be a global assessment of an area of functioning.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-08-06 12:44:49 +0100" MODIFIED_BY="[Empty name]">
<P>Again working independently, authors KK and SL assessed risk of bias using the tool described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases.</P>
<P>The risk of bias in each domain and overall were assessed and categorized into:</P>
<P>A. Low risk of bias: plausible bias unlikely to seriously alter the results (categorized as 'Yes' in Risk of Bias table)<BR/>B. High risk of bias: plausible bias that seriously weakens confidence in the results (categorized as 'No' in Risk of Bias table)<BR/>C. Unclear risk of bias: plausible bias that raises some doubt about the results (categorized as 'Unclear' in Risk of Bias table)</P>
<P>Trials with high risk of bias (defined as at least four out of seven domains were categorized as 'No') or where allocation was clearly not concealed were not included in the review. If the raters disagreed, the final rating was made by consensus with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials are provided, authors of the studies were contacted in order to obtain further information. Non-concurrence in quality assessment was reported.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-08-06 14:59:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Data types<BR/>We assessed outcomes using continuous (for example changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous (for example, either 'no important changes' or 'important change' in a person's behaviour) measures. Currently RevMan does not support categorical data so we were unable to analyse this.</P>
<P>2. Dichotomous data<BR/>We carried out an intention-to-treat analysis. Everyone allocated to the intervention were counted, whether they completed the follow-up or not. It was assumed that those who dropped out had no change in their outcome. This rule is conservative concerning response to treatment, because it assumes that those discontinuing the studies would not have responded. It is not conservative concerning adverse effects, but we felt that assuming that all those leaving early would have developed adverse effects would overestimate risk. Where possible, efforts were made to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>, <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
<P>We calculated the relative risk (RR) and its 95% confidence interval (CI) based on the random-effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. When the overall results were significant we calculated the number needed to treat (NNT) and the number needed to harm (NNH) as the inverse of the risk difference.</P>
<P>3. Continuous data<BR/>3.1 Normal distribution of the data<BR/>The meta-analytic formulas applied by RevMan Analyses (the statistical programme included in RevMan) require a normal distribution of data. The software is robust towards some skew, but to which degree of skewness meta-analytic calculations can still be reliably carried out is unclear. Conversely, excluding all studies on the basis of estimates of the normal distribution of the data also leads to a bias, because a considerable amount of data may be lost leading to a selection bias. Therefore, we included all studies in the primary analysis. In a sensitivity analysis we excluded potentially skewed data applying the following rules:</P>
<P>a) When a scale started from the finite number zero the standard deviation, when multiplied by two, was more than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>).<BR/>b) If a scale started from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.<BR/>c) In large studies (as a cut-off we used 200 participants) skewed data pose less of a problem. In these cases we entered the data in a synthesis.<BR/>d) The rules explained in a) and b) do not apply to change data. The reason is that when continuous data are presented on a scale which includes a possibility of negative values, it is difficult to tell whether data are non-normally distributed (skewed) or not. This is also the case for change data (endpoint minus baseline). In the absence of individual patient data it is impossible to know if data are skewed, though this is likely. After consulting the ALLSTAT electronic statistics mailing list, we presented change data in RevMan Analyses in order to summarise available information. In doing this, it was assumed either that data were not skewed or that the analysis could cope with the unknown degree of skew. Without individual patient data it is impossible to test this assumption. Change data were therefore included and a sensitivity analysis was not applied. For continuous outcomes we estimated a weighted mean difference (MD) between groups. MDs were again based on the random-effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. We combined both endpoint data and change data in the analysis, because there is no principal statistical reason why endpoint and change data should measure different effects (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). When standard errors instead of standard deviations (SD) were presented, we converted the former to standard deviations. If both were missing we estimated SDs from p-values or used the average SD of the other studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-08-06 12:47:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This can cause type 1 errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intraclass correlation coefficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect=1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies had been appropriately analysed taking into account intraclass correlation coefficients and relevant data documented in the report, we synthesised these with other studies using the generic inverse variance technique.</P>
<P>2. Cross-over trials<BR/>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in schizophrenia, we will only use data of the first phase of cross-over studies.</P>
<P>3. Studies with multiple treatment groups<BR/>Where a study involved more than two treatment groups, if relevant, the additional treatment groups were presented in additional relevant comparisons. Data were not double counted. Where the additional treatment groups were not relevant, these data were not reproduced.<BR/>
</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-07-03 10:10:08 +0100" MODIFIED_BY="[Empty name]">
<P>At some degree of loss of follow-up data must lose credibility (<LINK REF="REF-Xia-2007" TYPE="REFERENCE">Xia 2007</LINK>). Although high rates of premature discontinuation are a major problem in this field, we felt that it is unclear which degree of attrition leads to a high degree of bias. We, therefore, did not exclude trials on the basis of the percentage of participants completing them. However we addressed the drop-out problem in all parts of the review, including the abstract. For this purpose we calculated, presented and commented on frequency statistics (overall rates of leaving the studies early in all studies and comparators pooled).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-07-03 10:12:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical heterogeneity<BR/>We considered all the included studies within any comparison to judge for clinical heterogeneity. </P>
<P>2. Statistical<BR/>2.1 Visual inspection<BR/>We visually inspected graphs to investigate the possibility of statistical heterogeneity. </P>
<P>2.2 Employing the I<SUP>2</SUP> statistic<BR/>Visual inspection was supplemented using, primarily, the I<SUP>2</SUP>statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I<SUP>2</SUP> estimate was greater than or equal to 50% we interpreted this as indicating the presence of considerable levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-08-06 12:49:07 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in section 10.1 of the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We are aware that funnel plots may be useful in investigating small-study effects but are of limited power to detect such effects when there are few studies. We entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias. We did not undertake a formal test for funnel plot asymmetry.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-07-03 10:17:17 +0100" MODIFIED_BY="[Empty name]">
<P>Where possible for both dichotomous and continuous data we used the random-effects model for data synthesis as this takes into account any differences between studies even if there is no statistically significant heterogeneity. We understand that there is no closed argument for preference for use of fixed or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us, however, random-effects does put added weight onto the smaller of the studies - those trials that are most vulnerable to bias.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-08-06 12:49:32 +0100" MODIFIED_BY="[Empty name]">
<P>If data are clearly heterogeneous we checked that data were correctly extracted and entered and that we had made no unit of analysis errors. If inconsistency was high and clear reasons explaining the heterogeneity were found, we presented the data separately. If not, we commented on the heterogeneity of the data.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-08-06 12:49:52 +0100" MODIFIED_BY="[Empty name]">
<P>We planned sensitivity analyses a priori for examining the change in the robustness of the sensitivity to including studies with potentially skewed data. A recent report showed that some of the comparisons of atypical antipsychotics may have been biased by using inappropriate comparator doses (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). We therefore also analysed whether the exclusion of studies with inappropriate comparator doses changed the results of the primary outcome and the general mental state.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-03-12 13:59:27 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-03-12 13:59:27 +0000" MODIFIED_BY="[Empty name]">
<P>For a substantive description of studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2009-07-03 10:21:56 +0100" MODIFIED_BY="[Empty name]">
<P>The overall search yielded 3620 reports of which 18 were closely inspected. After excluding nine studies, twenty publications on nine studies and five comparisons were included: ziprasidone versus amisulpride (one), ziprasidone versus clozapine (one), ziprasidone versus olanzapine (four), ziprasidone versus quetiapine (two) and ziprasidone versus risperidone (three).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-08-06 13:25:59 +0100" MODIFIED_BY="[Empty name]">
<P>Nine studies met the inclusion criteria. All were double-blind and randomised 3361 participants with the diagnosis of schizophrenia or schizoaffective disorder. Four studies were sponsored by the manufacturer of ziprasidone, two studies were sponsored by pharmaceutical companies producing the comparator drugs, three studies had a neutral sponsor.</P>
<P>1. Length of studies<BR/>Four of the included studies were short-term trials with a duration of six to twelve weeks. Three studies fell in the medium-term category with a duration of 18 to 26 weeks and two fell in the long-term category with durations of 28 and 78 weeks.</P>
<P>2. Setting<BR/>Four studies reported the setting as in- and outpatient, one study outpatient setting, two studies inpatient setting and two studies did not describe their setting.</P>
<P>3. Participants<BR/>Eight studies used operationalised criteria to diagnose the participants, mainly based on the Diagnostic and Statistical Manual Version IV (DSM-IV), but one study applied DSM-III-R, another one the International Classification of Disease Version 10 (ICD-10) and one study did not provide further information. Three short-term studies included acutely ill participants with schizophrenia or schizoaffective disorder, three studies examined people with chronic schizophrenia or with previous non-response to treatment, one study restricted inclusion to participants with predominantly negative symptoms and one study focused on people with schizophrenia or schizoaffective disorder with predominantly depressive symptoms. On average the patients were relatively chronic with mean ages in the late-thirties when reported.</P>
<P>4. Study size<BR/>One study included less than fifty people, six studies included between 100 and 500 people and two studies included more than 500 people.</P>
<P>5. Interventions<BR/>In five studies ziprasidone was administered in flexible doses with a dose range from 80 to 160 mg per day, in two studies the dose range was 40 to 160 mg per day, one study used fixed doses of 80, 120 or 160 mg per day and one study did not provide information on the ziprasidone dose.</P>
<P>6. Outcomes<BR/>6.1 Leaving the study early<BR/>We analysed the number of participants leaving the studies early in the following categories: any reason, adverse effects and lack of efficacy.</P>
<P>6.2 Response to treatment<BR/>We prespecified at least 50% PANSS/BPRS total score reduction from baseline as a clinically relevant cut-off to define response, but the studies did not report this outcome. <LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK> used at least 50% PANSS negative subscore reduction from baseline, <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK> at least 40% BPRS total score reduction and <LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK> at least 30% PANSS total score reduction as response criteria.</P>
<P>6.3 Outcome scales<BR/>Details of scales that provided usable data are shown below. Reasons for exclusion of data from other instruments are presented under 'outcomes' in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section.</P>
<P>6.3.1 Global state scales<BR/>6.3.1.1 Clinical Global Impression Scale - CGI Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system is usually used with low scores showing decreased severity and/or overall improvement.</P>
<P>6.3.2 Mental state scales<BR/>6.3.2.1 Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from one - absent to seven - extreme. It can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity.</P>
<P>6.3.2.2 Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from zero to six or one to seven. Scores can range from 0-126, with high scores indicating more severe symptoms.</P>
<P>6.3.3 Quality of Life Scale - QLS (<LINK REF="REF-Carpenter-1984" TYPE="REFERENCE">Carpenter 1984</LINK>)<BR/>This semi-structured interview is administered and rated by trained clinicians. It contains 21 items rated on a seven-point scale based on the interviewers judgement of patient functioning. A total QLS and four sub-scale scores are calculated, with higher scores indicating less impairment.</P>
<P>6.3.4 Adverse effects scales<BR/>6.3.4.1 Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder and short-term movement disorders such as tremor.</P>
<P>6.3.4.2 Barnes Akathisia Scale - BAS (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)<BR/>The scale comprises items rating the observable, restless movements that characterise akathisia, a subjective awareness of restlessness and any distress associated with the condition. These items are rated from zero - normal to three - severe. In addition, there is an item for rating global severity (from zero - absent to five - severe). A low score indicates low levels of akathisia.</P>
<P>6.3.4.3 Extrapyramidal Symptom Rating Scale - ESRS (<LINK REF="REF-Chouinard-1980" TYPE="REFERENCE">Chouinard 1980</LINK>)<BR/>This consists of a questionnaire relating to Parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinetic movements (eight items), and a clinical global impression of tardive dyskinesia. High scores indicate severe levels of movement disorder.</P>
<P>6.3.4.4 Simpson Angus Scale - SAS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This ten-item scale, with a scoring system of zero to four for each item, measures drug-induced Parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism.</P>
<P>6.4 Adverse effects<BR/>Adverse effects were mainly ascertained in open interviews. In addition continuous adverse effect data were provided for weight, QTc time and glucose levels.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-03-12 13:59:27 +0000" MODIFIED_BY="[Empty name]">
<P>The search strategy yielded 3620 reports of which 20 studies were closely inspected. Nine of them had to be excluded for the following reasons: three not randomised, four open label, one pooled analysis and one no usable data.</P>
<SUBSECTION>
<HEADING LEVEL="4">Awaiting assessment</HEADING>
<P>254 citations of possible studies are awaiting assessment</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>Two studies appear to be ongoing (see '<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>' table).</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-08-06 13:36:48 +0100" MODIFIED_BY="[Empty name]">
<P>For details of risk of bias please refer to risk of bias table (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).<BR/>
</P>
<ALLOCATION MODIFIED="2009-02-11 17:11:44 +0000" MODIFIED_BY="[Empty name]">
<P>All of the included studies were randomised controlled trials. None of the studies gave further details about the randomisation process, therefore it remained unclear whether the randomisation procedure was adequate.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-08-06 13:35:14 +0100" MODIFIED_BY="[Empty name]">
<P>All included studies were described as 'double-blind', additionally two authors (<LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>, <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>) described using identical capsules for blinding. Whether blinding was effective is unclear because none of the studies examined this. The side-effect profiles of the compounds may differ which may have made blinding difficult. Therefore, the risk of bias for objective outcomes (e.g. death or laboratory values) may have been low but there was a risk of bias for subjective outcomes.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-08-06 13:36:23 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting on premature study discontinuation was high, only one study did not report on attrition (<LINK REF="STD-Svestka-2005" TYPE="STUDY">Svestka 2005</LINK>). Overall 59% of randomised people discontinued the studies prematurely for any reason. Most studies applied the last observation carried forward method to account for participants leaving the study early which is an imperfect method. It assumes that a participant who left the study prematurely would not have had a change of his condition if he had stayed in the study. This assumption can obviously be wrong. This may be less of a problem in the studies with low attrition but is clearly problematic in studies with high attrition.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-08-06 13:36:48 +0100" MODIFIED_BY="[Empty name]">
<P>None of the included studies was free of selective reporting. Two studies (<LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK> and <LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK>) reported only adverse events that occurred in at least 5 or 10% of the participants.This procedure is problematic, because rare but potentially serious adverse effects may be missed. One study (<LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>) excluded all data from one site from the analysis owing to concern about the integrity of data. <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK> focused on acutely ill subjects but failed to report on positive symptom reduction. For two studies there was only an abstract (<LINK REF="STD-Sacchetti-2006" TYPE="STUDY">Sacchetti 2006</LINK>) or no publication available (<LINK REF="STD-Svestka-2005" TYPE="STUDY">Svestka 2005</LINK>). Therefore most of the studies failed to fully report on secondary or even primary outcomes.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-07-03 10:34:04 +0100" MODIFIED_BY="[Empty name]">
<P>None of the included studies was free from other potential sources of bias. Six studies (<LINK REF="STD-Addington-2004" TYPE="STUDY">Addington 2004</LINK>, <LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK>, <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>, <LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK>, <LINK REF="STD-Sacchetti-2006" TYPE="STUDY">Sacchetti 2006</LINK>, <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>) were industry sponsored by the manufacturers of one of the compounds. There is evidence that pharmaceutical companies sometimes highlight the benefits of their compounds and tend to suppress their disadvantages (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). As an example <LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK> did not report on positive symptoms. In <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK> olanzapine doses higher than 15 mg per day were not allowed, although the official olanzapine dose range goes up to 20 mg/day. Further methodological shortcomings of included trials were short wash-out phases, selected and usually chronic participants and lack of standardised response criteria (for review see <LINK REF="REF-Leucht-2008" TYPE="REFERENCE">Leucht 2008</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-08-06 14:59:37 +0100" MODIFIED_BY="[Empty name]">
<P>Nine studies met the inclusion criteria. These studies provided data on five different comparisons of ziprasidone versus other second generation antipsychotic drugs.</P>
<P>1. Comparison 1. ZIPRASIDONE versus AMISULPRIDE<BR/>A single study compared ziprasidone (80-160 mg/day) with amisulpride (100 to 200 mg/day). It included only chronic participants with predominantly negative symptoms.</P>
<P>1.1 No clinically significant response - as defined by the original studies<BR/>There was no statistically significant difference between groups (1 RCT, n=123, RR 1.05 CI 0.93 to 1.19).</P>
<P>1.2 Leaving the study early<BR/>There was no statistically significant difference in the number of participants discontinuing the study due to any reason (1 RCT, n=123, RR 1.45 CI 0.78 to 2.70) or adverse effects (1 RCT, n=123, RR 0.79 CI 0.18 to 3.37), but more participants in the ziprasidone group than in the amisulpride group discontinued the study prematurely due to inefficacy (1 RCT, n=123, RR 4.73 CI 1.06 to 20 .98, NNH 8 CI 5 to 50).</P>
<P>1.3 Global state<BR/>1.3.1 Global state: no clinically important change (as defined by the original studies)<BR/>No significant difference was reported (1 RCT, n=123, RR 1.11 CI 0.82 to 1.51).</P>
<P>1.4 Mental state<BR/>1.4.1 General mental state: PANSS total score<BR/>There was no significant difference (1 RCT, n=123, MD 2.70 CI -3.55 to 8.95).</P>
<P>1.4.2 General mental state: BPRS total score<BR/>There was no significant difference (1 RCT, n=123, MD 2.10 CI -1.52 to 5.72).</P>
<P>1.4.3 Negative Symptoms: no clinically important change (less than 50% PANSS negative subscore reduction)<BR/>There was no significant difference (1 RCT, n=123, RR 1.05 CI 0.93 to 1.19).</P>
<P>1.4.4 Negative Symptoms: PANSS negative subscore<BR/>There was no significant difference (1 RCT, n=123, MD 0.80 CI -1.40 to 3.00).</P>
<P>1.5 Adverse effects<BR/>1.5.1 At least one adverse effect<BR/>There was no significant difference (1 RCT, n=123, RR 1.11 CI 0.82 to 1.51).</P>
<P>1.5.2 Cardiac effects - QTc prolongation<BR/>There was no occurrence of QTc prolongation in either group.</P>
<P>1.5.3 Extrapyramidal side-effects<BR/>There were no significant differences in the occurrence of akathisia (1 RCT, n=123, RR 1.58 CI 0.27 to 9.10), parkinsonism (1 RCT, n=123, RR 6.30 CI 0.78 to 50.80) or use of antiparkinson medication (1 RCT, n=123, RR 1.70 CI 0.94 to 3.07).</P>
<P>1.5.4 Sedation<BR/>There was no significant difference (1 RCT, n=123, RR 0.35 CI 0.07 to 1.67).</P>
<P>1.5.5 Weight gain of 7% or more of total body weight<BR/>There was no significant difference (1 RCT, n=123, RR 0.48 CI 0.18 to 1.29).</P>
<P>1.6 Publication bias<BR/>Due to the small number of included studies we did not apply the funnel plot method.</P>
<P>1.7 Investigation for heterogeneity and sensitivity analysis<BR/>The reasons given for the preplanned sensitivity analyses did not occur and they were therefore not performed.</P>
<P>2. Comparison 2. ZIPRASIDONE versus CLOZAPINE<BR/>A single study in treatment-resistant participants compared ziprasidone with clozapine.</P>
<P>2.1 Leaving the study early<BR/>There was no significant difference in the number of participants leaving the study early due to any reason (1 RCT, n=146, RR 1.00 CI 0.66 to 1.51). The number of participants leaving the study early for specific reasons (adverse events or inefficacy of treatment) has not been reported.</P>
<P>2.2 Mental state<BR/>2.2.1 General mental state: PANSS total score<BR/>There was no significant difference (1 RCT, n=146, MD -0.50 CI -7.72 to 6.72).</P>
<P>2.3 Adverse effects<BR/>2.3.1 Cardiac effects - QTc prolongation<BR/>There was no occurrence of Qtc prolongation.</P>
<P>2.4 Publication bias<BR/>Due to the small number of included studies a funnel plot analysis was not performed.</P>
<P>2.5 Investigation of heterogeneity and sensitivity analysis<BR/>The reasons given for the preplanned sensitivity analyses did not occur and they were therefore not performed.</P>
<P>3. Comparison 3. ZIPRASIDONE versus OLANZAPINE<BR/>3.1 No clinically significant response - as defined by the original studies<BR/>There was no significant difference in the number of participants responding to treatment (2 RCTs, n=817, RR 1.20 CI 0.92 to 1.56), but the data were heterogeneous (I<SUP>2</SUP> 84%). In <LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK> olanzapine was significantly superior, while <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK> (which restricted the upper olanzapine dose range to 15 mg per day) showed no difference between groups.</P>
<P>3.2 Leaving the study early<BR/>Olanzapine was statistically significantly superior in terms of leaving the study early for any reason (5 RCTs, n=1937, RR 1.26 CI 1.18 to 1.35, NNH 7 CI 5 to 10) and inefficacy of treatment (5 RCTs, n=1937, RR 1.57 CI 1.27 to 1.94, NNH 17 CI 11- 13), but there was no significant difference in leaving early for adverse effects (5 RCTs, n=1937, RR 1.12 CI 0.77 to 1.61).</P>
<P>3.3 Global state<BR/>There was no significant difference in global state (1 RCT, n=269, RR 1.18 CI 0.92 to 1.53).</P>
<P>3.4 Mental state<BR/>3.4.1 General mental state: no clinically important change (less than 30%)<BR/>There was a significant difference in terms of less than 30% PANSS reduction favouring olanzapine (1 RCT, n=548, RR 1.36 CI 1.15 to 1.61, NNT 6 CI 4 to 14).</P>
<P>3.4.2 General mental state: PANSS total score<BR/>In the overall analysis there was a significant difference in favour of olanzapine (4 RCTs, n=1291, MD 8.32 CI 5.64 to 10.99). Data were reported as short-term data (1 RCT, n=48, MD 8.37 CI -2.00 to 18.74), medium-term data (1 RCT, n=201, MD 6.50 CI -0.07 to 13.07) and long-term data (2 RCTs, n=1042, MD 8.71 CI 5.66 to 11.76).</P>
<P>3.4.3 General mental state: no clinically important change<BR/>There was no significant difference (1 RCT, n=269, RR 1.07 CI 0.94 to 1.21).</P>
<P>3.4.4 General mental state: BPRS total score<BR/>There was no significant difference (1 RCT, n=251, MD 0.50 CI -2.85 to 3.85).</P>
<P>3.4.5 Positive Symptoms: PANSS positive subscore<BR/>There was a significant difference in favour of olanzapine (2 RCTs, n=730, MD 3.11 CI 1.93 to 4.30) in the overall analysis, as well as in the analysis of medium-term data (1 RCT, n=201, MD 3.60 CI 1.45 to 5.75) and long-term data (1 RCT, n=529, MD 2.90 CI 1.47 to 4.33).</P>
<P>3.4.6 Negative Symptoms: PANSS negative subscore<BR/>Overall there was no significant difference but the results were heterogeneous and the two available studies are therefore reported separately. <LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK> (long-term data) found a significant difference in the PANSS negative subscore favouring olanzapine (1 RCT, n=529, MD 2.20 CI 0.92 to 3.48), while <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK> (medium-term data) reported no difference between groups (1 RCT, n=201, MD -1.00 CI -2.91 to 0.91).</P>
<P>3.5 General Functioning<BR/>3.5.1 No clinically important change<BR/>There was a significant difference favouring olanzapine (1 RCT, n=394, RR 1.20 CI 1.03 to 1.41, NNT 9 CI 5 to 50).</P>
<P>3.5.2 GAF total score<BR/>There was a significant superiority of olanzapine (1 RCT, n=326, MD 3.49 CI 0.64 to 6.34).</P>
<P>3.6 Quality of Life<BR/>3.6.1 QLS total score<BR/>There was no significant difference (1 RCT, n=393, MD 3.70 CI -1.21 to 8.61).</P>
<P>3.7 Cognitive Functioning<BR/>3.7.1 PANSS cognition subscore<BR/>There was a significant difference in the PANSS cognition subscore favouring olanzapine (1 RCT, n=528, MD 2.40 CI 1.17 to 3.63).</P>
<P>3.8 Service use<BR/>3.8.1 Number of patients re-hospitalised<BR/>There was a significant difference favouring olanzapine (2 RCTs, n=766, RR 1.54 CI 1.07 to 2.20, NNH 17 CI 9 to 100), which was also present in long-term data (1 RCT, n=521, RR 1.58 CI 1.03 to 2.44) but not in medium-term data (1 RCT, n=245, RR 1.45 CI 0.75 to 2.79).</P>
<P>3.9 Adverse effects<BR/>3.9.1 At least one adverse effect<BR/>There was no significant difference (4 RCTs, n=1583, RR 1.05 CI 0.94 to 1.18).</P>
<P>3.9.2 Cardiac effects - number of participants with QTc prolongation<BR/>There was no significant difference in the number of participants with QTc prolongation.</P>
<P>3.9.3 Cardiac effects - mean QTc change from baseline in ms<BR/>There was no significant difference (4 RCTs, n=1372, MD 2.19 CI -0.58 to 4.96).</P>
<P>3.9.4 Cholesterol - number of participants with abnormally high cholesterol<BR/>There was no significant difference in the number of participants with high cholesterol levels (1 RCT, n=394, RR 0.70 CI 0.12 to 4.15).</P>
<P>3.9.5 Cholesterol - mean change from baseline in mg/dl<BR/>There was a significant difference in favour of ziprasidone (4 RCTs, n=1502, MD -15.83 CI -25.72 to -5.95). The data were heterogeneous, but all of the single studies found a superiority of ziprasidone, as well (1 RCT, n=418, MD -7.39 CI -10.43 to -4.35), (1 RCT, n=521, MD -18.90 CI -29.89 to -7.91), (1 RCT, n=318, MD -9.43 CI -16.82 to -2.04) and (1 RCT, n=245, MD -30.40 CI -39.83 to -20.97). Therefore the studies varied only in the degree of difference, but not in the direction of the effect.</P>
<P>3.10 Death<BR/>There was no significant difference (2 RCTs, n=766, RR 1.60 CI 0.24 to 10.45).</P>
<P>3.11 Extrapyramidal side-effects<BR/>There was a significant difference in use of antiparkinson medication at least once favouring olanzapine (4 RCTs, n=1732, RR 1.43 CI 1.03 to 1.99, NNT not estimable), but there was no difference in akathisia (2 RCTs, n=766, RR 1.41 CI 0.78 to 2.53), dystonia (1 RCT, n=548, RR 13.29 CI 0.75 to 234.71) and any extrapyramidal symptoms (2 RCTs, n=793, RR 1.90 CI 0.77 to 4.73).</P>
<P>3.12 Extrapyramidal side-effects (scale measured)<BR/>There was no significant difference between ziprasidone and olanzapine in the results of rating scales for extrapyramidal side-effects (AIMS: 2 RCTs, n=925, MD 0.16, CI -0.15 to 0.46; BAS: 2 RCTs, n=925, MD 0.07 CI -0.04 to 0.17; ESRS:1 RCT, n=269 MD 0.40 CI -0.73 to 1.53 and SAS: 2 RCTs, n=922, MD 0.34 CI -0.13 to 0.19).</P>
<P>3.13 Glucose - number of participants with abnormally high fasting glucose<BR/>There was no significant difference (1 RCT, n=394, RR 1.05 CI 0.15 to 7.39).</P>
<P>3.14 Glucose - mean change from baseline in mg/dl<BR/>There was a significant difference in the mean change of glucose levels (4 RCTs, n=1420, MD -8.25 CI -13.72 to -2.77) favouring ziprasidone.</P>
<P>3.15 Prolactin associated side-effects<BR/>There was no significant difference in prolactin increase (1 RCT, n=394, RR 0.89, CI 0.59 to 1.35), amenorrhoea (1 RCT, n=148, RR 1.19 CI 0.51 to 2.79) or galactorrhoea (2 RCTs, n=580, RR 1.56 CI 0.53 to 4.56), but sexual dysfunction indicated a slight tendency to the intervention group (2 RCTs, n=766, RR 0.75 CI 0.56 to 1.01).</P>
<P>3.16 Prolactin - change from baseline in ng/ml<BR/>There was no significant difference (3 RCTs, n=1079, MD 0.20 CI -3.33 to 3.72).</P>
<P>3.17 Sedation<BR/>There was no significant difference. The data revealed some heterogeneity, but the direction of the effect was the same in both studies showing a trend in favour of ziprasidone (2 RCTs, n=766, RR 0.64 CI 0.39 to 1.04).</P>
<P>3.18 Weight gain<BR/>There was a significant difference favouring ziprasidone (4 RCTs, n=1808, RR 0.20 CI 0.14 to 0.30, NNH 2 CI 5 to 10).</P>
<P>3.19 Weight gain change from baseline in kg<BR/>Overall there was a significant difference in favour of ziprasidone (5 RCTs, n=1659, MD -3.82 CI -4.69 to -2.96). The data were heterogeneous but again the direction of the effect was the same in all single studies (n=48, MD -2.12 CI -4.36 to 0.12; n=238, MD -2.62 CI -3.92 to -1.32; n=529, MD -4.18 CI -5.18 to -3.18; n=468, MD -5.00 CI -6.25 to -3.75 and n=376, MD -4.18 CI -5.10 to -3.26).</P>
<P>3.20 Publication bias<BR/>Due to small number of included studies a funnel plot analysis was not meaningful.</P>
<P>3.21 Investigation for heterogeneity and sensitivity analysis<BR/>Excluding potentially skewed data in <LINK REF="STD-Svestka-2005" TYPE="STUDY">Svestka 2005</LINK> from the analysis of overall symptoms (PANSS total score) did not reverse the superiority of olanzapine.</P>
<P>4. Comparison 4. ZIPRASIDONE versus QUETIAPINE<BR/>We found two RCTs that compared ziprasidone with quetiapine.</P>
<P>4.1 Leaving the study early<BR/>There was no significant difference in leaving the studies early due to any reason (2 RCTs, n=722, RR 0.95 CI 0.88 to 1.00), adverse effects (2 RCTs, n=722, RR 0.96 CI 0.67 to 1.39) or inefficacy of treatment (2 RCTs, n=722, RR 0.87 CI 0.68 to 1.12).</P>
<P>4.2 Mental state<BR/>4.2.1 General mental state: PANSS total score<BR/>There was no significant difference between groups (2 RCTs, n=710, MD 0.11 CI -6.14 to 6.36). The data were heterogeneous, but reporting them separately showed no significant difference neither medium-term data (n=198, MD -3.70 CI -10.37 to 2.97) nor long-term data (n=511, MD 2.78 CI -1.25 to 6.81).</P>
<P>4.2.2 Positive symptoms: PANSS positive subscore<BR/>There was no significant difference (1 RCT, n=198, MD 0.00 CI -2.18 to 2.18).</P>
<P>4.2.3 Negative symptoms: PANSS negative subscore<BR/>There was no significant difference (1 RCT, n=198, MD -1.60 CI -3.54 to 0.34).</P>
<P>4.3 Service use<BR/>4.3.1 Number of participants re-hospitalised<BR/>There was no significant difference (2 RCTs, n=756, RR 0.86 CI 0.63 to 1.17). Data were presented as medium-term data (1 RCT, n=235, RR 0.80 CI 0.46 to 1.40) and long-term data (1 RCT, n=101, RR 0.88 CI 0.61 to 1.29).</P>
<P>4.4 Adverse effects<BR/>4.4.1 At least one adverse effect<BR/>There was no significant difference (2 RCTs, n=754, RR 0.97 CI 0.85 to 1.10).</P>
<P>4.4.2 Cardiac effects - number of participants with QTc prolongation<BR/>There was no significant difference (1 RCT, n=522, RR 0.61 CI 0.12 to 2.98).</P>
<P>4.4.3 Cardiac effects - mean change of QTc interval from baseline in ms<BR/>There was no significant difference (2 RCTs, n=549, MD -3.41 CI -8.18 to 1.37).</P>
<P>4.4.4 Cholesterol - change from baseline in mg/dl<BR/>There was a significant difference favouring ziprasidone (2 RCTs, n=754, MD -16.01 CI -23. 46 to -8.57).</P>
<P>4.4.5 Death<BR/>There was no significant difference (2 RCTs, n=754, RR 2.45 CI 0.32 to 18.83).</P>
<P>4.4.6 Extrapyramidal side-effects<BR/>There was a significant difference in the number of participants using at least one dose of antiparkinson medication favouring quetiapine (1 RCT, n=522, RR 2.32 CI 1.07 to 5.00, NNT not estimable), but there was no significant difference in akathisia (2 RCTs, n=754, RR 1.28 CI 0.69 to 2.39) or in any extrapyramidal symptoms (1 RCT, n=232, RR 0.50 CI 0.16 to 1.51).</P>
<P>4.4.7 Glucose - change from baseline in mg/dl<BR/>There was no significant difference (2 RCTs, n=754, MD -3.10 CI -10.19 to 3.99).</P>
<P>4.4.8 Prolactin associated side-effects<BR/>There was no significant difference in the number of women with amenorrhoea (1 RCT, n=138, RR 2.34 CI 0.81 to 6.79) and galactorrhoea (2 RCTs, n=202, RR 1.46 CI 0.50 to 4.31).</P>
<P>4.4.9 Prolactin - change from baseline in ng/ml<BR/>There was a statistically significant difference in favour of quetiapine (2 RCTs, n=754, MD 4.77 CI 1.37 to 8.16).</P>
<P>4.4.10 Sedation<BR/>There was a statistically significant difference in favour of ziprasidone (2 RCTs, n=754, RR 0.73 CI 0.55 to 0.97, NNT 13 CI 1 to 100).</P>
<P>4.4.11 Weight gain of 7% or more of total body weight<BR/>There was a significant difference favouring ziprasidone (2 RCTs, n=754, RR 0.45 CI 0.28 to 0.74, NNT 13 CI 8 to 33).</P>
<P>4.4.12 Weight gain change from baseline in kg<BR/>There was no significant difference (1 RCT, n=466, MD -1.20 CI -2.45 to 0.05).</P>
<P>4.5 Publication bias<BR/>Due to the small number of included studies a funnel plot analysis was not meaningful.</P>
<P>4.6 Investigation for heterogeneity and sensitivity analysis<BR/>The reasons given for the preplanned sensitivity analyses did not occur and they were therefore not performed.</P>
<P>5. Comparison 5. ZIPRASIDONE versus RISPERIDONE<BR/>Three trials contributed data to this comparison.</P>
<P>5.1 No clinically significant response - as defined by the original studies<BR/>There was no significant difference (1 RCT, n=296, RR 0.98 CI 0.89 to 1.07).</P>
<P>5.2 Leaving the study early<BR/>There was a significant difference in the number of participants leaving the studies early due to any reason favouring risperidone (3 RCTs, n=1019, RR 1.11 CI 1.02 to 1.20, NNH 14 CI 8 to 50). There was however no significant difference in leaving early for adverse effects (3 RCTs, n=1019, RR 1.23 CI 0.76 to 1.98) or for inefficacy of treatment (3 RCTs, n=1019, RR 1.14 CI 0.79 to 1.66).</P>
<P>5.3 Global state<BR/>5.3.1 No clinically important change - as defined by the original studies<BR/>There was no significant difference (1 RCT, n=296, RR 1.24 CI 0.96 to 1.60).</P>
<P>5.4 Mental state<BR/>5.4.1 General mental state: no clinically important change (less than 50% PANSS total reduction)<BR/>There was no significant difference (1 RCT, n=296, RR 0.98 CI 0.89 to 1.07).</P>
<P>5.4.2 General mental state: PANSS total score<BR/>Overall there was a significant superiority favouring risperidone (3 RCTs, n=1016, MD 3.91 CI 0.27 to 7.55). There was some heterogeneity, but the direction of the effect was the same in all three studies: short-term (n=516, MD 6.01 CI 1.99 to 10.03), medium-term (n=204, MD 6.30 CI -0.17 to 12.77) and long-term (n=196, MD 1.50 CI -0.16 to 3.16).</P>
<P>5.4.3 General mental state: BPRS total score<BR/>There was no significant difference (1 RCT, n=296, MD 0.70 CI -2.93 to 4.33).</P>
<P>5.4.4 Positive symptoms: PANSS positive subscore<BR/>There was a significant difference favouring risperidone (1 RCT, n=204, MD 2.50 CI 0.38 to 4.62).</P>
<P>5.4.5 Positive symptoms: BPRS positive subscore<BR/>There was no significant difference (1 RCT, n=296, MD 0.50 CI -0.15 to 1.15).</P>
<P>5.4.6 Negative symptoms: PANSS negative subscore<BR/>There was no significant difference in the overall analysis (2 RCTs, n=500, MD 0.04 CI -1.12 to 1.20) as well as in the analysis of short-term data (1 RCT, n=296, MD 0.00 CI -1.48 to 1.48) or medium-term data (1 RCT, n=204, MD 0.10 CI -1.78 to 1.98).</P>
<P>5.5 Service use<BR/>5.5.1 Number of patients re-hospitalised<BR/>There was no significant difference in the medium-term data analysis (1 RCT, n=241, RR 1.04 CI 0.58 to 1.89) as well as in the analysis of long-term data (1 RCT, n=526, RR 1.19 CI 0.80 to 1.78) and in the overall analysis (2 RCTs, n=767, RR 1.14 CI 0.82 to 1.59).</P>
<P>5.6 Adverse effects<BR/>5.6.1 At least one adverse effect<BR/>There was no significant difference (3 RCTs, n=1063, RR 0.93 CI 0.86 to 1.02).</P>
<P>5.6.2 Cardiac effects - number of participants with QTc prolongation<BR/>There was no significant difference (2 RCTs, n=822, RR 0.53 CI 0.11 to 2.51).</P>
<P>5.6.3 Cardiac effects - mean change of the QTc interval from baseline in ms<BR/>There was no significant difference ( 3 RCTs, n=798, MD 2.24 CI -1.92 to 6.39).</P>
<P>5.6.4 Cholesterol - change from baseline in mg/dl<BR/>There was a significant difference favouring ziprasidone (2 RCTs, n=767, MD -8.58 CI -16.04 to -1.11).</P>
<P>5.6.5 Death<BR/>There was no significant difference (2 RCTs, n=767, RR 1.18 CI 0.22 to 6.42).</P>
<P>5.6.6 Extrapyramidal side-effects (dichotomous)<BR/>There was a significant difference favouring ziprasidone in terms of 'any EPS' (1 RCT, n=241, RR 0.32 CI 0.12 to 0.87, NNT 13 CI 7 to 100) and use of antiparkinson medication (2 RCTs, n=826, RR 0.70 CI 0.51 to 0.97, NNT not estimable), but no significant difference in akathisia (3 RCTs, n=1063, RR 0.98 CI 0.53 to 1.81) or tremor (1 RCT, n=296, RR 1.06 CI 0.53 to 2.11).</P>
<P>5.6.7 Extrapyramidal side-effects (scale measured)<BR/>Scale measured results on extrapyramidal side-effects showed a statistically significant difference in dyskinesia (AIMS: 1 RCT, n=296, MD -0.21 CI -0.25 to -0.17), akathisia (BAS: 1 RCT, n=296, MD -0.56 CI -0.61 to -0.51) and general EPS (SAS: 1 RCT, n=296, MD -0.34 CI -0.60 to -0.14), all in favour of ziprasidone.</P>
<P>5.6.8 Glucose - mean change from baseline in mg/dl<BR/>There was no significant difference between groups (2 RCTs, n=767, MD -4.94 CI -11.80 to 1.91).</P>
<P>5.6.9 Prolactin associated side-effects<BR/>There was a significant difference in the frequency of sexual dysfunction (2 RCTs, n=822, RR 0.69 CI 0.50 to 0.97, NNH not estimable) favouring ziprasidone, but not in the frequency of abnormal ejaculation (1 RCT, n=215, RR 0.48 CI 0.15 to 1.54), amenorrhoea (1 RCT, n=81, RR 1.08 CI 0.23 to 5.02), decreased libido (1 RCT, n=298, RR 0.61 CI 0.26 to 1.42), erectile dysfunction (1 RCT, n=215, RR 0.95 CI 0.35 to 2.63) or galactorrhoea (3 RCTs, n=303, RR 0.56 CI 0.25 to 1.28).</P>
<P>5.6.10 Prolactin - change from baseline in ng/ml<BR/>There was a significant difference favouring ziprasidone (2 RCTs, n=667, MD -21.97 CI -27.34 to -16.60).</P>
<P>5.6.11 Sedation<BR/>There was no significant difference (3 RCTs, n=1063, RR 0.87 CI 0.63 to 1.20).</P>
<P>5.6.12 Weight gain - number of participants with 7% or more increase in total body weight<BR/>There was a significant difference (3 RCTs, n=1063, RR 0.49 CI 0.33 to 0.74, NNH 14 CI 10 to 33) favouring ziprasidone.</P>
<P>5.6.13 Weight gain - mean change from baseline in kg<BR/>There was no significant difference (1 RCT, n=461, MD -1.10, CI -2.35 to 0.15).</P>
<P>5.7 Publication bias<BR/>Due to the small number of included studies a funnel plot analysis was not meaningful.</P>
<P>5.8 Investigation for heterogeneity and sensitivity analysis<BR/>The reasons given for the preplanned sensitivity analyses did not occur and they were therefore not performed.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-03-12 14:00:14 +0000" MODIFIED_BY="[Empty name]">
<P>There are several limitations of the evidence. For three comparisons (ziprasidone versus aripiprazole, sertindole and zotepine) not a single study could be included. Thus, nothing can be said about the effects of ziprasidone compared to these second generation antipsychotic drugs. The overall rate of premature study termination was very high (59.1%) limiting the validity of any findings beyond dropout, because more than 50% of the data must be synthesised by statistical modelling. Only one study fell in the long-term category (<LINK REF="REF-Liebermann-2005" TYPE="REFERENCE">Liebermann 2005</LINK>). Therefore, little is known about the long-term effects of ziprasidone. Six of nine included studies were industry-sponsored. We showed in a blinded analysis of abstracts that pharmaceutical companies emphasize the positive aspects of their compounds (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). All this is not ideal for judging the comparative effects of antipsychotic drugs in a chronic disorder such as schizophrenia.<BR/>
</P>
<SUMMARY_OF_RESULTS MODIFIED="2013-03-12 14:00:14 +0000" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>Currently randomised evidence comparing ziprasidone with amisulpride, clozapine, olanzapine, quetiapine and risperidone is available. A major limitation is the high overall rate of premature study discontinuation (59.1%). Ziprasidone was a less acceptable treatment than olanzapine and risperidone. It was less efficacious than amisulpride, olanzapine and risperidone. Ziprasidone induced less weight gain than olanzapine, quetiapine or risperidone. It was associated with less cholesterol increase than olanzapine, quetiapine and risperidone. Conversely ziprasidone induced slightly more extrapyramidal side-effects than olanzapine and slightly more prolactin increase than quetiapine but less movement disorders and less prolactin increase than risperidone.</P>
<P>Note: the 254 citations in the awaiting classification section of the review may alter the results and conclusions of the review once assessed.</P>
<P>2. Comparison 1. ZIPRASIDONE versus AMISULPRIDE<BR/>Only one study with 123 chronic participants and predominantly negative symptoms could be included in this comparison.</P>
<P>2.1 Leaving the study early<BR/>The overall number of participants leaving the study early was 25% which is less than in many other current antipsychotic drug trials. As there was no difference in leaving the studies early due to any reason both compounds may be similarly acceptable for people with schizophrenia, at least in the context of a trial. That more participants in the ziprasidone group left the study early due to inefficacy of treatment reflects an efficacy advantage of amisulpride.<BR/>
</P>
<P>2.2 Efficacy outcomes (global, general, and specific mental state)<BR/>There was no difference in overall efficacy and in negative symptoms which is important because the study focused on participants with predominantly negative symptoms. Nevertheless, the positive subscore of the PANSS was not reported in this study sponsored by ziprasidone's manufacturer. We interpreted this failure as an example of selective reporting.</P>
<P>2.3 Adverse effects<BR/>There were no significant differences in the following adverse events: at least one adverse effect, extrapyramidal side-effects, QTc prolongation, sedation and weight gain. The tolerability of amisulpride and ziprasidone may therefore be similar but such a conclusion would be premature due to the small number of included participants.</P>
<P>3. Comparison 2. ZIPRASIDONE versus CLOZAPINE<BR/>Only one study with 146 participants and treatment resistant schizophrenia compared ziprasidone with clozapine.</P>
<P>3.1 Leaving the study early<BR/>The overall number of participants leaving the study early was considerable (38.4%) and calls the validity of any other outcomes into question.</P>
<P>3.2 Efficacy related outcomes (global, general, and specific mental state)<BR/>Efficacy data were poorly reported. Dichotomous data on clinically significant response were not available. Nevertheless overall there was no difference in efficacy according to the PANSS total score which improved similarly in both groups.</P>
<P>3.3 Adverse effects<BR/>The only adverse effect reported was the occurrence of QTc prolongation. As there was no case in either group we can not come up with a clear judgement.</P>
<P>4. Comparison 3. ZIPRASIDONE versus OLANZAPINE<BR/>This was the largest comparison with five trials and 1985 randomised participants.</P>
<P>4.1 Leaving the study early<BR/>The overall number of participants discontinuing the studies prematurely was again high (59.1%), although this may be partly explained by a relatively high number of mid-term and long-term studies. Data on leaving the study early for any reason and for inefficacy of treatment showed a benefit for olanzapine compared to ziprasidone. Therefore, olanzapine may be more acceptable than ziprasidone, largely due to a better efficacy.</P>
<P>4.2 Efficacy outcomes (global state, general and specific mental state)<BR/>There was a significant superiority of olanzapine in most aspects of efficacy as measured by the PANSS total score, PANSS positive subscore and PANSS negative subscore. The exception were the BPRS data, but these were derived from only one study which limited the olanzapine dose to 15 mg/day which is below the upper limit of 20 mg/day in olanzapine's label (<LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>). As already mentioned above the high rate of patients discontinuing the studies prematurely has to be taken into account.</P>
<P>4.3 General functioning and quality of life<BR/>Limited data from one study suggest that olanzapine may improve participants functioning more than ziprasidone but there was no difference in quality of life.<BR/>
</P>
<P>4.4 Cognitive functioning<BR/>The PANSS cognition score demonstrated a benefit for olanzapine. More data on this item are needed, because the PANSS cognition score is not ideal for measuring cognitive effects as the scale has never been validated for this purpose. In addition, there is little evidence whether positive effects in cognition translate in better functioning, e.g. in an improved ability to work.</P>
<P>4.5 Service use<BR/>Olanzapine was associated with fewer re-hospitalisations, which can be important from a cost-effectiveness point of view.</P>
<P>4.6 Adverse effects<BR/>Adverse effects reporting was relatively detailed concerning extrapyramidal side-effects, QTc prolongation, sedation, death, weight gain, cholesterol increase and prolactin increase. Olanzapine was better in terms of use of antiparkinson medication (a proxy measure for extrapyramidal side-effects), while ziprasidone was associated with lower weight gain, cholesterol and glucose increase. The latter side-effects are very important, because in the long run they may lead to vascular problems such as myocardial infarction or stroke.</P>
<P>5. Comparison 4. ZIPRASIDONE versus QUETIAPINE<BR/>Two studies with 722 participants fell into this category.</P>
<P>5.1 Leaving the study early<BR/>The overall percentage of participants discontinuing the studies early was extremely high (80.7%). This high rate limits any interpretation of outcomes other than premature study discontinuation, although the relatively long study durations of 26 and 51 weeks may have played a role. As there were no significant differences between groups, ziprasidone and quetiapine may be similarly acceptable for people with schizophrenia, at least within the confines of clinical trials.<BR/>
</P>
<P>5.2 Efficacy outcomes (global state, overall and specific mental state)<BR/>Data on the number of participants with a clinically significant response were not reported. There was no significant difference in the general and specific mental state, but the small number of included trials and randomised people, and the very high dropout rates are certainly important limitations of this evidence.</P>
<P>5.3 Adverse effects<BR/>We found limited data on extrapyramidal symptoms, cardiac effects, cholesterol, glucose, prolactin, weight and sedation. Results on cholesterol, weight gain and sedation showed a significant benefit for ziprasidone whereas fewer people in the quetiapine group needed antiparkinson medication (a proxy measure for movement disorders) or developed prolactin increase. This might make ziprasidone somewhat more recommendable than quetiapine for people at risk to develop a metabolic syndrome, but less recommendable for EPS sensitive patients or patients suffering from prolactin associated side-effects. But these conclusions are very tentative because of the limited amount of available data.</P>
<P>6. Comparison 5. ZIPRASIDONE versus RISPERIDONE<BR/>Three studies with an overall dropout rate of 63.1% were available for this comparison.</P>
<P>6.1 Leaving the studies early<BR/>As more participants in the ziprasidone groups than in the risperidone groups left the studies prematurely, risperidone may be more acceptable for people with schizophrenia. There were no significant differences in specific reasons (adverse events or inefficacy of treatment) for study discontinuation, the reason for this improved acceptability is unclear.</P>
<P>6.2 Efficacy outcomes (global state, general and specific mental state)<BR/>A significant benefit for risperidone was present in general mental state and in positive symptoms. Although the small number of included trials and the high dropout rates limit the validity of this finding, risperidone maybe somewhat more efficacious for the positive symptoms of schizophrenia than ziprasidone.</P>
<P>6.3 Adverse effects<BR/>Ziprasidone was more tolerable than risperidone concerning a number of adverse events: certain extrapyramidal side-effects, glucose, cholesterol, prolactin increase, and weight gain. In treatment decisions this better tolerability profile of ziprasidone needs to be weighted with the somewhat lower efficacy, always keeping in mind the small amount of available data.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2008-12-13 16:40:38 +0000" MODIFIED_BY="[Empty name]">
<P>For almost half of the possible comparisons of ziprasidone with other second generation antipsychotic drugs not a single study was identified. Therefore the evidence is incomplete. Furthermore, most of the included studies were efficacy studies, therefore external validity is limited and further effectiveness studies are needed.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-07-03 11:14:51 +0100" MODIFIED_BY="[Empty name]">
<P>All studies were randomised and double-blind, but details on these procedures were rarely presented. Therefore it is unclear whether randomisation and blinding were really appropriately done. Additionally two thirds of the studies were industry sponsored and in two of them a potential dose-related bias could not be excluded. Furthermore high rates of participants leaving the studies prematurely (overall 59%) and the scarcity of long-term studies limit the overall quality.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-03-13 13:34:53 +0000" MODIFIED_BY="[Empty name]">
<P>We are not aware of any obvious flaws in our review process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-03-13 13:35:03 +0000" MODIFIED_BY="[Empty name]">
<P>A previous Cochrane review compared the effects of ziprasidone with those of any other antipsychotic drugs in schizophrenia (<LINK REF="REF-Bagnall-2000" TYPE="REFERENCE">Bagnall 2000</LINK>). However, at that time not a single randomised controlled trial comparing ziprasidone with another second generation antipsychotic drug was available.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-08-06 14:23:04 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-08-06 14:23:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. For people with schizophrenia<BR/>People with schizophrenia should know that based on this review ziprasidone may be slightly less efficacious than amisulpride, olanzapine and risperidone. The main advantage of ziprasidone is its low propensity to induce weight gain and associated metabolic problems such as cholesterol increase which has been demonstrated compared to olanzapine, quetiapine and risperidone.</P>
<P>2. For clinicians<BR/>Clinicians should know that randomised evidence of the effects of ziprasidone compared to other second generation antipsychotic drugs is only available for amisulpride, clozapine, olanzapine, quetiapine and risperidone. Even this evidence is limited, especially by high rates of premature study discontinuation, and more studies are needed to clarify the role of ziprasidone compared to other second generation antipsychotic drugs. Nevertheless, in their decision making process clinicians could weigh the above mentioned possible differences in efficacy and side-effects between ziprasidone and other second generation antipsychotic drugs.</P>
<P>3. For managers/policy makers<BR/>For the comparison of ziprasidone with olanzapine only there are very limited data on service use and functioning in society available that are important for managers and policy makers. Even these data are too scarce to make any recommendations.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-07-03 11:17:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>High numbers of participants leaving the studies early as in the current review are an enormous threat to the validity of current antipsychotic drug trials. Furthermore, strict adherence to the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) would make such studies much more informative.</P>
<P>2. Specific<BR/>RCTs comparing ziprasidone with second generation antipsychotic drugs other than amisulpride, clozapine, olanzapine, quetiapine and risperidone are urgently needed (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). New studies could address different disease stages (acute, chronic, first episode, maintenance) and different variants of the illness. Further long-term studies are needed to know more about ziprasidone's relative efficacy and tolerability.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-08-06 14:24:09 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank the editorial base of the Cochrane Schizophrenia Group for its assistance. We would also like to thank the following authors and pharmaceutical companies for providing additional information on their studies: D. Addington, J. Svestka, Eli Lilly and Pfizer.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-08-06 14:24:29 +0100" MODIFIED_BY="[Empty name]">
<P>Katja Komossa - none known.<BR/>Stefan Leucht - has received speaker/consultancy honoraria from Sanofi-Aventis, BMS, Eli Lilly, Janssen, Lundbeck and Pfizer. He has received research support from Sanofi-Aventis and Eli Lilly.<BR/>Christine Rummel - has received lecture honoraria and travel grants to attend scientific meetings from AstraZeneca, Janssen-Cilag, Eli Lilly and Pfizer.<BR/>Werner Kissling - has received speaker or consultancy honoraria from SanofiAventis, BMS, Lilly, Janssen, Lundbeck, Bayer and Pfizer.<BR/>Heike Hunger - none known.<BR/>Franziska Schmid - none known.<BR/>Sandra Schwarz - none known.<BR/>Paranthaman Seth Bhoopathi - none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-08-12 10:17:31 +0100" MODIFIED_BY="[Empty name]">
<P>Katja Komossa - protocol development, search strategy, study selection, data extraction, report writing.<BR/>Christine Rummel - protocol development, search strategy, study selection, data extraction.<BR/>Stefan Leucht - protocol development, search strategy, study selection, data extraction, report writing.<BR/>Werner Kissling - protocol development.<BR/>Heike Hunger - helped with data extraction and writing.<BR/>Franziska Schmid - helped with data extraction and writing.<BR/>Sandra Schwarz - helped with data extraction and writing.<BR/>Paranthaman Seth Bhoopathi - protocol development.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-08-06 14:24:39 +0100" MODIFIED_BY="[Empty name]">
<P>The review was adapted to new formatting and functions available in Review Manager 5, notably the risk of bias tables.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-08-22 14:49:21 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-08-22 14:49:21 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-07-30 09:55:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Addington-2004" MODIFIED="2009-07-30 09:55:42 +0100" MODIFIED_BY="[Empty name]" NAME="Addington 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-11 16:54:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addington D, Pantelis C, Benattia I</AU>
<TI>Ziprasidone vs risperidone in schizophrenia: efficacy and safety in an 8-week trial</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S125</PG>
<IDENTIFIERS MODIFIED="2009-02-11 16:54:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-30 09:55:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ</AU>
<TI>Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>12</NO>
<PG>1624-33</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:55:00 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breier-2005" MODIFIED="2009-02-11 16:55:08 +0000" MODIFIED_BY="[Empty name]" NAME="Breier 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Roychowdhury SM, Kane JM</AU>
<TI>Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<PG>1879-1887</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-11 16:55:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D</AU>
<TI>The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>9</NO>
<PG>1397-403</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:55:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2006" MODIFIED="2009-02-11 16:55:15 +0000" MODIFIED_BY="[Empty name]" NAME="Kinon 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-11 16:55:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG</AU>
<TI>A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>2</NO>
<PG>157-62</PG>
<ED>United States</ED>
<IDENTIFIERS MODIFIED="2009-02-11 16:55:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lieberman-2005" MODIFIED="2009-02-11 16:55:22 +0000" MODIFIED_BY="[Empty name]" NAME="Lieberman 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-11 16:55:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>12</NO>
<PG>1209-23</PG>
<IDENTIFIERS MODIFIED="2009-02-11 16:55:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olie-2006" MODIFIED="2009-02-11 16:55:35 +0000" MODIFIED_BY="[Empty name]" NAME="Olie 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-11 16:55:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olie JP, Spina E, Benattia I</AU>
<TI>Ziprasidone vs amisulpride for negative symptoms of schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Suppl 3</NO>
<PG>S313</PG>
<IDENTIFIERS MODIFIED="2009-02-11 16:55:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-11 16:55:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olie JP, Spina E, Murray S, Yang R</AU>
<TI>Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>3</NO>
<PG>143-51</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:55:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2006" MODIFIED="2009-03-14 18:03:15 +0000" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-14 18:03:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L</AU>
<TI>Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind 18-week trial</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</SO>
<YR>2006</YR>
<PB>American Psychiatric Association</PB>
<CY>Toronto</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:55:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-11 16:55:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L</AU>
<TI>Efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S374</PG>
<IDENTIFIERS MODIFIED="2009-02-11 16:55:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-2004" MODIFIED="2009-03-14 18:02:51 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-14 17:55:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Bowie C, Loebel AD</AU>
<TI>Long-term cognitive improvement: ziprasidone versus olanzapine:</TI>
<SO>Proceeding of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA</SO>
<YR>2004</YR>
<PB>American Psychiatric Association</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:55:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-14 17:58:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Bowie CR, Loebel A, Warrington L</AU>
<TI>Cognitive improvement and neuropsychological normalization with ziprasidone or olanzapine: Results of a 6-month study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S294</PG>
<IDENTIFIERS MODIFIED="2009-02-11 16:55:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-11 16:56:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Siu CO, Romano S</AU>
<TI>Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder</TI>
<SO>Psychopharmacology</SO>
<YR>2004</YR>
<VL>172</VL>
<NO>3</NO>
<PG>324-32</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-14 18:02:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Masand PS, Loebel AD</AU>
<TI>Analysis of remission in a six-month double-blind continuation study of ziprasidone versus olanzapine</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</SO>
<YR>2006</YR>
<PB>American Psychiatric Association</PB>
<CY>Toronto</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-14 18:02:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meyer J, Nasrallah H, Loebel A, Parsons B</AU>
<TI>Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia</TI>
<SO>Proceedings of the Collegium Internationale Neuro-Psychopharmacologium 25th Biennial Congress; 2006 July 9-13; Chicago, Illinois</SO>
<YR>2006</YR>
<PB>Internationale Neuro-Psychopharmacologium</PB>
<CY>Chicago</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:09 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-14 18:01:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meyer JM, Loebel AD</AU>
<TI>Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a six-week randomized study in patients with acute schizophrenia</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25;Toronto, Canada</SO>
<YR>2006</YR>
<PB>American Psychiatric Association</PB>
<CY>Toronto</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-11 16:56:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO, Simpson</AU>
<TI>Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>10</NO>
<PG>1837-47</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-11 16:56:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ</AU>
<TI>Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>8</NO>
<PG>1535-8</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stroup-2006" MODIFIED="2009-02-11 16:56:27 +0000" MODIFIED_BY="[Empty name]" NAME="Stroup 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-11 16:56:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK</AU>
<TI>Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>4</NO>
<PG>611-22</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-2005" MODIFIED="2008-12-13 17:09:09 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-13 17:09:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J</AU>
<TI>Comparison of olanzapine versus ziprasidone in acute schizophrenia</TI>
<SO>Psychiatrie Prague</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-03-14 18:06:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ascher_x002d_Svanum-2006" MODIFIED="2009-03-14 17:43:35 +0000" MODIFIED_BY="[Empty name]" NAME="Ascher-Svanum 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-14 17:43:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J</AU>
<TI>Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia</TI>
<SO>BMC Psychiatry</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>8</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:36 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baloescu-2006" MODIFIED="2009-02-11 16:56:40 +0000" MODIFIED_BY="[Empty name]" NAME="Baloescu 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-11 16:56:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baloescu A, Vasile D, Gheorghe MD, Grigorescu G</AU>
<TI>Side effects of atypical antipsychotics - prediction factor for compliance</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S403</PG>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hagger-1997" MODIFIED="2009-03-14 18:04:56 +0000" MODIFIED_BY="[Empty name]" NAME="Hagger 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-03-14 18:04:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hagger C, Mitchell D, Wise AL, Schulz SC</AU>
<TI>Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: Preliminary data</TI>
<SO>Proceedings of the10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria</SO>
<YR>1997</YR>
<PB>Neuropsychopharmacology</PB>
<CY>Vienna</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrigan-2004" MODIFIED="2009-02-11 16:56:50 +0000" MODIFIED_BY="[Empty name]" NAME="Harrigan 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-11 16:56:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M</AU>
<TI>A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>62-9</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrison-2004" MODIFIED="2009-03-14 18:05:44 +0000" MODIFIED_BY="[Empty name]" NAME="Harrison 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-14 18:05:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harrison D, Leaderer M, Loebel A, Murray S</AU>
<TI>Ziprasidone vs. Olanzapine: change in coronary heart disease risk during a 6-week trial</TI>
<SO>Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy</SO>
<YR>2004</YR>
<PB>World Psychiatric Association</PB>
<CY>Florence</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:56:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swanson-2006" MODIFIED="2009-03-14 18:06:50 +0000" MODIFIED_BY="[Empty name]" NAME="Swanson 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-14 18:06:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Swanson JW, Swartz MS, Van Dorn RA</AU>
<TI>Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</SO>
<YR>2006</YR>
<PB>American Psychiatric Association</PB>
<CY>Toronto</CY>
<IDENTIFIERS MODIFIED="2009-02-11 16:57:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2005" MODIFIED="2009-02-11 16:57:06 +0000" MODIFIED_BY="[Empty name]" NAME="Tang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-11 16:57:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang B, Lu Z, Zhou Z</AU>
<TI>A control study of ziprasidone vs clozapine in the treatment of refractory schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>303-4</PG>
<IDENTIFIERS MODIFIED="2009-02-11 16:57:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tudor-2006" MODIFIED="2009-02-11 16:57:11 +0000" MODIFIED_BY="[Empty name]" NAME="Tudor 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-11 16:57:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tudor C, Ungureanu D, Gheorghe MD</AU>
<TI>Olanzapine versus ziprasidone in parenteral administration in psychotic relapse of schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S397</PG>
<IDENTIFIERS MODIFIED="2009-02-11 16:57:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uzun-2002" MODIFIED="2009-02-11 16:57:17 +0000" MODIFIED_BY="[Empty name]" NAME="Uzun 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-02-11 16:57:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uzun S, Folnegovic-Smalc V, Mimica N, Ljubin T, Makaric G, Ivezic S, Jelacic P, Vilibic M, Markan-Sosic V</AU>
<TI>Ziprasidone clinical trials conducted in Croatia</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl 1</NO>
<PG>182</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS MODIFIED="2009-02-11 16:57:17 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-08-22 14:49:21 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-A1281039" MODIFIED="2012-08-12 22:55:48 +0100" MODIFIED_BY="[Empty name]" NAME="A1281039" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:55:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>A1281039</AU>
<TI>double blind, double-dummy multicenter, parallel group comparison of the efficacy and the tolerability of ziprasidone vs. Clozapine in schizophrenic patients who are refractory and/or intolerant to antipsychotic therapy</TI>
<SO>ClinicalStudyResults.org</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ACTRN12610000954022" MODIFIED="2012-08-12 22:57:40 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN12610000954022" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 22:57:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12610000954022</AU>
<TI>An open randomised clinical trial involving haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone in first episode never-treated psychosis</TI>
<SO>http://www.anzctr.org.au</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Addington-2004a" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Addington 2004a" YEAR="2004">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Addington D, Pantelis C, Dineen M, Loebel A, Murray S, Dunn J</AU>
<TI>Ziprasidone vs risperidone in schizophrenia: 52 weeks&#8217; comparison</TI>
<SO>Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Addington-2009" MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" NAME="Addington 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addington DE, Labelle A, Kulkarni J, Johnson G, Loebel A, Mandel FS</AU>
<TI>A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study</TI>
<SO>Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]</SO>
<YR>2009</YR>
<VL>54</VL>
<NO>1</NO>
<PG>46-54</PG>
<CY>Canada</CY>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19175979"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Agid-2010" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Agid 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agid O, Siu C, Vanderburg D, Pappadopulos E, Brambilla C, Kapur S</AU>
<TI>Scoring algorithm for predicting long-term global functioning in patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2-3</NO>
<PG>256-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allison-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Allison 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allison D, Loebel A, Lombardo I, Siu C</AU>
<TI>Effect of regression to the mean on drug-induced weight change</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>418</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anon-2002" MODIFIED="2012-08-22 11:24:57 +0100" MODIFIED_BY="[Empty name]" NAME="Anon 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-08-22 11:24:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>New Antipsychotic, new benefits?</TI>
<SO>Current Drug Discovery</SO>
<YR>2002</YR>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baldacara-2011" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Baldacara 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP</AU>
<TI>Rapid tranquilization for agitated patients in emergency psychiatric rooms: A randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone</TI>
<SO>Revista Brasileira de Psiquiatria</SO>
<YR>2011</YR>
<VL>33</VL>
<NO>1</NO>
<PG>30-9</PG>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="BIOSIS:PREV201100319442"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuzen-2005" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Beuzen 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen J-N, Pans M, Modell S, Hagens P, McQuade R, Iwamato T, et al</AU>
<TI>Broad effectiveness trial with aripiprazole in Europe Eu-Beta</TI>
<SO>Proceedings of the 13th Congress of the Association of European Psychiatrists; 2005 Apr 2-6; Munich, Germany</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuzen-2006" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Beuzen 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen J-N, Schirr K, Pans M, Hagens P, Kostic D, Carson W, et al</AU>
<TI>Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breier-2005a" MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" NAME="Breier 2005a" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, et al</AU>
<TI>Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>10</NO>
<PG>1879-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caroff-2011" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Caroff 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caroff SN, Hurford I, Lybrand J, Campbell EC</AU>
<TI>Movement disorders induced by antipsychotic drugs: Implications of the catie schizophrenia trial</TI>
<SO>Neurologic Clinics</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>1</NO>
<PG>127-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CATIE" MODIFIED="2012-08-12 23:01:54 +0100" MODIFIED_BY="[Empty name]" NAME="CATIE" YEAR="">
<REFERENCE MODIFIED="2012-08-12 23:01:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Addington D</AU>
<TI>Impact of second generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia</TI>
<SO>Proceedings of the 164th annual general meeting of the American Psychiatric Association; 2011 May 14-18; Honolulu, Hawaii</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, et al</AU>
<TI>Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2011</YR>
<VL>72</VL>
<NO>1</NO>
<PG>75-80</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20868641"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adkins DE, Khachane AN, McClay JL, Aberg K, Bukszar J, Sullivan PF, et al</AU>
<TI>Snp-based analysis of neuroactive ligand-receptor interaction pathways implicates pge2 as a novel mediator of antipsychotic treatment response: Data from the catie study</TI>
<SO>Schizophrenia Research</SO>
<YR>2012</YR>
<VL>135</VL>
<NO>1-3</NO>
<PG>200-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B</AU>
<TI>Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients</TI>
<SO>Psychopharmacology</SO>
<YR>2009</YR>
<VL>206</VL>
<NO>3</NO>
<PG>491-9</PG>
<CY>Germany</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bick P, Knoesen N, Castle D</AU>
<TI>Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists</TI>
<SO>Australasian Psychiatry</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>6</NO>
<PG>465-9</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17999256"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caroff SN, Davis VG, Miller del D, Davis SM, Rosenheck RA, McEvoy JP, et al</AU>
<TI>Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2011</YR>
<VL>72</VL>
<NO>3</NO>
<PG>295-303</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20816031"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, et al</AU>
<TI>The impact of obesity on health care costs among persons with schizophrenia</TI>
<SO>General Hospital Psychiatry</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>1</NO>
<PG>1-7</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19134502"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark SL, Adkins DE, van den Oord EJCG</AU>
<TI>Analysis of efficacy and side effects in catie demonstrates drug response subgroups and potential for personalized medicine</TI>
<SO>Schizophrenia Research</SO>
<YR>2011</YR>
<VL>132</VL>
<NO>2-3</NO>
<PG>114-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Covell NH</AU>
<TI>Antipsychotic medications do not differ substantially in ability to reduce violent behaviour in people with schizophrenia</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>1</NO>
<PG>13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, et al</AU>
<TI>Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>105</VL>
<NO>1-3</NO>
<PG>175-87</PG>
<CY>Netherlands</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies A, Vardeva K, Loze JY, L&#8217;Italien GJ, Sennfalt K, Pugner K, et al</AU>
<TI>Cost-effectiveness of aripiprazole for the management of schizophrenia in the United Kingdom</TI>
<SO>Value in Health</SO>
<YR>2008</YR>
<VL>11</VL>
<PG>A119</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeLisi LE, Nasrallah HA</AU>
<TI>The CATIE schizophrenia effectiveness trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<NO>1</NO>
<PG>5-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fagiolini A, Goracci A</AU>
<TI>The long term--maximising potential for rehabilitation in patients with schizophrenia</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>Suppl 2</NO>
<PG>S123-S9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glick ID, Stekoll AH, Hays S</AU>
<TI>The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>1</NO>
<PG>82-5</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="BIOSIS:PREV201100089386"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haddad PM, Dursun S</AU>
<TI>Selecting antipsychotics in schizophrenia: lessons from CATIE</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>3</NO>
<PG>332-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heinrichs RW</AU>
<TI>Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>6</NO>
<PG>631-2</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17548745"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heres S, Kissling W, Leucht S</AU>
<TI>Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>4</NO>
<PG>112</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17962661"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, et al</AU>
<TI>The association between weight change and symptom reduction in the catie schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2011</YR>
<VL>128</VL>
<NO>1-3</NO>
<PG>166-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 23:01:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, et al</AU>
<TI>Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2010</YR>
<VL>1</VL>
<PG>73-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al</AU>
<TI>Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>6</NO>
<PG>633-47</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17548746"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RS, McEvoy JP, et al</AU>
<TI>Substance use and schizophrenia: Adverse correlates in the catie study sample</TI>
<SO>Schizophrenia Research</SO>
<YR>2011</YR>
<VL>132</VL>
<NO>2-3</NO>
<PG>177-82</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="21872443"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 23:01:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries D, Lawson T</AU>
<TI>Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the catie study</TI>
<SO>Value in Health</SO>
<YR>2011</YR>
<VL>7</VL>
<PG>14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH</AU>
<TI>Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the catie study</TI>
<SO>Schizophrenia Research</SO>
<YR>2011</YR>
<VL>133</VL>
<NO>1-3</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H</AU>
<TI>Treatment response trajectories and antipsychotic medications: Examination of up to18months of treatment in the catie chronic schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2012</YR>
<VL>137</VL>
<NO>1-3</NO>
<PG>141-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al</AU>
<TI>Dr. Lieberman and colleagues reply</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>3</NO>
<PG>555-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>Suppl 1</NO>
<PG>S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McIntyre RS, Cragin L, Sorensen S, Naci H, Baker T, Roussy JP</AU>
<TI>Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in canada: A cost-effectiveness analysis</TI>
<SO>Journal of evaluation in clinical practice</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>4</NO>
<PG>744-55</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20545800"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, et al</AU>
<TI>Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>103</VL>
<NO>1-3</NO>
<PG>104-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al</AU>
<TI>Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study</TI>
<SO>Biological Psychiatry</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>11</NO>
<PG>1013-22</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19640511"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al</AU>
<TI>The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<NO>1</NO>
<PG>9-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:57:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al</AU>
<TI>Extrapyramidal side-effects of antipsychotics in a randomised trial</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>193</VL>
<NO>4</NO>
<PG>279-88</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18827289"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al</AU>
<TI>Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<NO>1</NO>
<PG>33-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA</AU>
<TI>Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>2</NO>
<PG>336-46</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18586692"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS</AU>
<TI>Relationship of cognition and psychopathology to functional impairment in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>165</VL>
<NO>8</NO>
<PG>978-87</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18450928"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00014001</AU>
<TI>Comparative effectiveness of antipsychotic medications in patients with schizophrenia (CATIE schizophrenia trial)</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nasrallah HA, Meyer JM, McEvoy JP, Davis VG, Goff DC, Davis SM</AU>
<TI>Inflammatory markers in schizophrenia: comparing antipsychotic effects in the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>Suppl 1</NO>
<PG>37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nasrallah HA</AU>
<TI>Metabolic findings from the CATIE trial and their relation to tolerability</TI>
<SO>CNS Spectrums</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>7 Suppl 7</NO>
<PG>32-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penn DL, Keefe RSE, Davis SM, Meyer PS, Perkins DO, Losardo D, et al</AU>
<TI>The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>115</VL>
<NO>1</NO>
<PG>17-23</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19766459"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA</AU>
<TI>Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>2-3</NO>
<PG>118-25</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19864114"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S</AU>
<TI>Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of catie data</TI>
<SO>Schizophrenia Research</SO>
<YR>2012</YR>
<VL>137</VL>
<NO>1-3</NO>
<PG>147-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, et al</AU>
<TI>Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia</TI>
<SO>Journal of Behavioral Health Services and Research</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>2</NO>
<PG>215-25</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18246429"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck R, Swartz M, McEvoy J, Stroup TS, Davis S, Keefe RS, et al</AU>
<TI>Second-generation antipsychotics: Reviewing the cost-effectiveness component of the catie trial</TI>
<SO>Expert Review of Pharmacoeconomics and Outcomes Research</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>2</NO>
<PG>103-11</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20528436"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al</AU>
<TI>Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>107</VL>
<NO>1</NO>
<PG>22-9</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18993031"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:55:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, et al</AU>
<TI>Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>113</VL>
<NO>1</NO>
<PG>12-8</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19545976"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck RA</AU>
<TI>Cost-effectiveness of atypical antipsychotics in the CATIE schizophrenia trial</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>Suppl 1</NO>
<PG>S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, et al</AU>
<TI>Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, et al</AU>
<TI>Longitudinal consent-related abilities among research participants with schizophrenia: Results from the catie study</TI>
<SO>Schizophrenia Research</SO>
<YR>2011</YR>
<VL>130</VL>
<NO>1-3</NO>
<PG>47-52</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="21561740"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RSE, et al</AU>
<TI>Results of phase 3 of the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>107</VL>
<NO>1</NO>
<PG>1-12</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19027269"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan P, David G</AU>
<TI>Pharmacogenetic studies in CATIE, a large randomized clinical trial for schizophrenia</TI>
<SO>American Journal of Medical Genetics</SO>
<YR>2006</YR>
<VL>141B</VL>
<NO>7</NO>
<PG>707</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, et al</AU>
<TI>Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>193</VL>
<NO>1</NO>
<PG>37-43</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RSE, et al</AU>
<TI>What CATIE found: results from the schizophrenia trial</TI>
<SO>Psychiatric Services</SO>
<YR>2008</YR>
<VL>59</VL>
<NO>5</NO>
<PG>500-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, et al</AU>
<TI>The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>1-3</NO>
<PG>39-52</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18191383"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsai H-T, Caroff SN, Miller DD, McEvoy J, Lieberman JA, North KE, et al</AU>
<TI>A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial</TI>
<SO>American Journal of Medical Genetics</SO>
<YR>2010</YR>
<VL>153B</VL>
<NO>1</NO>
<PG>336-40</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19475583"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, et al</AU>
<TI>Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the catie study</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2011</YR>
<VL>51</VL>
<NO>11</NO>
<PG>1587-91</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="WOS:000295893400010"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiste A, McGrath LM, Lee PH, Smoller JW</AU>
<TI>Genome-wide association study of smoking behavior among schizophrenics: Preliminary results</TI>
<SO>Biological Psychiatry</SO>
<YR>2011</YR>
<VL>69</VL>
<NO>9 Suppl S</NO>
<PG>250-1</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="BIOSIS:PREV201100354672"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yolken RH, Torrey EF, Lieberman JA, Yang S, Dickerson FB</AU>
<TI>Serological evidence of exposure to herpes simplex virus type 1 is associated with cognitive deficits in the catie schizophrenia sample</TI>
<SO>Schizophrenia Research</SO>
<YR>2011</YR>
<VL>128</VL>
<NO>1-3</NO>
<PG>61-5</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="BIOSIS:PREV201100413831"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang F, Bigos K, Weinberger D</AU>
<TI>Genome-wide analysis of antipsychotic drug response in schizophrenia</TI>
<SO>Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8; Waikoloa, Hawaii</SO>
<YR>2011</YR>
<VL>50</VL>
<PG>135</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ChiCTR_x002d_TRC_x002d_10000934" MODIFIED="2012-08-12 22:53:19 +0100" MODIFIED_BY="[Empty name]" NAME="ChiCTR-TRC-10000934" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 22:53:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ChiCTR-TRC-10000934</AU>
<TI>Pharmacogenomic study of schizophrenia</TI>
<SO>http://www.chictr.org/</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunn-2005" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Dunn 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dunn J, Harrison DJ, Cheli A, Loebel A, Murray S</AU>
<TI>Ziprasidone vs olanzapine: change in CHD risk during a 6-week trial</TI>
<SO>Proceedings of the 13th Association of European Psychiatrists Congress; 2005 Apr 2-6; Munich, Germany</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eng-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Eng 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Eng SM, Strom BL, Faich G, Reynolds RF, D&#8217;Agostino RB, Ruskin J, et al</AU>
<TI>Comparative mortality associated with ziprasidone vs. olanzapine in real-world use: the ziprasidone observational study of cardiac outcomes (ZODIAC)</TI>
<SO>Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EUFEST" MODIFIED="2012-08-22 11:46:50 +0100" MODIFIED_BY="[Empty name]" NAME="EUFEST" YEAR="">
<REFERENCE MODIFIED="2012-08-09 15:10:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boter H, Derks EM, Fleischhacker WW, Davidson M, Kahn RS, Grp ES</AU>
<TI>Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST)</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2010</YR>
<VL>71</VL>
<NO>1</NO>
<PG>58-65</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19852905"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, et al</AU>
<TI>Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>115</VL>
<NO>2-3</NO>
<PG>97-103</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19819114"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Boter H</AU>
<TI>The European First Episode Schizophrenia Trial (EUFEST): comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens</TI>
<SO>http://www.controlled-trials.com</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al</AU>
<TI>"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)": correction</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<NO>6</NO>
<PG>731</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al</AU>
<TI>Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<NO>6</NO>
<PG>675-82</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19369319"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, et al</AU>
<TI>Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>5</NO>
<PG>310-6</PG>
<CY>Netherlands</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, et al</AU>
<TI>Correlates of cognitive impairment in first episode schizophrenia: The eufest study</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>115</VL>
<NO>2-3</NO>
<PG>104-14</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19822407"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahn R, Boter H</AU>
<TI>EUFEST: A randomized pragmatic long-term trial in first episode schizophrenia</TI>
<SO>European Psychiatry</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>S56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kahn R, Fleischhacker WW, Karayal O, Siu C, Pappadopulos E</AU>
<TI>EUFEST: the effects of first and second generation antipsychotics on metabolic and cardiovascular risk factors</TI>
<SO>Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:57:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahn R</AU>
<TI>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial</TI>
<SO>Early Intervention in Psychiatry</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>Suppl 1</NO>
<PG>A24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:57:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al</AU>
<TI>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9618</NO>
<PG>1085-97</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18374841"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kahn RS</AU>
<TI>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial</TI>
<SO>Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>Suppl 1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 23:02:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kahn RS</AU>
<TI>Effectiveness of second-generation antipsychotics in first episode schizophrenia: the EUFEST study</TI>
<SO>Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW, et al</AU>
<TI>Sexual dysfunction in first-episode schizophrenia patients results from european first episode schizophrenia trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>3</NO>
<PG>274-80</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="BIOSIS:PREV201100315033"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-12 23:02:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NTR25</AU>
<TI>The european first episode schizophrenia trial (eufest): Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens</TI>
<SO>http://www.trialregister.nl/trialreg/index.asp</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>No authorshipindicated</AU>
<TI>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder</TI>
<SO>African Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>1</NO>
<PG>82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-22 11:26:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabe-Jablonska J, Pawelczyk T, Jarema M, Olajossy M, Rybakowski J</AU>
<TI>Polish patients of the eufest study after 1 year antipsychotic treatment: Drug discontinuation and metabolic syndrome parameters</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>3</NO>
<PG>S467</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-22 11:46:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rybakowski JK, Vansteelandt K, Szafranski T, Thys E, Jarema M, Wolfgang Fleischhacker W, et al</AU>
<TI>Treatment of depression in first episode of schizophrenia: Results from eufest</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2012 May 22 [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szafranski T, Jarema M, Olajossy M, Rabe-Jablons J, Rybakowski JK</AU>
<TI>Depressive symptoms in the first episode of schizophrenia - analysis of polish results of the eufest study</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2-3</NO>
<PG>503</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="ISI:000276936801329"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 15:10:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, et al</AU>
<TI>Efficacy of antipsychotic drugs against hostility in the european first-episode schizophrenia trial (eufest)</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2011</YR>
<VL>72</VL>
<NO>7</NO>
<PG>955-61</PG>
<IDENTIFIERS MODIFIED="2012-08-09 15:10:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="21824456"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fahnestock-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Fahnestock 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fahnestock P, Haupt D, Schweiger J, Westerhaus E, Stevens A, Flavin K, et al</AU>
<TI>Feasibility of quantifying activity energy expenditure and caloric intake by doubly-labeled water in treated patients with schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>498-9</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischhacker-2009" MODIFIED="2012-08-12 23:03:10 +0100" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 23:03:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fleischhacker WW</AU>
<TI>Safety and tolerability of first and second generation antipsychotics</TI>
<SO>Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geng-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Geng 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geng Y-C, Geng S-X</AU>
<TI>A control study of olanzapine and ziprasidone in the treatment of adolescent schizophrenia</TI>
<TO>&#22885;&#27694;&#24179;&#19982;&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#38738;&#23569;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#30340;&#23545;&#27604;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#25351;&#21335;</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>18</NO>
<PG>60-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldstein-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Goldstein 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein D</AU>
<TI>The genetics and pharmacogenetics of neurocognition in patients with schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>299</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gong-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Gong 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gong D</AU>
<TI>The clinical study of ziprasidone in treatment of first - episode schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#29616;&#20195;&#21307;&#33647;&#26434;&#24535;</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>6</NO>
<PG>61-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gouzoulis_x002d_Mayfrank-2006" MODIFIED="2012-08-12 22:57:40 +0100" MODIFIED_BY="[Empty name]" NAME="Gouzoulis-Mayfrank 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:57:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gouzoulis-Mayfrank E</AU>
<TI>Efficacy and tolerability of ziprasidone versus clozapine in the treatment of dually diagnosed (dd-) patients with schizophrenia and cannabis use disorder: a randomised study</TI>
<SO>http://www.controlled-trials.com</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grootens-2009" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Grootens 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Grootens K, Veelen N, Sitskoom M, Verkes RJ, Kahn R</AU>
<TI>Effects of olanzapine and ziprasidone on cognitve outcome in recent-onset schizophrenia</TI>
<SO>Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grootens-2010" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Grootens 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grootens KP, van Veelen NMJ, Sitskoorn MM, Sabbe BGC, Peuskens J, Buitelaar JK, et al</AU>
<TI>Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>12</NO>
<PG>907-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grootens-2011" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Grootens 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grootens KP, Van Veelen NMJ, Peuskens J, Sabbe BGC, Thys E, Buitelaar JK, et al</AU>
<TI>Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: Results of an 8-week double-blind randomized controlled trial</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2011</YR>
<VL>37</VL>
<NO>2</NO>
<PG>352-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrison-2004a" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Harrison 2004a" YEAR="2004">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harrison D, Mackell J, Leaderer M</AU>
<TI>Ziprasidone versus olanzapine: changes in CHD risk during a 6-week trial</TI>
<SO>Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2004" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Harvey 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Cohen GM, Loebel A</AU>
<TI>Ziprasidone versus olanzapine in schizophrenia: 6-month cognitive data</TI>
<SO>Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2007" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Harvey 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Galluzzo A, Sachetti E, Romeo F, Warrington L</AU>
<TI>Cognitive benefits of ziparasidone vs. clozapine in treatment resistant schizophrenia: a randomized double-blind comparative study</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>560</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2007a" MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" NAME="Harvey 2007a" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey P, Warrington L, Loebel A, Romeo F, Gorini B, Galluzzo A, et al</AU>
<TI>Cognitive effects of ziprasidone and clozapine: results from an 18-week double-blind trial</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>Suppl 4</NO>
<PG>S439</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2007b" MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" NAME="Harvey 2007b" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Harvey PD, Warrington L, Loebel AD, Romeo F, Gorini B, Galluzzo A, et al</AU>
<TI>Cognitive effects of ziprasidone and clozapine in treatment-resistant schizophrenia: results from an 18-week double-blind trial</TI>
<SO>Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2008" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Harvey 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Sacchetti E, Galluzzo A, Romeo F, Gorini B, Bilder RM, et al</AU>
<TI>A randomized double-blind comparison of ziprasidone vs clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>105</VL>
<NO>1-3</NO>
<PG>138-43</PG>
<CY>Netherlands</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Houston-2004" MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" NAME="Houston 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Houston JP, Kaiser CJ, Ahl J, Berg PH, Ahmed S, Carlson C, et al</AU>
<TI>A comparison of the reduction of agitation in schizophrenic patients treated with olanzapine vs. ziprasidone in a 28-week double-blind study</TI>
<SO>Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Jiang 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang C</AU>
<TI>Observation of therapeutic effect of zipraside in the treatment of chronic schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#24930;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>12</NO>
<PG>1389-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2008a" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Jiang 2008a" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang C, Wang G</AU>
<TI>The clincal study on ziprasidone and risperidone in the treatment of patients with first-onset schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>3</NO>
<PG>212-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnsen-2009" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Johnsen 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Johnsen E, Kroken RA, Wentzel-Larsen T, Jorgensen HA</AU>
<TI>A practical, randomized comparison of the effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone</TI>
<SO>Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnsen-2010" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Johnsen 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnsen E, Kroken RA, Wentzel-Larsen T, Jorgensen HA</AU>
<TI>Effectiveness of second-generation antipsychotics: A naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone</TI>
<SO>BMC Psychiatry</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>26</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20334680"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnsen-2010a" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Johnsen 2010a" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnsen E, Kroken RA, Jorgensen HA</AU>
<TI>Anti-depressive effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone: A randomized, naturalistic study</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2-3</NO>
<PG>377-78</PG>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="ISI:000276936801045"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnsen-2011" MODIFIED="2012-08-22 11:47:30 +0100" MODIFIED_BY="[Empty name]" NAME="Johnsen 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 11:47:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Johnsen E, Jorgensen HA, Kroken RA, Loberg EM</AU>
<TI>Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: A pragmatic, randomized trial</TI>
<SO>European Psychiatry</SO>
<YR>2011 Dec 6 [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2012-08-22 11:47:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-22 11:47:21 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="22153730"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-2010" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Kane 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, et al</AU>
<TI>Primary and readjudication mortality results from zodiac, a large simple trial of ziprasidone vs. olanzapine in patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2-3</NO>
<PG>183-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keefe-2008" MODIFIED="2012-08-12 22:59:22 +0100" MODIFIED_BY="[Empty name]" NAME="Keefe 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:59:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keefe RSE, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, et al</AU>
<TI>Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>33</VL>
<NO>6</NO>
<PG>1217-28</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17625502"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2004" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Kinon 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Lipkovich I, Carlson C, Dunayevich E, Edwards SB</AU>
<TI>Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder</TI>
<SO>Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kjelby-2011" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Kjelby 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kjelby E, Jorgensen HA, Kroken RA, Loberg EM, Johnsen E</AU>
<TI>Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: A pragmatic, randomized trial</TI>
<SO>BMC Psychiatry</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>1</NO>
<PG>145</PG>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="21884578"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuwilsky-2010" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Kuwilsky 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuwilsky A, Krumm B, Englisch S, Dressing H, Zink M</AU>
<TI>Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2010</YR>
<VL>43</VL>
<NO>6</NO>
<PG>216-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li H</AU>
<TI>Comparison of efficacy and safety of aripiprazole and ziprasidone in the treatment of schizophrenia</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#21644;&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#27604;&#36739;</TO>
<SO>International Medicine and Health Guidance News [&#22269;&#38469;&#21307;&#33647;&#21355;&#29983;&#23548;&#25253;]</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>11</NO>
<PG>77-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2007a" MODIFIED="2012-08-22 11:56:42 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2007a" YEAR="2007">
<REFERENCE MODIFIED="2012-08-22 11:56:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li X-L, Lu X-B, Zheng S-Y</AU>
<TI>Olanzapine and ziprasidone in the treatment of schizophrenia</TI>
<TO>&#22885;&#27694;&#24179;&#19982;&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>3</NO>
<PG>157-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-2007" MODIFIED="2012-08-22 11:57:31 +0100" MODIFIED_BY="[Empty name]" NAME="Liang 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-22 11:57:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang S</AU>
<TI>Control study of ziprasidone and risperidone in the treatment of schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>China Pharmaceuticals [&#20013;&#22283;&#34277;&#26989;]</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>17</NO>
<PG>52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2008" MODIFIED="2012-08-22 11:57:51 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 11:57:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu X, Jia J</AU>
<TI>Comparative study on ziprasidone and risperidone in the treatment of schizophrenia patients</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#21644;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of the Binzhou Medical College</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>2</NO>
<PG>119-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2008a" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2008a" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu W, Zhang X</AU>
<TI>A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia with predominantly negative symptoms</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#38463;&#31435;&#21708;&#21777;&#27835;&#30103;&#20197;&#38452;&#24615;&#30151;&#29366;&#20026;&#20027;&#30340;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>2</NO>
<PG>124-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loza-2011" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Loza 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loza B, Patejuk-Mazurek I, Polikowska M, Bednarski P, Mosiolek A, Kwasna J, et al</AU>
<TI>Crossover comparison of serum glycemia variability of intramuscular forms of antipsychotics: Aripiprazole, olanzapine and ziprasidone</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>Suppl 3</NO>
<PG>S499-500</PG>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="BIOSIS:PREV201200044572"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu C</AU>
<TI>Comparative study of ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#32500;&#24605;&#36890;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#38738;&#23707;&#21307;&#33647;&#21355;&#29983;</SO>
<YR>2007</YR>
<VL>39</VL>
<NO>5</NO>
<PG>336-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu X, Wang J-L</AU>
<TI>Comparing ziprasidone and olanzapine in treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#22885;&#27694;&#24179;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>5</NO>
<PG>335-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lublin-2009" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Lublin 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA</AU>
<TI>Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial</TI>
<SO>World Journal of Biological Psychiatry</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>4 Pt 3</NO>
<PG>710-8</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-2005" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Meyer 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer J, Loebel A, Nasrallah H</AU>
<TI>Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>Suppl 1</NO>
<PG>S202-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-2006" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Meyer 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meyer J, Nasrallah H, Loebel A, Parsons B</AU>
<TI>Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-2006a" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Meyer 2006a" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer J, Loebel A, Nasrallah H, Templeton HB</AU>
<TI>Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>8 Suppl</NO>
<PG>159S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-2006b" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Meyer 2006b" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meyer J, Loebel A, Nasrallah H, Parsons B</AU>
<TI>Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: Results of a 6-week randomized study in patients with acute schizophrenia</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland</SO>
<YR>2006</YR>
<PG>93</PG>
<PB>Elsevier Science Bv</PB>
<CY>Davos, SWITZERLAND</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murray-2003" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Murray 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Murray SR, Addington DE, Pantelis C, Dineen M, Romano SJ</AU>
<TI>Ziprasidone versus risperidone in schizophrenia: a 52 weeks' comparison</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nai-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Nai 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nai X-Z, Shi L, Song C-L, Zhao S-F</AU>
<TI>Comparative study on ziprasidone and risperidone in treating first episode schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of the Henan Medical College for Staff and Workers</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>3</NO>
<PG>226-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00077727" MODIFIED="2012-08-12 23:03:58 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00077727" YEAR="2004">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00077727</AU>
<TI>A study of galantamine hbr as an adjunctive treatment to atypical antipsychotic medications in outpatients with schizophrenia and associated cognitive deficits</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00145444" MODIFIED="2012-08-12 23:04:08 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00145444" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00145444</AU>
<TI>A multicenter, double-blind, randomized trial of ziprasidone (80 - 160 mg) versus olanzapine (10 - 20 mg) in patients with recent-onset schizophrenia, schizoaffective and schizophreniform disorder</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00148564" MODIFIED="2012-08-12 23:04:16 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00148564" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00148564</AU>
<TI>Energy homeostasis and metabolism in patients with schizophrenic disorders under treatment with atypical antipsychotics</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00159770" MODIFIED="2012-08-12 23:04:30 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00159770" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00159770</AU>
<TI>Tolerability, safety, and efficacy of ziprasidone (80 - 160 mg/d) versus olanzapine (10 - 20 mg/d), risperidone (4 - 8 mg/d) or quetiapine (300 - 750 mg/d) in pretreated patients with schizophrenia, schizoaffective disorder or schizophreniform disorders - a 12-week open-label, multicenter clinical trial</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00224315" MODIFIED="2012-08-12 23:04:23 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00224315" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00224315</AU>
<TI>Clozapine-augmentation with ziprasidone or risperidone, a randomized, prospective trial</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00225498" MODIFIED="2012-08-12 23:04:58 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00225498" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00225498</AU>
<TI>Neurocognitive effects of ziprasidone: relationship to working memory and dopamine blockade</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00239109" MODIFIED="2012-08-12 23:04:42 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00239109" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00239109</AU>
<TI>Ziprasidone versus olanzapine in the treatment of schizophrenia: a six months, double blind randomized, parallel group study</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00283179" MODIFIED="2012-08-12 23:05:18 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00283179" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00283179</AU>
<TI>Efficacy and safety of aripiprazole in the treatment of acutely relapsed patients with schizophrenia or schizoaffective disorder with risperidone as an active control</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00418171" MODIFIED="2012-08-12 23:05:05 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00418171" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00418171</AU>
<TI>An international, multicenter, large simple trial (LST) to compare the cardiovascular safety of ziprasidone and olanzapine</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00515723" MODIFIED="2012-08-12 23:05:27 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00515723" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00515723</AU>
<TI>Glucose and lipid metabolism on antipsychotic medication</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00634348" MODIFIED="2012-08-12 23:05:36 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00634348" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00634348</AU>
<TI>A study comparing the efficacy and safety of ziprasidone and aripiprazole for the treatment of schizophrenia or schizoaffective disorder in hospitalized patients</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00645372" MODIFIED="2012-08-12 23:05:50 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00645372" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00645372</AU>
<TI>A study to compare the efficacy and safety of ziprasidone and risperidone for the treatment of schizophrenia in Chinese patients</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00645515" MODIFIED="2012-08-12 23:05:43 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00645515" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00645515</AU>
<TI>A study comparing the safety and efficacy of ziprasidone and risperidone for the treatment of chronic schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00649844" MODIFIED="2012-08-12 23:06:08 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00649844" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00649844</AU>
<TI>A study comparing the efficacy and tolerability of ziprasidone vs clozapine for the treatment of schizophrenia in patients who continue to have symptoms on or cannot tolerate other antipsychotic drugs</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00932529" MODIFIED="2012-08-12 23:06:17 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00932529" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00932529</AU>
<TI>Use, effects and side-effects of second-generation antipsychotics in a naturalistic setting</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newcomer-2009" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Newcomer 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Newcomer JW, Haupt DW, Fahnestock PA, Flavin KS, Nicol GE, Schweiger JA, et al</AU>
<TI>Changes in adiposity, insulin sensitivity and lipid metabolism during randomized antipsychotic treatment in schizophrenia</TI>
<SO>Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newcomer-2009a" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Newcomer 2009a" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Newcomer JW, Haupt D, Fahnestock P, Flavin K, Nicol G, Schweiger J, et al</AU>
<TI>Changes in adiposity, insulin sensitivity and lipid metabolism during randomized antipsychotic treatment in schizophrenia</TI>
<SO>Proceedings of the 12th International Congress on Schizophrenia Research; 2009 Mar 28-Apr 1; San Diego, CA</SO>
<YR>2009</YR>
<PG>361-2</PG>
<PB>Oxford Univ Press</PB>
<CY>San Diego, CA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nie-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Nie 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nie S-C, Zhang Y-C, Dai M-Z</AU>
<TI>A comparative study of ziprasidone and clozapine in treating schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>11</NO>
<PG>952-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olfson-2011" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Olfson 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olfson M, Ascher-Svanum H, Faries DE, Marcus SC</AU>
<TI>Predicting psychiatric hospital admission among adults with schizophrenia</TI>
<SO>Psychiatric Services</SO>
<YR>2011</YR>
<VL>62</VL>
<NO>10</NO>
<PG>1138-45</PG>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="21969639"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parsons-2008" MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" NAME="Parsons 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Parsons B, Zhang H, Shu L, Li H, Gu N, Wang G, et al</AU>
<TI>double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia</TI>
<SO>Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfizer-2005" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Pfizer 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pfizer</AU>
<TI>Effects of ziprasidone (80 - 160 mg/d) versus olanzapine (10-20 mg/d) on cognitive function in patients with schizophrenia or schizophrenic disorder previously treated with a typical neuroleptic drug (fluphenazine) - multicenter, randomized, double-blind (double-dummy), comparative study over 4 weeks with an open-label ziprasidone extension phase of up to one year</TI>
<SO>http://www.clinicalstudyresults.org/</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfizer-2006" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Pfizer 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pfizer</AU>
<TI>Down-titration schedules of amisulpride in patients suffering from schizophrenia or schizoaffective disorders when initiating therapy with ziprasidone: an open-label, three-months study</TI>
<SO>http://www.clinicalstudyresults.org/</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfizer-2007" MODIFIED="2012-08-12 23:06:29 +0100" MODIFIED_BY="[Empty name]" NAME="Pfizer 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 23:06:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pfizer</AU>
<TI>A six week, multicenter, double-blind, double-dummy, parallel, comparative study to compare the efficacy, safety and tolerability of ziprasidone with risperidone in the treatment of Chinese subjects with acute exacerbation of schizophrenia</TI>
<SO>ClinicalStudyResults.org</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rappard-2006" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Rappard 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rappard F, Meyer J, Loebel A, Nasrallah H</AU>
<TI>Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>S287</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ross-2005" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Ross 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ross DE</AU>
<TI>"randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder": comment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>7</NO>
<PG>1391</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roychowdhury-2004" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Roychowdhury 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Roychowdhury SM, Sethuraman G, Phillips GA, Enerson M, Berg PH, Breier A</AU>
<TI>Comparison of olanzapine to other atypical antipsychotics in preventing relapse in patients with schizophrenia</TI>
<SO>Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2006a" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2006a" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L</AU>
<TI>Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2006b" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2006b" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L, et al</AU>
<TI>Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial</TI>
<SO>Biological Psychiatry</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>8 Suppl</NO>
<PG>158S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2006c" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2006c" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Romeo F, Galluzzo A, Valsecchi P, Gorini B, Warrington L</AU>
<TI>Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>S274</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sacchetti E, Galluzzo A, Romeo F, Gorini B, Warrington L</AU>
<TI>Comparison of ziprasidone and clozapine in subgroups of patients with treatment-resistant schizophrenia</TI>
<SO>Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2007a" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2007a" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sacchetti E, Galluzzo A, Romeo F, Gorini B, Warrington L</AU>
<TI>Long-term efficacy of ziprasidone in treatment- resistant schizophrenia: results from a 1-year, open-label extension study</TI>
<SO>Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2009" MODIFIED="2012-08-22 11:54:06 +0100" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 11:54:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E</AU>
<TI>Efficacy of ziprasidone in the treatment of resistant schizophrenia (organized by Pfizer)</TI>
<SO>World Psychiatry</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>Suppl 1</NO>
<PG>SME4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2009a" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2009a" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L</AU>
<TI>Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>110</VL>
<NO>1-3</NO>
<PG>80-9</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19269791"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2009b" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2009b" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L</AU>
<TI>Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study (DOI:10.1016/j.schres.2009.02.017)</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>113</VL>
<NO>1</NO>
<PG>112-21</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19606529"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2009c" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2009c" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L</AU>
<TI>"Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study": corrigendum</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>113</VL>
<NO>1</NO>
<PG>111</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samochowiec-2009" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Samochowiec 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Samochowiec J, Tybura P, Wysiecka JP</AU>
<TI>Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia</TI>
<SO>Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schooler-2011" MODIFIED="2012-08-12 23:06:47 +0100" MODIFIED_BY="[Empty name]" NAME="Schooler 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 23:06:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schooler NR, Buckley PF, Mintz J, Goff DC, Kopelowicz A, Lauriello J, et al</AU>
<TI>Proactive: Initial results of an rct comparing long-acting injectable risperidone to 2nd generation oral antipsychotics</TI>
<SO>Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8;a, Waikoloa, Hawaii</SO>
<YR>2011</YR>
<PG>S104-S5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schooler-2011a" MODIFIED="2012-08-12 23:06:59 +0100" MODIFIED_BY="[Empty name]" NAME="Schooler 2011a" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 23:06:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schooler NR, Buckley PF, Mintz J, Goff DC, Kopelowicz A, Lauriello J, et al</AU>
<TI>Proactive: Initial results of an rct comparing long-acting injectable risperidone to 2nd generation oral antipsychotics</TI>
<SO>Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8; Waikoloa, Hawaii</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shang-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Shang 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shang X-Z, Zhu J-S, Zeng D-Z, Cheng P, Sun Q-X, Chen K-Q</AU>
<TI>Comparative analysis between ziprasidone and risperidone in treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#20998;&#26512;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>6</NO>
<PG>392-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shang-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Shang 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shang X-Z, Zeng D-Z, Zhu J-S</AU>
<TI>Influence of ziprasidone on quality on life of patients with schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#29983;&#27963;&#36136;&#37327;&#30340;&#24433;&#21709;</TO>
<SO>Chinese Journal of Rehabilitation [&#20013;&#22283;&#24247;&#24489;]</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>1</NO>
<PG>69-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shuai-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Shuai 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shuai H-L</AU>
<TI>Ziprasidone versus risperidone in the treatment of schizophrenia: cost-effectiveness analysis</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#25104;&#26412;-&#25928;&#26524;&#20998;&#26512;</TO>
<SO>Evaluation and Analysis of Drug-Use in Hospital of China</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>4</NO>
<PG>289-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-2005" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO</AU>
<TI>Correction: "randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder"</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>3</NO>
<PG>644</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-2006" MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Simpson GM, Loebel A, Warrington L, Yang R</AU>
<TI>Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder: results of a double-blind, six-week study, with a six-month, double-blind, continuation phase</TI>
<SO>Progress in Neurotherapeutics and Neuropsychopharmacology</SO>
<YR>2006</YR>
<PG>149-63, xi</PG>
<ED>Cummings JL</ED>
<PB>Cambridge University Press</PB>
<CY>New York, NY, US</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sonmez-2009" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Sonmez 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sonmez B, Vardar E, Altun GD, Abay E, Bedel D</AU>
<TI>Ziprasidone versus risperidone: comparison of clinical efficacy and cardiac, extrapyramidal, and metabolic side effects in patients with acute exacerbation of schizophrenia and schizoaffective disorders</TI>
<SO>Bulletin of Clinical Psychopharmacology</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>2</NO>
<PG>101-12</PG>
<CY>Turkey</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sramek-2003" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Sramek 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sramek JJ, Cutler NR, Shiovitz T</AU>
<TI>The effect of antipsychotics on plasma lipids</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6</NO>
<PG>679-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Street-2000" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Street 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street JS, Tollefson GD, Tohen M, Sanger TM, Clark WS, Gannon KS, et al</AU>
<TI>Olanzapine for psychotic conditions in the elderly</TI>
<SO>Psychiatric Annals</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>191-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strom-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Strom 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strom B, Faich G, Reynolds RF, Eng SM, Kane M</AU>
<TI>Cardiac risk factors and schizophrenia: an analysis of 18,094 patients enrolled in an international comparative trial of olanzapine and ziprasidone</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>462</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strom-2007a" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Strom 2007a" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Strom BL, Faich G, Lombardo I, Reynolds RF, Eng SM, Kane JM</AU>
<TI>Cardiac risk factors and schizophrenia: an analysis of 18,094 patients enrolled in an international comparative trial of olanzapine and ziprasidone</TI>
<SO>Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strom-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Strom 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strom BL, Faich GA, Reynolds RF, Eng SM, D'Agostino RB, Ruskin JN, et al</AU>
<TI>The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>1</NO>
<PG>114-21</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18312045"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strom-2010" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Strom 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, et al</AU>
<TI>The Ziprasidone Observational Study of Cardiac outcomes (ZODIAC): findings from a large simple trial of ziprasidone vs. Olanzapine in real-world use among 18154 patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2-3</NO>
<PG>311</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strom-2011" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Strom 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, et al</AU>
<TI>Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The ziprasidone observational study of cardiac outcomes (zodiac)</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2011</YR>
<VL>168</VL>
<NO>2</NO>
<PG>193-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun Q-X, Zeng D-Z, Chen K-Q</AU>
<TI>Clinical comparative study of ziprasidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#20020;&#24202;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>3</NO>
<PG>150-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-2005a" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Svestka 2005a" YEAR="2005">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J</AU>
<TI>Comparison of olanzapine versus ziprasidone in acute schizophrenia</TI>
<TO>Olanzapin v. ziprasidon v lecbe akutnich exacerbaci schizofrennich a schizoafektivnich poruch</TO>
<SO>Psychiatrie Prague</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swartz-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Swartz 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al</AU>
<TI>Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<NO>3</NO>
<PG>428-36</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17329467"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tao-2008" MODIFIED="2012-08-12 23:07:19 +0100" MODIFIED_BY="[Empty name]" NAME="Tao 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 23:07:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tao S-W, Chen Q, Yang C, Pan R-D, Pan T-W, Li L, et al</AU>
<TI>A comparison of the effects on lipid metabolic among four different atypical antipsychotic agents</TI>
<TO>4&#31181;&#38750;&#20856;&#22411;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#33026;&#20195;&#35874;&#30340;&#24433;&#21709;</TO>
<SO>Journal of the Youjiang Medical College for Nationalities</SO>
<YR>2008</YR>
<VL>6</VL>
<PG>927-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Taylor 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor D</AU>
<TI>Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>3</NO>
<PG>76</PG>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17652558"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Brunt-2004" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Van Brunt 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Van Brunt DL, Namjoshi M, Xu W, Berg PH, Roychowdhury SM, Cavazzoni P, et al</AU>
<TI>Clinical efficacy and quality of life in a clinical trial comparing olanzapine and ziprasidone</TI>
<SO>Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Veelen-2010" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Van Veelen 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Veelen NMJ, Grootens KP, Peuskens J, Sabbe BGC, Salden ME, Verkes RJ, et al</AU>
<TI>Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>120</VL>
<NO>1-3</NO>
<PG>191-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007" MODIFIED="2012-08-12 23:08:52 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 23:08:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang Y, Guo H, Liu Y</AU>
<TI>Comparative study on the influence of ziprasidone and clozapine on quality of life in schizophrenic</TI>
<SO>Proceedings of the 8th National Academic Congress of CSP with the Regional Meeting of the WPA; 2007 Sep 20-23; Shanghai</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008" MODIFIED="2012-08-22 11:59:26 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 11:59:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang G-P, Xie R, Pei G-X</AU>
<TI>Comparative study between ziprasidone and risperidone in treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>1</NO>
<PG>55-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008a" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2008a" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X-Q, Zhou H-X, Zhang Y-L, Li G, Xie P-L</AU>
<TI>A comparison study of ziprasidone and risperidone in treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>1</NO>
<PG>35-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008b" MODIFIED="2012-08-22 11:59:47 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2008b" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 11:59:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang L, Guo H, Feng W</AU>
<TI>Contrast study of treating schizophrenia by ziprasidone and risperidone</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#29255;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Medical Forum [&#21307;&#33647;&#35770;&#22363;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>1</NO>
<PG>11-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warrington-2006" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Warrington 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warrington L, Harvey PD, Galluzzo A, Sachetti E, Romeo F</AU>
<TI>Cognitive benefits of ziparasidone vs. clozapine in treatment resistant schizophrenia: a randomized double-blind comparative study</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>Suppl 1</NO>
<PG>S243</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Wei 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei Y, Wang X</AU>
<TI>A comparative study of ziprasidone and risperdone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Sichuan Mental Health [&#22235;&#24029;&#31934;&#31070;&#21355;&#29983;]</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>2</NO>
<PG>94-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiden-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Weiden 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE</AU>
<TI>Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>33</VL>
<NO>5</NO>
<PG>985-94</PG>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17637612"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-2007" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Wolf 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolf J, Janssen F, Lublin H, Salokangas RKR, Allain H, Smeraldi E, et al</AU>
<TI>A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA)</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>10</NO>
<PG>2313-23</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17706003"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woodruff-2003" MODIFIED="2012-08-12 22:57:40 +0100" MODIFIED_BY="[Empty name]" NAME="Woodruff 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-08-12 22:57:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Woodruff P</AU>
<TI>A phase IIIb, 12 week, muli-centre, double-blind, double-dummy, randomised, parallel group study comparing the effects of ziprasidone (40-80mg bid) versus olanzapine (5-20 mg od) on quality of life in the treatment of schizophrenia</TI>
<SO>National Research Register</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2012" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Wu 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu XL, Wang JH, Hu SH, Tao J</AU>
<TI>Serum prolactin levels and the acute-phase efficacy in drug-naive schizophrenia treated with ziprasidone and olanzapine (translated version)</TI>
<SO>East Asian Archives of Psychiatry</SO>
<YR>2012</YR>
<VL>22</VL>
<NO>1</NO>
<PG>7-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang J, Zhu G-H, Xie J</AU>
<TI>A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#38463;&#31435;&#21708;&#21777;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>23</NO>
<PG>2760-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yi-2007" MODIFIED="2012-08-22 12:00:10 +0100" MODIFIED_BY="[Empty name]" NAME="Yi 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-22 12:00:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yi Q-M, Zhang B</AU>
<TI>A comparative study between ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#21644;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of the North Sichuan Medical College</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>4</NO>
<PG>328-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yue-2010" MODIFIED="2012-08-12 23:09:06 +0100" MODIFIED_BY="[Empty name]" NAME="Yue 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 23:09:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Yue W, Zhang D</AU>
<TI>Pharmacogenomic study of schizophrenia</TI>
<SO>http://www.chictr.org/</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang W-M</AU>
<TI>Contrast study of treating schizophrenia by ziprasidone, clozapine and risperidone</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#12289;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>11</NO>
<PG>1122-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2008a" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2008a" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang X, Zhang J</AU>
<TI>A comparative study on the efficacy of ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#23545;&#29031;&#20998;&#26512;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>5</NO>
<PG>367-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2008b" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2008b" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang S-J, Wang M-J, Hu J</AU>
<TI>Comparative analysis between ziprasidone and risperidone in treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>17</NO>
<PG>2002, 2004</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2011" MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:57:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang H, Li H, Shu L, Gu N, Wang G, Weng Y, et al</AU>
<TI>double-blind comparison of ziprasidone and risperidone in the treatment of chinese patients with acute exacerbation of schizophrenia</TI>
<SO>Neuropsychiatric Disease and Treatment</SO>
<YR>2011</YR>
<VL>7</VL>
<PG>77-85</PG>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="21552309"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Zhao 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao L-P, Wang J-C</AU>
<TI>A comparative study between ziprasidone and clozapine in the treatment of patients with schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>5</NO>
<PG>403-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2010" MODIFIED="2012-08-22 12:04:18 +0100" MODIFIED_BY="[Empty name]" NAME="Zhu 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 12:04:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu H</AU>
<TI>Ziprasidone and clozapine in treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>1</NO>
<PG>16-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zimbroff-2007" MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Zimbroff 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:58:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zimbroff D, Warrington L, Loebel A, Yang R, Siu C</AU>
<TI>Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>6</NO>
<PG>363-70</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17917555"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zink-2009" MODIFIED="2012-08-12 22:57:40 +0100" MODIFIED_BY="[Empty name]" NAME="Zink 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:57:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zink M, Kuwilsky A, Krumm B, Dressing H</AU>
<TI>Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>3</NO>
<PG>305-14</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2012-08-12 22:16:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18562423"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zou-2008" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Zou 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zou X-H, Zhou Y-F, He L-Y, Jin Y, Rong W</AU>
<TI>A comparative study of ziprasidone and olanzapine in schizophrenia with predominantly negative symptoms</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#22885;&#27694;&#24179;&#27835;&#30103;&#20197;&#38452;&#24615;&#30151;&#29366;&#20026;&#20027;&#30340;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Strait Pharmaceutical Journal</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>3</NO>
<PG>87-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x4efb__x5217__x002c_-2009" MODIFIED="2012-08-22 12:05:25 +0100" MODIFIED_BY="[Empty name]" NAME="&#20219;&#21015;, 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 12:05:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#20219;&#21015;, &#26417;&#27589;&#24179;, &#23385;&#33738;&#27700;</AU>
<TI>30 cases of ziprasidone in combination with low-dose clozapine treatment of refractory schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#32852;&#21512;&#23567;&#21058;&#37327;&#27695;&#27694;&#24179;&#27835;&#30103;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;30&#20363;</TO>
<SO>Herald of Medicine [&#21307;&#33647;&#23548;&#25253;] [&#37291;&#34277;&#23566;&#22577;]</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>7</NO>
<PG>872-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x4f55__x6587__x521a_-2011" MODIFIED="2012-08-22 12:07:02 +0100" MODIFIED_BY="[Empty name]" NAME="&#20309;&#25991;&#21018; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 12:07:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#20309;&#25991;&#21018;</AU>
<TI>Ziprasidone, and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#27604;&#36739;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#25351;&#21335;</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>20</NO>
<PG>50-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5170__x5e86__x699c_-2011" MODIFIED="2012-08-22 14:43:16 +0100" MODIFIED_BY="[Empty name]" NAME="&#20848;&#24198;&#27036; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 12:07:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#20848;&#24198;&#27036;, &#40644;&#28023;&#29141;, &#38518;&#19990;&#27494;</AU>
<TI>Three kinds of atypical antipsychotic drugs on the ECG of patients with schizophrenia</TI>
<TO>3&#31181;&#38750;&#20856;&#22411;&#25239;&#31934;&#31070;&#30149;&#33647;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#24515;&#30005;&#22270;&#30340;&#24433;&#21709;</TO>
<SO>&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>04</NO>
<PG>267-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5189__x660c__x534e_-2011" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="&#20873;&#26124;&#21326; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#20873;&#26124;&#21326;</AU>
<TI>Ziprasidone, and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22806;&#21307;&#23398;&#30740;&#31350;</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>27</NO>
<PG>124</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5192__x96f7__x660e_-2010" MODIFIED="2012-08-22 12:16:53 +0100" MODIFIED_BY="[Empty name]" NAME="&#20882;&#38647;&#26126; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 12:16:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#20882;&#38647;&#26126;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#21335;&#36890;&#22823;&#23398;&#23398;&#25253;(&#21307;&#23398;&#29256;)</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>4</NO>
<PG>311-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x51af__x9f99__x559c_-2010" MODIFIED="2012-08-22 14:43:24 +0100" MODIFIED_BY="[Empty name]" NAME="&#20911;&#40857;&#21916; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 12:18:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#20911;&#40857;&#21916;, &#21016;&#24314;&#21326;, &#26446;&#23071;, &#26472;&#32654;&#23071;, &#24352;&#21355;&#21326;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>2</NO>
<PG>106-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x56fd__x96c4_-2007" MODIFIED="2012-08-22 14:43:31 +0100" MODIFIED_BY="[Empty name]" NAME="&#21016;&#22269;&#38596; 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21016;&#22269;&#38596;, &#38451;&#29756;, &#34203;&#22763;&#20581;, &#34081;&#39062;&#33714;, &#26446;&#29233;&#20964;</AU>
<TI>A controlled study of domestic ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#22269;&#20135;&#40784;&#25289;&#35199;&#37230;&#19982;&#32500;&#24605;&#36890;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>International Medicine and Health Guidance News [&#22269;&#38469;&#21307;&#33647;&#21355;&#29983;&#23548;&#25253;]</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>7</NO>
<PG>48-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x5fe0_-2009" MODIFIED="2012-08-22 14:43:38 +0100" MODIFIED_BY="[Empty name]" NAME="&#21016;&#24544; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 12:20:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21016;&#24544;, &#29579;&#31435;&#23071;, &#26446;&#20029;</AU>
<TI>Quetiapine and ziprasidone on the impact of ECG qtc</TI>
<TO>&#22862;&#30827;&#24179;&#21450;&#40784;&#25289;&#35199;&#37230;&#23545;&#24515;&#30005;&#22270;qtc&#24433;&#21709;&#30340;&#30740;&#31350;</TO>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>17</VL>
<NO>11</NO>
<PG>1302-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x6653__x7ea2_-2008" MODIFIED="2012-08-22 14:43:44 +0100" MODIFIED_BY="[Empty name]" NAME="&#21016;&#26195;&#32418; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 12:20:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21016;&#26195;&#32418;, &#26446;&#21355;&#20891;</AU>
<TI>Ziprasidone and risperidone in the treatment of 60 female patients with schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;60&#20363;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>23</NO>
<PG>2778, 2780</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x6d2a__x79cb_-2010" MODIFIED="2012-08-22 14:43:52 +0100" MODIFIED_BY="[Empty name]" NAME="&#21016;&#27946;&#31179; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 12:44:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21016;&#27946;&#31179;, &#20005;&#26126;, &#27611;&#26143;</AU>
<TI>Ziprasidone and risperidone in the treatment of Schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Jilin Medical Journal</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>22</NO>
<PG>3636-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x743c__x534e_-2011" MODIFIED="2012-08-22 12:44:35 +0100" MODIFIED_BY="[Empty name]" NAME="&#21016;&#29756;&#21326; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 12:44:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21016;&#29756;&#21326;</AU>
<TI>Pharmacoeconomic analysis of clinical four antipsychotic treatment of schizophrenia</TI>
<TO>&#20020;&#24202;&#24120;&#29992;&#22235;&#31181;&#25239;&#31934;&#31070;&#30149;&#33647;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#33647;&#29289;&#32463;&#27982;&#23398;&#20998;&#26512;</TO>
<SO>&#20013;&#22269;&#24403;&#20195;&#21307;&#33647;</SO>
<YR>2011</YR>
<VL>18</VL>
<NO>21</NO>
<PG>182-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5355__x7f8e__x8273_-2009" MODIFIED="2012-08-22 12:45:25 +0100" MODIFIED_BY="[Empty name]" NAME="&#21333;&#32654;&#33395; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 12:45:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21333;&#32654;&#33395;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia double-blind controlled study</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21452;&#30450;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>1</NO>
<PG>55-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5362__x6bbf__x519b_-2011" MODIFIED="2012-08-22 14:44:00 +0100" MODIFIED_BY="[Empty name]" NAME="&#21346;&#27583;&#20891; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 12:45:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21346;&#27583;&#20891;, &#23425;&#27905;, &#21556;&#32988;</AU>
<TI>Ziprasidone and quetiapine in the treatment of schizophrenia and security</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#22862;&#30827;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#19982;&#23433;&#20840;&#24615;&#27604;&#36739;</TO>
<SO>&#20013;&#22269;&#33647;&#19994;</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>15</NO>
<PG>75-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5362__x6bbf__x519b_-2011a" MODIFIED="2012-08-22 14:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="&#21346;&#27583;&#20891; 2011a" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 12:46:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21346;&#27583;&#20891;, &#23425;&#27905;, &#21556;&#32988;</AU>
<TI>The treatment of schizophrenia, the efficacy and safety of ziprasidone hydrochloride</TI>
<TO>&#30416;&#37240;&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#37253;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#21450;&#23433;&#20840;&#24615;&#27604;&#36739;</TO>
<SO>&#37325;&#24198;&#21307;&#23398;</SO>
<YR>2011</YR>
<VL>40</VL>
<NO>17</NO>
<PG>1693-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5434__x8fdc__x82b3_-2008" MODIFIED="2012-08-22 12:46:46 +0100" MODIFIED_BY="[Empty name]" NAME="&#21556;&#36828;&#33459; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 12:46:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21556;&#36828;&#33459;</AU>
<TI>Control study observed 50 cases of the treatment of youth schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#38738;&#26149;&#22411;&#31934;&#31070;&#20998;&#35010;&#30151;50&#20363;&#23545;&#29031;&#30740;&#31350;&#35266;&#23519;</TO>
<SO>&#20853;&#22242;&#21307;&#23398;</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>2</NO>
<PG>47-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5468__x4e91_-2009" MODIFIED="2012-08-22 12:47:31 +0100" MODIFIED_BY="[Empty name]" NAME="&#21608;&#20113; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 12:47:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21608;&#20113;</AU>
<TI>Ziprasidone and clozapine in the treatment of the negative symptoms of schizophrenia research </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#38452;&#24615;&#30151;&#29366;&#30740;&#31350;</TO>
<SO>Modern Research of Integrated Chinese and Western Medicine [&#29616;&#20195;&#20013;&#35199;&#21307;&#32467;&#21512;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>18</NO>
<PG>2142-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5468__x6d77__x6653_-2009" MODIFIED="2012-08-22 14:44:14 +0100" MODIFIED_BY="[Empty name]" NAME="&#21608;&#28023;&#26195; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 12:48:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21608;&#28023;&#26195;, &#19969;&#24535;&#26480;, &#29579;&#20891;, &#29579;&#23567;&#20840;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>3</NO>
<PG>190-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x55bb__x5fd7__x654f_-2010" MODIFIED="2012-08-22 14:44:21 +0100" MODIFIED_BY="[Empty name]" NAME="&#21947;&#24535;&#25935; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 12:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21947;&#24535;&#25935;, &#37041;&#32946;&#24179;, &#24352;&#19994;&#31077;</AU>
<TI>Ziprasidone and aripiprazole the efficacy and safety of the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#38463;&#31435;&#21708;&#21777;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#21644;&#23433;&#20840;&#24615;&#27604;&#36739;</TO>
<SO>&#23454;&#29992;&#20020;&#24202;&#21307;&#23398;</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>10</NO>
<PG>17-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5b59__x4ed8__x6839_-2009" MODIFIED="2012-08-22 14:44:46 +0100" MODIFIED_BY="[Empty name]" NAME="&#23385;&#20184;&#26681; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 12:51:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23385;&#20184;&#26681;, &#33891;&#29790;&#20848;, &#29579;&#20113;, &#39532;&#25964;</AU>
<TI>Ziprasidone for schizophrenia and the effect of quality of life</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#23545;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#30103;&#25928;&#21450;&#29983;&#27963;&#36136;&#37327;&#30340;&#24433;&#21709;</TO>
<SO>Occupation and Health [&#32844;&#19994;&#19982;&#20581;&#24247;]</SO>
<YR>2009</YR>
<VL>25</VL>
<NO>19</NO>
<PG>2109-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5b59__x4ed8__x6839_-2009a" MODIFIED="2012-08-22 14:44:26 +0100" MODIFIED_BY="[Empty name]" NAME="&#23385;&#20184;&#26681; 2009a" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 12:52:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23385;&#20184;&#26681;, &#33891;&#29790;&#20848;, &#36213;&#23781;, &#28504;&#33495;</AU>
<TI>Efficacy and adverse reactions of ziprasidone in 30 female patients with schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;30&#20363;&#30340;&#30103;&#25928;&#21450;&#19981;&#33391;&#21453;&#24212;</TO>
<SO>Chinese Journal of New Drugs and Clinical Remedies [&#20013;&#22269;&#26032;&#33647;&#19982;&#20020;&#24202;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>5</NO>
<PG>360-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5b59__x5e73_-2011" MODIFIED="2012-08-22 14:44:53 +0100" MODIFIED_BY="[Empty name]" NAME="&#23385;&#24179; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 12:52:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23385;&#24179;, &#27575;&#20891;&#27874;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia analysis</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#20998;&#26512;</TO>
<SO>&#40657;&#40857;&#27743;&#21307;&#33647;&#31185;&#23398;</SO>
<YR>2011</YR>
<VL>34</VL>
<NO>04</NO>
<PG>16-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5b59__x6bc5_-2008" MODIFIED="2012-08-22 14:45:08 +0100" MODIFIED_BY="[Empty name]" NAME="&#23385;&#27589; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 12:53:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23385;&#27589;, &#37011;&#26195;&#33323;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#21644;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>11</NO>
<PG>1141-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5b59__x7231__x6c11_-2010" MODIFIED="2012-08-22 12:56:07 +0100" MODIFIED_BY="[Empty name]" NAME="&#23385;&#29233;&#27665; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 12:56:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23385;&#29233;&#27665;</AU>
<TI>Ziprasidone given with Risperdal in the treatment of schizophrenia</TI>
<TO>&#21331;&#20048;&#23450;&#19982;&#32500;&#24605;&#36890;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#20998;&#26512;</TO>
<SO>Aerospace Medicine</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>3</NO>
<PG>350</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5b63__x6797__x5f71_-2009" MODIFIED="2012-08-22 14:45:17 +0100" MODIFIED_BY="[Empty name]" NAME="&#23395;&#26519;&#24433; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 12:58:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23395;&#26519;&#24433;, &#21016;&#23567;&#33457;, &#21556;&#31601;&#33452;</AU>
<TI>30 cases of ziprasidone on the quality of life of patients with schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#23545;30&#20363;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#29983;&#27963;&#36136;&#37327;&#30340;&#24433;&#21709;</TO>
<SO>China Pharmaceuticals [&#20013;&#22283;&#34277;&#26989;]</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>21</NO>
<PG>64-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5b8b__x65b0__x8679_-2010" MODIFIED="2012-08-22 14:45:31 +0100" MODIFIED_BY="[Empty name]" NAME="&#23435;&#26032;&#34425; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:01:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23435;&#26032;&#34425;, &#26472;&#20029;</AU>
<TI>Ziprasidone and risperidone in the treatment of women with schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Jilin Medical Journal</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>31</NO>
<PG>5556-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5bc7__x6842__x654f__x002c_-2009" MODIFIED="2012-08-22 13:04:07 +0100" MODIFIED_BY="[Empty name]" NAME="&#23495;&#26690;&#25935;, 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 13:04:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23495;&#26690;&#25935;, &#20313;&#29747;, &#21525;&#24314;&#21326;</AU>
<TI>Ziprasidone and clozapine in the treatment of schizophrenia control study</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;</TO>
<SO>&#20013;&#22269;&#29616;&#20195;&#33647;&#29289;&#24212;&#29992;</SO>
<YR>2009</YR>
<VL>3</VL>
<NO>17</NO>
<PG>10-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5c48__x5efa__x65b0_-2008" MODIFIED="2012-08-22 14:45:38 +0100" MODIFIED_BY="[Empty name]" NAME="&#23624;&#24314;&#26032; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 13:04:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23624;&#24314;&#26032;, &#36793;&#27427;&#19985;, &#23828;&#26149;&#38738;</AU>
<TI>Risperidone and ziprasidone on cognitive function in patients with schizophrenia </TI>
<TO>&#21033;&#22521;&#37230;&#21644;&#40784;&#25289;&#35199;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#35748;&#30693;&#21151;&#33021;&#30340;&#24433;&#21709;</TO>
<SO>Hebei Medical Journal</SO>
<YR>2008</YR>
<VL>30</VL>
<NO>10</NO>
<PG>1505-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5d14__x5f00__x8273_-2010" MODIFIED="2012-08-22 14:45:46 +0100" MODIFIED_BY="[Empty name]" NAME="&#23828;&#24320;&#33395; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:06:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23828;&#24320;&#33395;, &#21016;&#20848;&#33452;, &#26472;&#20029;&#25935;</AU>
<TI>Ziprasidone and risperidone on prolactin in patients with schizophrenia and body mass, blood glucose, blood lipid</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#27852;&#20083;&#32032;&#21450;&#20307;&#36136;&#37327;&#12289;&#34880;&#31958;&#12289;&#34880;&#33026;&#30340;&#24433;&#21709;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>1</NO>
<PG>7-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5d14__x96bd__x002c_-2007" MODIFIED="2012-08-22 13:07:12 +0100" MODIFIED_BY="[Empty name]" NAME="&#23828;&#38589;, 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-22 13:07:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23828;&#38589;, &#40644;&#33395;, &#40644;&#26397;</AU>
<TI>Domestic ziprasidone treatment of schizophrenia clinical observation</TI>
<TO>&#22269;&#20135;&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>&#20013;&#22269;&#29616;&#20195;&#21307;&#29983;</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>4</NO>
<PG>61-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5e9e__x826f__x4fca_-2010" MODIFIED="2012-08-22 14:45:56 +0100" MODIFIED_BY="[Empty name]" NAME="&#24222;&#33391;&#20426; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:09:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24222;&#33391;&#20426;, &#26472;&#29738;, &#35874;&#24605;&#24605;, &#26417;&#36947;&#26126;</AU>
<TI>Ziprasidone and clozapine in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>2</NO>
<PG>119-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x5c0f__x667a_-2010" MODIFIED="2012-08-22 14:46:05 +0100" MODIFIED_BY="[Empty name]" NAME="&#24352;&#23567;&#26234; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:10:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#23567;&#26234;, &#29976;&#20840;&#21916;, &#38446;&#38742;</AU>
<TI>Ziprasidone and clozapine in the treatment of schizophrenia with negative symptoms associated control study</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#32852;&#29992;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#38452;&#24615;&#30151;&#29366;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>5</NO>
<PG>568-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x5cf0_-2010" MODIFIED="2012-08-22 14:46:27 +0100" MODIFIED_BY="[Empty name]" NAME="&#24352;&#23792; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:11:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#23792;, &#38065;&#31168;&#20029;, &#36154;&#21551;&#20803;</AU>
<TI>Change-control study of ziprasidone and risperidone-induced weight and metabolic indicators</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#25152;&#33268;&#20307;&#37325;&#21450;&#20195;&#35874;&#25351;&#26631;&#21464;&#21270;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>22</NO>
<PG>2840-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x660e__x677e_-2009" MODIFIED="2012-08-22 14:46:14 +0100" MODIFIED_BY="[Empty name]" NAME="&#24352;&#26126;&#26494; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#26126;&#26494;, &#23435;&#20029;, &#36213;&#33395;&#21326;, &#27146;&#20940;&#23039;</AU>
<TI>Control study of ziprasidone and risperdone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#23454;&#29992;&#31070;&#32463;&#30142;&#30149;&#26434;&#24535;</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>13</NO>
<PG>31-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x7396__x9f99_-2010" MODIFIED="2012-08-22 14:46:35 +0100" MODIFIED_BY="[Empty name]" NAME="&#24352;&#29590;&#40857; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:13:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#29590;&#40857;, &#37101;&#26032;&#23431;, &#26446;&#32654;&#23071;</AU>
<TI>Ziprasidone treatment of schizophrenia with depressive symptoms were observed</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#20276;&#25233;&#37057;&#30151;&#29366;&#23545;&#29031;&#35266;&#23519;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>1</NO>
<PG>44-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x8273__x7426_-2010" MODIFIED="2012-08-22 14:46:20 +0100" MODIFIED_BY="[Empty name]" NAME="&#24352;&#33395;&#29734; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:16:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#33395;&#29734;, &#20110;&#25391;&#19996;</AU>
<TI>Ziprasidone and clozapine in the treatment of refractory schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>5</NO>
<PG>532-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x9999__x829d_-2009" MODIFIED="2012-08-22 14:46:56 +0100" MODIFIED_BY="[Empty name]" NAME="&#24352;&#39321;&#33437; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 13:19:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#39321;&#33437;, &#20110;&#20426;&#20029;, &#23380;&#24503;&#33635;, &#38669;&#20891;</AU>
<TI>Ziprasidone treatment of simple type schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#21333;&#32431;&#22411;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>5</NO>
<PG>320-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x9e3f__x71d5__x002c_-2010" MODIFIED="2012-08-22 13:19:58 +0100" MODIFIED_BY="[Empty name]" NAME="&#24352;&#40511;&#29141;, 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:19:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#40511;&#29141;, &#21016;&#31929;, &#38379;&#20426;, &#33298;&#33391;, &#26446;&#21326;&#33459;, &#39038;&#29275;&#33539;, et al</AU>
<TI>Efficacy and safety of ziprasidone treatment of schizophrenia with acute exacerbation</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#24613;&#24615;&#21457;&#20316;&#30340;&#30103;&#25928;&#21644;&#23433;&#20840;&#24615;</TO>
<SO>&#20013;&#22269;&#26032;&#33647;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>22</NO>
<PG>2076-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f6d__x4eae_-2010" MODIFIED="2012-08-22 13:21:39 +0100" MODIFIED_BY="[Empty name]" NAME="&#24429;&#20142; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:21:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24429;&#20142;</AU>
<TI>Ziprasidone clinical study of treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>&#20013;&#22806;&#21307;&#30103;</SO>
<YR>2010</YR>
<VL>21</VL>
<PG>125</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f6d__x6c5d__x6625_-2009" MODIFIED="2012-08-22 14:47:11 +0100" MODIFIED_BY="[Empty name]" NAME="&#24429;&#27741;&#26149; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 13:23:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24429;&#27741;&#26149;, &#21016;&#29233;&#36745;</AU>
<TI>Comparative analysis of ziprasidone risperidone in the treatment of female schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#27604;&#36739;&#20998;&#26512;</TO>
<SO>Sichuan Mental Health [&#22235;&#24029;&#31934;&#31070;&#21355;&#29983;]</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>3</NO>
<PG>168-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f90__x56fd__x6d2a_-2010" MODIFIED="2012-08-22 13:25:55 +0100" MODIFIED_BY="[Empty name]" NAME="&#24464;&#22269;&#27946; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:25:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24464;&#22269;&#27946;</AU>
<TI>Ziprasidone and olanzapine schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#22885;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#25351;&#21335;</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>3</NO>
<PG>98-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f90__x5a1f_-2009" MODIFIED="2012-08-22 14:47:20 +0100" MODIFIED_BY="[Empty name]" NAME="&#24464;&#23071; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 13:26:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24464;&#23071;, &#21016;&#26195;&#26757;, &#37041;&#22823;&#23439;, &#38472;&#19996;&#33805;, &#40644;&#32676;&#26126;, &#37073;&#36828;&#26494;</AU>
<TI>A randomized, double blind, double dummy parallel controlled study schizophrenia treated with ziprasidone tablets and risperidone orally disintegrating tablets</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#21475;&#33108;&#23849;&#35299;&#29255;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#38543;&#26426;&#12289;&#21452;&#30450;&#12289;&#21452;&#27169;&#25311;&#24179;&#34892;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Chinese Journal of Rehabilitation Theory and Practice [&#20013;&#22269;&#24247;&#22797;&#29702;&#35770;&#19982;&#23454;&#36341;]</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>6</NO>
<PG>556-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f90__x677e__x002c_-2010" MODIFIED="2012-08-22 13:28:12 +0100" MODIFIED_BY="[Empty name]" NAME="&#24464;&#26494;, 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:28:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24464;&#26494;, &#35885;&#24198;&#33635;, &#37101;&#21147;, &#20184;&#26149;&#23433;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>2</NO>
<PG>87-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f90__x8389__x840d_-2011" MODIFIED="2012-08-22 14:47:27 +0100" MODIFIED_BY="[Empty name]" NAME="&#24464;&#33673;&#33805; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 13:28:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24464;&#33673;&#33805;, &#35874;&#27704;&#26631;, &#26446;&#20305;&#36745;</AU>
<TI>Risperidone sustained release tablets and the ziprasidone treatment of schizophrenia</TI>
<TO>&#24085;&#21033;&#21708;&#37230;&#32531;&#37322;&#29255;&#19982;&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>03</NO>
<PG>174-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x65b9__x4f20__x8363_-2010" MODIFIED="2012-08-22 13:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="&#26041;&#20256;&#33635; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:30:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26041;&#20256;&#33635;</AU>
<TI>Ziprasidone and quetiapine in the treatment of women with schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21945;&#30827;&#24179;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>15</NO>
<PG>1942-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6613__x5cf0_-2010" MODIFIED="2012-08-22 14:47:38 +0100" MODIFIED_BY="[Empty name]" NAME="&#26131;&#23792; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:31:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26131;&#23792;, &#26446;&#37329;&#39321;, &#33487;&#26093;&#27743;, &#29579;&#24535;, &#36807;&#23159;</AU>
<TI>Aripiprazole and ziprasidone in patients with schizophrenia glucose, lipids</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#40784;&#25289;&#35199;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#34880;&#31958;&#12289;&#34880;&#33026;&#30340;&#24433;&#21709;</TO>
<SO>&#20013;&#22269;&#33647;&#29289;&#24212;&#29992;&#19982;&#30417;&#27979;</SO>
<YR>2010</YR>
<VL>7</VL>
<NO>06</NO>
<PG>330-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6731__x5fd7__x9ad8_-2010" MODIFIED="2012-08-22 13:32:58 +0100" MODIFIED_BY="[Empty name]" NAME="&#26417;&#24535;&#39640; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:32:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26417;&#24535;&#39640;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Information</SO>
<YR>2010</YR>
<VL>8</VL>
<PG>2196-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x4ed5__x519b_-2010" MODIFIED="2012-08-22 13:34:02 +0100" MODIFIED_BY="[Empty name]" NAME="&#26446;&#20181;&#20891; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:34:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#20181;&#20891;</AU>
<TI>Ziprasidone and clozapine in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>22</NO>
<PG>2841-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x4f5c__x73cd_-2010" MODIFIED="2012-08-22 13:35:25 +0100" MODIFIED_BY="[Empty name]" NAME="&#26446;&#20316;&#29645; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:35:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#20316;&#29645;</AU>
<TI>Ziprasidone and clozapine in patients with first-episode schizophrenia Comparison of the effects of ECG</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#23545;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#24515;&#30005;&#22270;&#24433;&#21709;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>15</NO>
<PG>1924-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x542f__x658c_-2008" MODIFIED="2012-08-22 14:47:57 +0100" MODIFIED_BY="[Empty name]" NAME="&#26446;&#21551;&#25996; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 13:36:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#21551;&#25996;, &#24352;&#38634;&#29747;, &#38886;&#32418;&#26085;</AU>
<TI>Ziprasidone and risperidone in the treatment of senile schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Acta Medicinae Sinica [&#21326;&#22799;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>3</NO>
<PG>440-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x56fd__x80dc_-2010" MODIFIED="2012-08-22 14:47:45 +0100" MODIFIED_BY="[Empty name]" NAME="&#26446;&#22269;&#32988; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:37:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#22269;&#32988;, &#38472;&#29577;&#36745;</AU>
<TI>Ziprasidone and olanzapine clinical control study of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#21644;&#22885;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#20020;&#24202;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>11</NO>
<PG>1358-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x57f9__x8f69_-2010" MODIFIED="2012-08-22 14:48:08 +0100" MODIFIED_BY="[Empty name]" NAME="&#26446;&#22521;&#36713; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:37:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#22521;&#36713;, &#21608;&#27704;&#26126;, &#34081;&#26093;&#26126;, &#23609;&#32487;&#32493;</AU>
<TI>Ziprasidone treatment of schizophrenia, randomized, double-blind controlled study</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#38543;&#26426;&#21452;&#30450;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>06</NO>
<PG>404-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x6625__x82b1_-2011" MODIFIED="2012-08-22 13:38:01 +0100" MODIFIED_BY="[Empty name]" NAME="&#26446;&#26149;&#33457; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 13:38:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#26149;&#33457;</AU>
<TI>Ziprasidone merged observation and care of small doses of clozapine treatment of refractory schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#21512;&#24182;&#23567;&#21058;&#37327;&#27695;&#27694;&#24179;&#27835;&#30103;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#35266;&#23519;&#21450;&#25252;&#29702;</TO>
<SO>&#27714;&#21307;&#38382;&#33647;(&#19979;&#21322;&#26376;)</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>07</NO>
<PG>98-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x6811__x654f_-2008" MODIFIED="2012-08-22 13:38:37 +0100" MODIFIED_BY="[Empty name]" NAME="&#26446;&#26641;&#25935; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 13:38:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#26641;&#25935;</AU>
<TI>Ziprasidone and risperidone in the treatment of chronic schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#24930;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>17</NO>
<PG>2020-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x6881_-2009" MODIFIED="2012-08-22 14:48:18 +0100" MODIFIED_BY="[Empty name]" NAME="&#26446;&#26753; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 13:39:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#26753;, &#40644;&#28023;&#29141;, &#38518;&#19990;&#27494;, &#38472;&#24378;, &#26472;&#35802;, &#28504;&#22825;&#20255;</AU>
<TI>Three kinds of antipsychotic drugs on glucose metabolism in patients with schizophrenia</TI>
<TO>3&#31181;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#31958;&#20195;&#35874;&#30340;&#24433;&#21709;</TO>
<SO>&#24403;&#20195;&#21307;&#23398;</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>24</NO>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x8f76__x7fa4_-2009" MODIFIED="2012-08-22 13:39:39 +0100" MODIFIED_BY="[Empty name]" NAME="&#26446;&#36726;&#32676; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 13:39:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#36726;&#32676;</AU>
<TI>Ziprasidone and clozapine in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Jiangxi Medical Journal [&#27743;&#35199;&#21307;&#33647;]</SO>
<YR>2009</YR>
<VL>44</VL>
<NO>2</NO>
<PG>151-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x660e__x534e__x002c_-2011" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="&#26472;&#26126;&#21326;, 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26472;&#26126;&#21326;, &#26472;&#33459;</AU>
<TI>Controlled study of aripiprazole and ziprasidone treatment of schizophrenia</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#25351;&#21335;</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>25</NO>
<PG>242-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x8001__x864e_-2009" MODIFIED="2012-08-22 14:48:25 +0100" MODIFIED_BY="[Empty name]" NAME="&#26472;&#32769;&#34382; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 13:41:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26472;&#32769;&#34382;, &#36213;&#28113;&#25935;, &#27743;&#33465;&#26222;, &#19975;&#29233;&#21326;, &#40784;&#22269;&#23077;</AU>
<TI>Ziprasidone and risperidone in the treatment of female control study of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#20020;&#24202;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>17</VL>
<NO>10</NO>
<PG>1156-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x80dc__x826f_-2008" MODIFIED="2012-08-22 13:42:10 +0100" MODIFIED_BY="[Empty name]" NAME="&#26472;&#32988;&#33391; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 13:42:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26472;&#32988;&#33391;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia control study </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Herald of Medicine [&#21307;&#33647;&#23548;&#25253;] [&#37291;&#34277;&#23566;&#22577;]</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>10</NO>
<PG>1197-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x8bda__x002c_-2010" MODIFIED="2012-08-22 13:42:26 +0100" MODIFIED_BY="[Empty name]" NAME="&#26472;&#35802;, 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:42:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26472;&#35802;, &#38518;&#19990;&#27494;, &#38472;&#24378;, &#28504;&#28070;&#24503;, &#28504;&#22825;&#20255;, &#26446;&#26753;, et al</AU>
<TI>Association study of four kinds of antipsychotics and glucose metabolism in patients with schizophrenia and glycosylated hemoglobin</TI>
<TO>4&#31181;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#19982;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#31958;&#20195;&#35874;&#21450;&#31958;&#21270;&#34880;&#32418;&#34507;&#30333;&#30340;&#20851;&#32852;&#24615;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#29616;&#20195;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>18</NO>
<PG>2816-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x987a__x624d_-2008" MODIFIED="2012-08-22 14:48:38 +0100" MODIFIED_BY="[Empty name]" NAME="&#26472;&#39034;&#25165; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 13:43:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26472;&#39034;&#25165;, &#39640;&#30003;&#33635;, &#26460;&#35265;&#33459;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia control study </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>5</NO>
<PG>409-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6797__x5353__x6bc5_-2009" MODIFIED="2012-08-22 14:48:47 +0100" MODIFIED_BY="[Empty name]" NAME="&#26519;&#21331;&#27589; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 13:44:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26519;&#21331;&#27589;, &#26472;&#23389;, &#26446;&#31119;&#29699;, &#33487;&#20255;&#32988;</AU>
<TI>Comparison of health economics ziprasidone, clozapine treatment</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#12289;&#27695;&#27694;&#24179;&#27835;&#30103;&#30340;&#21355;&#29983;&#32463;&#27982;&#23398;&#27604;&#36739;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>2</NO>
<PG>97-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6797__x654f_-2011" MODIFIED="2012-08-22 14:49:03 +0100" MODIFIED_BY="[Empty name]" NAME="&#26519;&#25935; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 13:45:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26519;&#25935;, &#31461;&#23551;&#26126;</AU>
<TI>Controlled study of ziprasidone, and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2011</YR>
<VL>23</VL>
<NO>14</NO>
<PG>1708-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6bb5__x6b66__x521a_-2010" MODIFIED="2012-08-22 14:42:54 +0100" MODIFIED_BY="[Empty name]" NAME="&#27573;&#27494;&#21018; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:47:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#27573;&#27494;&#21018;, &#26366;&#24503;&#24535;, &#24464;&#33391;&#38596;, &#31069;&#23792;, &#21830;&#31168;&#29645;</AU>
<TI>Ziprasidone and clozapine in the treatment of female schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#21644;&#27695;&#27694;&#24179;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#27604;&#36739;</TO>
<SO>Journal of the Hainan Medical College</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>6</NO>
<PG>771-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6bb5__x6b66__x94a2_-2010" MODIFIED="2012-08-22 14:42:45 +0100" MODIFIED_BY="[Empty name]" NAME="&#27573;&#27494;&#38050; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:49:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#27573;&#27494;&#38050;, &#26366;&#24503;&#24535;, &#32599;&#24314;&#27494;, &#21830;&#31168;&#29645;</AU>
<TI>Ziprasidone social function in patients with schizophrenia and quality of life</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#31038;&#20250;&#21151;&#33021;&#21644;&#29983;&#27963;&#36136;&#37327;&#30340;&#24433;&#21709;</TO>
<SO>Chinese Journal of Rehabilitation [&#20013;&#22283;&#24247;&#24489;]</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>2</NO>
<PG>156-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6bb7__x6708__x73cd_-2010" MODIFIED="2012-08-22 14:42:33 +0100" MODIFIED_BY="[Empty name]" NAME="&#27575;&#26376;&#29645; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:50:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#27575;&#26376;&#29645;, &#40644;&#23398;&#20891;</AU>
<TI>80 controls were observed ziprasidone and risperidone in the treatment of schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;80&#20363;&#23545;&#29031;&#35266;&#23519;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>23</NO>
<PG>3042-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6e29__x5360__x7ea2_-2011" MODIFIED="2012-08-22 13:50:18 +0100" MODIFIED_BY="[Empty name]" NAME="&#28201;&#21344;&#32418; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 13:50:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#28201;&#21344;&#32418;</AU>
<TI>Controlled study of ziprasidone and risperidone in the treatment of women with schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#21271;&#26041;&#33647;&#23398;</SO>
<YR>2011</YR>
<VL>8</VL>
<NO>04</NO>
<PG>44-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6f58__x5929__x4f1f_-2008" MODIFIED="2012-08-22 14:42:21 +0100" MODIFIED_BY="[Empty name]" NAME="&#28504;&#22825;&#20255; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 13:51:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#28504;&#22825;&#20255;, &#40644;&#20029;&#33805;</AU>
<TI>Controlled clinical studies of ziprasidone and clozapine in the treatment of schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Guangxi Medical Journal</SO>
<YR>2008</YR>
<VL>30</VL>
<NO>3</NO>
<PG>348-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6f58__x6587__x71d5_-2008" MODIFIED="2012-08-22 14:42:09 +0100" MODIFIED_BY="[Empty name]" NAME="&#28504;&#25991;&#29141; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 13:52:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#28504;&#25991;&#29141;, &#26519;&#25391;&#19996;, &#38472;&#20912;&#23481;</AU>
<TI>Ziprasidone impact on the quality of life in patients with schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#29983;&#27963;&#36136;&#37327;&#30340;&#24433;&#21709;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#25351;&#21335;</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>13</NO>
<PG>22-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x718a__x8f89_-2011" MODIFIED="2012-08-22 14:42:00 +0100" MODIFIED_BY="[Empty name]" NAME="&#29066;&#36745; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 13:52:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#29066;&#36745;, &#26446;&#27946;&#27589;, &#29579;&#32500;&#21191;, &#24429;&#24535;</AU>
<TI>Randomized study of ziprasidone and risperidone in the treatment of acute schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#24613;&#24615;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#38543;&#26426;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#26816;&#39564;&#21307;&#23398;&#19982;&#20020;&#24202;</SO>
<YR>2011</YR>
<VL>8</VL>
<NO>01</NO>
<PG>9-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x738b__x4f53__x5bbe_-2011" MODIFIED="2012-08-22 14:41:54 +0100" MODIFIED_BY="[Empty name]" NAME="&#29579;&#20307;&#23486; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 13:53:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#29579;&#20307;&#23486;, &#23380;&#24503;&#33635;, &#24352;&#23721;&#28392;, &#26446;&#23781;, &#32993;&#38596;, &#38669;&#20891;, et al</AU>
<TI>Comparison of the effects of ziprasidone and clozapine, risperidone on lipid metabolism in patients with schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#12289;&#21033;&#22521;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#33026;&#20195;&#35874;&#24433;&#21709;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#23454;&#29992;&#31070;&#32463;&#30142;&#30149;&#26434;&#24535;</SO>
<YR>2011</YR>
<VL>14</VL>
<NO>12</NO>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x738b__x5929__x9f99_-2008" MODIFIED="2012-08-22 14:41:49 +0100" MODIFIED_BY="[Empty name]" NAME="&#29579;&#22825;&#40857; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 13:53:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#29579;&#22825;&#40857;, &#31243;&#24179;, &#38472;&#32418;&#20809;, &#21776;&#40527;, &#21608;&#26690;&#26126;</AU>
<TI>Ziprasidone treatment of schizophrenia with predominantly negative symptoms </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#20197;&#38452;&#24615;&#30151;&#29366;&#20026;&#20027;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>3</NO>
<PG>206-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x738b__x5b66__x519b_-2009" MODIFIED="2012-08-22 14:41:10 +0100" MODIFIED_BY="[Empty name]" NAME="&#29579;&#23398;&#20891; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 13:55:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#29579;&#23398;&#20891;, &#39532;&#23500;&#26195;</AU>
<TI>Efficacy of ziprasidone treatment of schizophrenia and quality of life</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#21450;&#29983;&#27963;&#36136;&#37327;&#30340;&#24433;&#21709;&#23545;&#29031;&#35266;&#23519;</TO>
<SO>&#20013;&#22269;&#23454;&#29992;&#21307;&#33647;</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>23</NO>
<PG>156-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x738b__x65b9__x56fd_-2010" MODIFIED="2012-08-22 14:41:05 +0100" MODIFIED_BY="[Empty name]" NAME="&#29579;&#26041;&#22269; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:57:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#29579;&#26041;&#22269;, &#38472;&#24935;&#33465;, &#29579;&#32988;</AU>
<TI>Ziprasidone and risperidone in the treatment of women with schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#31038;&#21306;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>1</NO>
<PG>26-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x738b__x6c38__x5b66_-2010" MODIFIED="2012-08-22 14:40:57 +0100" MODIFIED_BY="[Empty name]" NAME="&#29579;&#27704;&#23398; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 13:57:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#29579;&#27704;&#23398;, &#24352;&#24314;, &#23385;&#26757;&#29618;</AU>
<TI>Ziprasidone and clozapine on cognitive function in patients with schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#35748;&#30693;&#21151;&#33021;&#30340;&#24433;&#21709;</TO>
<SO>&#20013;&#22269;&#23454;&#29992;&#21307;&#33647;</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>36</NO>
<PG>5-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x738b__x79c0__x82b3_-2011" MODIFIED="2012-08-22 14:40:50 +0100" MODIFIED_BY="[Empty name]" NAME="&#29579;&#31168;&#33459; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 13:59:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#29579;&#31168;&#33459;, &#37101;&#32418;&#20029;, &#24352;&#27946;&#20255;, &#21556;&#38634;&#39134;, &#24352;&#24314;</AU>
<TI>Aripiprazole and ziprasidone, the prevalence of metabolic syndrome in patients with schizophrenia</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#21644;&#40784;&#25289;&#35199;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20195;&#35874;&#32508;&#21512;&#24449;&#24739;&#30149;&#29575;&#30340;&#24433;&#21709;</TO>
<SO>&#21307;&#23398;&#20449;&#24687;(&#20013;&#26092;&#21002;)</SO>
<YR>2011</YR>
<VL>6</VL>
<PG>2570-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x738b__x91d1__x5802_-2010" MODIFIED="2012-08-22 14:40:46 +0100" MODIFIED_BY="[Empty name]" NAME="&#29579;&#37329;&#22530; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:00:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#29579;&#37329;&#22530;, &#23588;&#21152;&#27704;, &#24120;&#20313;&#21892;</AU>
<TI>Effective control study of ziprasidone and risperidone in first episode schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#30103;&#25928;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>23</NO>
<PG>2993-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x767d__x5251__x6587_-2009" MODIFIED="2012-08-22 14:00:28 +0100" MODIFIED_BY="[Empty name]" NAME="&#30333;&#21073;&#25991; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 14:00:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#30333;&#21073;&#25991;</AU>
<TI>Ziprasidone and aripiprazole in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#38463;&#31435;&#21708;&#21777;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#38738;&#23707;&#21307;&#33647;&#21355;&#29983;</SO>
<YR>2009</YR>
<VL>41</VL>
<NO>3</NO>
<PG>199-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x767d__x9526__x6ce2_-2010" MODIFIED="2012-08-22 14:40:41 +0100" MODIFIED_BY="[Empty name]" NAME="&#30333;&#38182;&#27874; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:02:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#30333;&#38182;&#27874;, &#40644;&#28023;&#29141;, &#38518;&#19990;&#27494;, &#28504;&#22825;&#20255;, &#26446;&#26753;</AU>
<TI>Three kinds of atypical antipsychotic drugs on lipid metabolism in patients with schizophrenia</TI>
<TO>3&#31181;&#38750;&#20856;&#22411;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#33026;&#20195;&#35874;&#30340;&#24433;&#21709;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#25351;&#21335;</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>17</NO>
<PG>8-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x76ae__x73a5__x73a5_-2010" MODIFIED="2012-08-22 14:03:30 +0100" MODIFIED_BY="[Empty name]" NAME="&#30382;&#29605;&#29605; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:03:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#30382;&#29605;&#29605;</AU>
<TI>Ziprasidone and risperidone in the treatment of Schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>5</NO>
<PG>573-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x79e6__x6377_-2010" MODIFIED="2012-08-22 14:40:36 +0100" MODIFIED_BY="[Empty name]" NAME="&#31206;&#25463; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:03:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#31206;&#25463;, &#25140;&#26032;&#22269;</AU>
<TI>Ziprasidone and clozapine on ECG</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#21644;&#27695;&#27694;&#24179;&#23545;&#24515;&#30005;&#22270;&#30340;&#24433;&#21709;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>21</NO>
<PG>2714-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x7a0b__x5e73_-2009" MODIFIED="2012-08-22 14:40:31 +0100" MODIFIED_BY="[Empty name]" NAME="&#31243;&#24179; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 14:04:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#31243;&#24179;, &#29579;&#22825;&#40857;, &#38472;&#32418;&#20809;, &#21776;&#40527;, &#21608;&#26690;&#26126;</AU>
<TI>Ziprasidone and aripiprazole in the treatment of schizophrenia with predominantly negative symptoms </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#38463;&#31435;&#21617;&#21777;&#27835;&#30103;&#20197;&#38452;&#24615;&#30151;&#29366;&#20026;&#20027;&#30340;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of the Xianning Medical College [&#26032;&#20065;&#21307;&#23398;&#38498;&#23398;&#25253;]</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>2</NO>
<PG>106-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x7a0b__x71d5_-2009" MODIFIED="2012-08-22 14:05:51 +0100" MODIFIED_BY="[Empty name]" NAME="&#31243;&#29141; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 14:05:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#31243;&#29141;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia in the clinical control study</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#29616;&#20195;&#33647;&#29289;&#24212;&#29992;</SO>
<YR>2009</YR>
<VL>3</VL>
<NO>14</NO>
<PG>157</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x7ba1__x92ae__x53cb_-2009" MODIFIED="2012-08-22 14:07:11 +0100" MODIFIED_BY="[Empty name]" NAME="&#31649;&#37550;&#21451; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 14:07:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#31649;&#37550;&#21451;</AU>
<TI>Ziprasidone and quetiapine in the treatment of senile schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#22862;&#30827;&#24179;&#27835;&#30103;&#32769;&#24180;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Military Surgeon in Southwest China</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>5</NO>
<PG>843-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x80e1__x534e__x5ef7_-2011" MODIFIED="2012-08-22 14:39:53 +0100" MODIFIED_BY="[Empty name]" NAME="&#32993;&#21326;&#24311; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 14:07:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#32993;&#21326;&#24311;, &#39640;&#37329;&#39321;</AU>
<TI>Controlled study of ziprasidone, and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#24403;&#20195;&#21307;&#33647;</SO>
<YR>2011</YR>
<VL>18</VL>
<NO>20</NO>
<PG>71-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x83ab__x4e9a__x8389_-2010" MODIFIED="2012-08-22 14:09:10 +0100" MODIFIED_BY="[Empty name]" NAME="&#33707;&#20122;&#33673; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:09:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#33707;&#20122;&#33673;</AU>
<TI>Ziprasidone treatment of low dose clozapine in refractory schizophrenia 33 patients</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#32852;&#21512;&#23567;&#21058;&#37327;&#27695;&#27694;&#24179;&#27835;&#30103;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;33&#20363;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Zhejiang Practical Medicine</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>1</NO>
<PG>43-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8463__x4f1f_-2008" MODIFIED="2012-08-22 14:39:44 +0100" MODIFIED_BY="[Empty name]" NAME="&#33891;&#20255; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 14:09:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#33891;&#20255;, &#26472;&#32724;</AU>
<TI>Ziprasidone and quetiapine treatment episode schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21945;&#30827;&#24179;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>12</NO>
<PG>1275, 1380</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8463__x4f1f_-2010" MODIFIED="2012-08-22 14:39:36 +0100" MODIFIED_BY="[Empty name]" NAME="&#33891;&#20255; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:11:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#33891;&#20255;, &#39038;&#21355;&#38686;</AU>
<TI>Ziprasidone and risperidone in the treatment of female patients with schizophrenia control study</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#30103;&#25928;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Modern Diagnosis and Treatment</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>77-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8463__x592a__x65b0_-2007" MODIFIED="2012-08-22 14:39:26 +0100" MODIFIED_BY="[Empty name]" NAME="&#33891;&#22826;&#26032; 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-22 14:12:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#33891;&#22826;&#26032;, &#38446;&#27743;&#32418;, &#26446;&#27704;&#33437;, &#26446;&#26161;</AU>
<TI>Ziprasidone in the treatment of first diagnosis of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#39318;&#35786;&#31934;&#31070;&#20998;&#35010;&#30151;&#20020;&#24202;&#20998;&#26512;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>12</NO>
<PG>1061</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8521__x8fdb__x4f1f_-2009" MODIFIED="2012-08-22 14:39:22 +0100" MODIFIED_BY="[Empty name]" NAME="&#34081;&#36827;&#20255; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#34081;&#36827;&#20255;, &#23395;&#26519;&#24433;</AU>
<TI>Ziprasidone and risperidone on treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>China Pharmacist</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>3</NO>
<PG>363-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8983__x677e_-2009" MODIFIED="2012-08-22 14:18:01 +0100" MODIFIED_BY="[Empty name]" NAME="&#35203;&#26494; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 14:18:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#35203;&#26494;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>3</VL>
<PG>190-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8bb8__x4e9a__x5e73_-2010" MODIFIED="2012-08-22 14:18:37 +0100" MODIFIED_BY="[Empty name]" NAME="&#35768;&#20122;&#24179; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:18:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#35768;&#20122;&#24179;</AU>
<TI>Ziprasidone, and risperidone in the treatment of adolescent schizophrenia-control study</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#21644;&#21033;&#22521;&#37230;&#27835;&#30103;&#38738;&#23569;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#20020;&#24202;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20122;&#22826;&#20256;&#32479;&#21307;&#33647;</SO>
<YR>2010</YR>
<VL>6</VL>
<NO>10</NO>
<PG>123-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8bb8__x5fd7__x5e73_-2008" MODIFIED="2012-08-22 14:39:16 +0100" MODIFIED_BY="[Empty name]" NAME="&#35768;&#24535;&#24179; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 14:19:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#35768;&#24535;&#24179;, &#38472;&#24039;&#24179;</AU>
<TI>Ziprasidone and clozapine treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>23</NO>
<PG>2788, 2793</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8c22__x709c__x9e9f_-2009" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="&#35874;&#28828;&#40607; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#35874;&#28828;&#40607;</AU>
<TI>The comparative investigation between ziprasidone and risperidone in the treatment of schizophrenia in children</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#20799;&#31461;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#22269;&#38469;&#31934;&#31070;&#30149;&#23398;&#26434;&#24535;</SO>
<YR>2009</YR>
<VL>36</VL>
<NO>3</NO>
<PG>137-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8c22__x80b2__x5357_-2010" MODIFIED="2012-08-22 14:39:06 +0100" MODIFIED_BY="[Empty name]" NAME="&#35874;&#32946;&#21335; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:20:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#35874;&#32946;&#21335;, &#37021;&#20113;&#33322;, &#21016;&#29486;&#26631;, &#32599;&#21326;</AU>
<TI>Ziprasidone treatment of schizophrenia clinical analysis of 65 cases</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;65&#20363;&#30340;&#20020;&#24202;&#20998;&#26512;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>11</NO>
<PG>1380-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8d75__x656c__x5e73_-2010" MODIFIED="2012-08-22 14:20:55 +0100" MODIFIED_BY="[Empty name]" NAME="&#36213;&#25964;&#24179; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:20:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#36213;&#25964;&#24179;</AU>
<TI>Controlled study of ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#21307;&#23398;&#20449;&#24687;(&#20013;&#26092;&#21002;)</SO>
<YR>2010</YR>
<VL>12</VL>
<PG>3715-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8d75__x660e__x4e3d_-2010" MODIFIED="2012-08-22 14:39:02 +0100" MODIFIED_BY="[Empty name]" NAME="&#36213;&#26126;&#20029; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:22:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#36213;&#26126;&#20029;, &#24120;&#20313;&#21892;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#21644;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>5</NO>
<PG>559-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8d75__x9752__x971e_-2009" MODIFIED="2012-08-22 14:38:54 +0100" MODIFIED_BY="[Empty name]" NAME="&#36213;&#38738;&#38686; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 14:23:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#36213;&#38738;&#38686;, &#32993;&#28023;&#28059;, &#24352;&#20029;&#38686;</AU>
<TI>Ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#20998;&#26512;</TO>
<SO>Journal of Medical Forum [&#21307;&#33647;&#35770;&#22363;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>24</NO>
<PG>72-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9093__x5e7f_-2011" MODIFIED="2012-08-22 14:24:14 +0100" MODIFIED_BY="[Empty name]" NAME="&#37011;&#24191; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 14:24:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#37011;&#24191;, &#40644;&#28977;&#26126;</AU>
<TI>Ziprasidone and aripiprazole improve control study of first episode schizophrenia and social functions</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#38463;&#31435;&#21708;&#21777;&#25913;&#21892;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#31038;&#20250;&#21151;&#33021;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#21307;&#23398;&#20449;&#24687;(&#19978;&#26092;&#21002;)</SO>
<YR>2011</YR>
<VL>24</VL>
<NO>07</NO>
<PG>4219-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x90a2__x9999__x7136_-2011" MODIFIED="2012-08-22 14:38:48 +0100" MODIFIED_BY="[Empty name]" NAME="&#37026;&#39321;&#28982; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#37026;&#39321;&#28982;, &#24352;&#25913;&#33521;</AU>
<TI>Ziprasidone and aripiprazole treatment of first episode of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#38463;&#31435;&#21708;&#21777;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#22522;&#23618;&#21307;&#23398;&#35770;&#22363;</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>10</NO>
<PG>929-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x90d1__x5b66__x5b9d_-2008" MODIFIED="2012-08-22 14:38:40 +0100" MODIFIED_BY="[Empty name]" NAME="&#37073;&#23398;&#23453; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 14:25:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#37073;&#23398;&#23453;, &#26446;&#37329;&#20142;, &#32599;&#24544;, &#31456;&#26093;&#19996;</AU>
<TI>Ziprasidone and risperidone in the treatment of female schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#21644;&#21033;&#22521;&#37230;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#27604;&#36739;</TO>
<SO>Modern Research of Integrated Chinese and Western Medicine [&#29616;&#20195;&#20013;&#35199;&#21307;&#32467;&#21512;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>20</NO>
<PG>3110-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x90d1__x5e86__x6885_-2008" MODIFIED="2012-08-22 14:38:35 +0100" MODIFIED_BY="[Empty name]" NAME="&#37073;&#24198;&#26757; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 14:26:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#37073;&#24198;&#26757;, &#38472;&#24039;&#24179;, &#35768;&#24535;&#24179;</AU>
<TI>Ziprasidone risperdal in the treatment of schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#32500;&#24605;&#36890;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22806;&#21307;&#30103;</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x949f__x5c0f__x5175_-2009" MODIFIED="2012-08-22 14:38:28 +0100" MODIFIED_BY="[Empty name]" NAME="&#38047;&#23567;&#20853; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 14:27:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38047;&#23567;&#20853;, &#26519;&#24535;&#38596;</AU>
<TI>Ziprasidone and olanzapine in schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#21644;&#22885;&#27694;&#24179;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#27604;&#36739;</TO>
<SO>Journal of the Guangdong Medical College</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>4</NO>
<PG>434-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x963f__x6000__x7ea2_-2011" MODIFIED="2012-08-22 14:38:24 +0100" MODIFIED_BY="[Empty name]" NAME="&#38463;&#24576;&#32418; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 14:27:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38463;&#24576;&#32418;, &#24352;&#21457;&#25996;</AU>
<TI>Ziprasidone treatment of female patients with schizophrenia, efficacy and quality of life impact study</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#30103;&#25928;&#21450;&#29983;&#27963;&#36136;&#37327;&#24433;&#21709;&#30740;&#31350;</TO>
<SO>&#38738;&#28023;&#21307;&#33647;&#26434;&#24535;</SO>
<YR>2011</YR>
<VL>41</VL>
<NO>05</NO>
<PG>11-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9646__x7231__x76ca_-2009" MODIFIED="2012-08-22 14:28:29 +0100" MODIFIED_BY="[Empty name]" NAME="&#38470;&#29233;&#30410; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 14:28:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38470;&#29233;&#30410;</AU>
<TI>Ziprasidone and quetiapine treatment 30 patients in each episode schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21945;&#30827;&#24179;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#21508;30&#20363;&#23545;&#29031;&#20998;&#26512;</TO>
<SO>&#20869;&#31185;</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>4</NO>
<PG>577-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9648__x6069__x6c11_-2010" MODIFIED="2012-08-22 14:33:02 +0100" MODIFIED_BY="[Empty name]" NAME="&#38472;&#24681;&#27665; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:33:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38472;&#24681;&#27665;</AU>
<TI>Ziprasidone Efficacy of first-episode schizophrenia treatment</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>&#31038;&#21306;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>15</NO>
<PG>10-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9648__x6167_-2011" MODIFIED="2012-08-22 14:33:22 +0100" MODIFIED_BY="[Empty name]" NAME="&#38472;&#24935; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 14:33:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38472;&#24935;</AU>
<TI>Randomized study of ziprasidone and risperidone in the treatment of acute schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#24613;&#24615;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#38543;&#26426;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#25351;&#21335;</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>18</NO>
<PG>111-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9648__x6625__x6885_-2010" MODIFIED="2012-08-22 14:35:05 +0100" MODIFIED_BY="[Empty name]" NAME="&#38472;&#26149;&#26757; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:35:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38472;&#26149;&#26757;</AU>
<TI>Ziprasidone substitution of female patients with schizophrenia. Risperidone study of the Effect of prolactin</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#26367;&#25442;&#21033;&#22521;&#37230;&#23545;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20652;&#20083;&#32032;&#27700;&#24179;&#24433;&#21709;&#30340;&#30740;&#31350;</TO>
<SO>Nei Moivgol Medical Journal</SO>
<YR>2010</YR>
<VL>42</VL>
<NO>1</NO>
<PG>38-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x96f7__x5e86__x534e_-2008" MODIFIED="2012-08-22 14:38:16 +0100" MODIFIED_BY="[Empty name]" NAME="&#38647;&#24198;&#21326; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 14:35:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38647;&#24198;&#21326;, &#38472;&#19996;&#33829;, &#21016;&#33452;, &#29579;&#33395;&#26757;</AU>
<TI>Control study of ziprasidone and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>12</NO>
<PG>1273, 1301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x989c__x5efa__x8f89_-2011" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="&#39068;&#24314;&#36745; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#39068;&#24314;&#36745;</AU>
<TI>Clozapine with ziprasidone capsules with a single controlled clinical study the treatment of schizophrenia with clozapine</TI>
<TO>&#27695;&#27694;&#24179;&#21512;&#24182;&#40784;&#25289;&#35199;&#37230;&#33014;&#22218;&#19982;&#21333;&#29992;&#27695;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22806;&#21307;&#23398;&#30740;&#31350;</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>24</NO>
<PG>56-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9a6c__x5146__x5cf0_-2009" MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="&#39532;&#20806;&#23792; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#39532;&#20806;&#23792;</AU>
<TI>The comparation of effects and security of ziprasidone and quetiapine in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21945;&#30827;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#21644;&#23433;&#20840;&#24615;&#27604;&#36739;</TO>
<SO>&#23665;&#19996;&#21307;&#23398;&#39640;&#31561;&#19987;&#31185;&#23398;&#26657;&#23398;&#25253;</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>3</NO>
<PG>163-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9ad8__x661f__x6d77_-2008" MODIFIED="2012-08-22 14:38:09 +0100" MODIFIED_BY="[Empty name]" NAME="&#39640;&#26143;&#28023; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-22 14:36:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#39640;&#26143;&#28023;, &#19975;&#20029;&#33673;</AU>
<TI>Ziprasidone efficacy of cognitive function in patients with chronic schizophrenia </TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#25913;&#21892;&#24930;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#35748;&#30693;&#21151;&#33021;&#30340;&#30103;&#25928;&#20998;&#26512;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>15</NO>
<PG>1748-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9ec4__x5cf0_-2010" MODIFIED="2012-08-22 14:36:51 +0100" MODIFIED_BY="[Empty name]" NAME="&#40644;&#23792; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-22 14:36:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#40644;&#23792;</AU>
<TI>Ziprasidone and risperidone in the treatment of elderly clinical controlled study of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>10</NO>
<PG>1214-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9ec4__x632f__x82f1_-2010" MODIFIED="2012-08-22 14:49:21 +0100" MODIFIED_BY="[Empty name]" NAME="&#40644;&#25391;&#33521; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-12 22:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#40644;&#25391;&#33521;, &#39038;&#24191;&#21892;</AU>
<TI>Ziprasidone and quetiapine in the treatment of elderly schizophrenia control analysis</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21945;&#30827;&#24179;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#20998;&#26512;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#25351;&#21335;</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>35</NO>
<PG>297-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9ec4__x667a__x8f89_-2011" MODIFIED="2012-08-22 14:37:45 +0100" MODIFIED_BY="[Empty name]" NAME="&#40644;&#26234;&#36745; 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-22 14:37:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#40644;&#26234;&#36745;, &#26472;&#31435;&#32676;</AU>
<TI>Ziprasidone, and risperidone in the treatment of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#35266;&#23519;</TO>
<SO>&#20013;&#22269;&#29616;&#20195;&#21307;&#33647;&#26434;&#24535;</SO>
<YR>2011</YR>
<VL>13</VL>
<NO>06</NO>
<PG>70-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-02-11 16:57:35 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Mortimer-2001" MODIFIED="2009-02-11 16:57:28 +0000" MODIFIED_BY="[Empty name]" NAME="Mortimer 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-02-11 16:57:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mortimer A</AU>
<TI>A1281014 a phase IIIb, 12 week, multi-centre, double-blind, double-dummy, randomised, parallel group study comparing the effects of ziprasidone versus olanzapine on quality of life in the treatment of schizophrenia and schizoaffective disorder</TI>
<SO>National Research Register</SO>
<YR>2001</YR>
<VL>3</VL>
<IDENTIFIERS MODIFIED="2009-02-11 16:57:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reveley-2003" MODIFIED="2009-02-11 16:57:35 +0000" MODIFIED_BY="[Empty name]" NAME="Reveley 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-11 16:57:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Reveley M</AU>
<TI>MREC/00/1/47 a phase IIIb multicentre randomised double-blind trial of ziprasidone vs olanzapine in schizophrenia</TI>
<SO>National Research Register</SO>
<YR>2003</YR>
<VL>2</VL>
<IDENTIFIERS MODIFIED="2009-02-11 16:57:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-08-08 09:52:08 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-08-08 09:52:08 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2009-08-06 14:50:31 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2009-02-11 16:58:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-APA-2004" MODIFIED="2009-03-14 18:09:52 +0000" MODIFIED_BY="[Empty name]" NAME="APA 2004" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Practice guidelines for the treatment of patients with schizophrenia</SO>
<YR>2004</YR>
<PG>1-114</PG>
<EN>2nd</EN>
<PB>American Journal of Psychiatry</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnt-1998" NAME="Arnt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Arnt J, Skarsfeldt T</AU>
<TI>Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>63-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bagnall-2000" MODIFIED="2012-08-08 09:50:04 +0100" MODIFIED_BY="[Empty name]" NAME="Bagnall 2000" TYPE="COCHRANE_REVIEW">
<AU>Bagnall A, Kleijnen J, Leitner M, Lewis R</AU>
<TI>Ziprasidone for schizophrenia and severe mental illness</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-08-08 09:50:04 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-08 09:50:04 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001945"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" MODIFIED="2008-11-03 14:58:54 +0000" MODIFIED_BY="[Empty name]" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1984" MODIFIED="2009-03-13 15:37:19 +0000" MODIFIED_BY="[Empty name]" NAME="Carpenter 1984" TYPE="JOURNAL_ARTICLE">
<AU>Heinrichs DW, Hanlon ET, Carpenter WT Jr</AU>
<TI>The quality of life scale an instrument for rating the schizophrenic deficit syndrome</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1984</YR>
<VL>10</VL>
<PG>388-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chouinard-1980" MODIFIED="2009-03-14 18:11:17 +0000" MODIFIED_BY="[Empty name]" NAME="Chouinard 1980" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Ross-Chouinard A, Annable L, Jones BD</AU>
<TI>The Extrapyramidal Symptom Rating Scale</TI>
<SO>Canadian Journal Neurological Sciences</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2009-03-14 18:11:53 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<PB>Cochrane Collaboration</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2005" MODIFIED="2012-08-08 09:50:12 +0100" MODIFIED_BY="[Empty name]" NAME="Duggan 2005" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-08-08 09:50:09 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-08 09:50:09 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-07-03 10:15:14 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder CSO</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Sayeh-2006" MODIFIED="2012-08-08 09:50:47 +0100" MODIFIED_BY="[Empty name]" NAME="El-Sayeh 2006" TYPE="COCHRANE_REVIEW">
<AU>El-Sayeh HG, Morganti C</AU>
<TI>Aripiprazole for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-08-08 09:50:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-08 09:50:47 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004578.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2009-07-03 14:46:44 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="11914310"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaebel-2006" NAME="Gaebel 2006" TYPE="OTHER">
<AU>Gaebel W, Falkai P, Weinmann S, Wobrock T</AU>
<TI>Treatment guidelines for schizophrenia</TI>
<TO>Behandlungsleitlinie Schizophrenie</TO>
<SO>Steinkopf</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2009-03-14 17:44:43 +0000" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="OTHER">
<AU>Guy 1976</AU>
<TI>ECDEU assessment for psychopharmacology.</TI>
<SO>National Institute of Mental Health</SO>
<YR>1976</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heres-2006" NAME="Heres 2006" TYPE="JOURNAL_ARTICLE">
<AU>Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S</AU>
<TI>Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>185-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-03-14 18:15:17 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2006" MODIFIED="2009-03-14 18:15:54 +0000" MODIFIED_BY="[Empty name]" NAME="Jones 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW</AU>
<TI>Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<PG>1079-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1988" NAME="Kane 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group</AU>
<TI>Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>789-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988325813"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kane-1993" NAME="Kane 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Treatment programme and long term outcome in chronic schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>46</VL>
<PG>585-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda (NY)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale Scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2008" MODIFIED="2008-12-04 14:06:47 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leucht C, Kitzmantel M, Chua L, Leucht S</AU>
<TI>Haloperidol versus chlorpromazine for treatment of schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2008</YR>
<VL>34</VL>
<PG>813-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liebermann-2005" NAME="Liebermann 2005" TYPE="JOURNAL_ARTICLE">
<AU>Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>1209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marvaha-2004" MODIFIED="2009-07-14 11:44:37 +0100" MODIFIED_BY="[Empty name]" NAME="Marvaha 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marvaha S, Johnson S</AU>
<TI>Schizophrenia and employment - a review</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2008-11-04 10:25:05 +0000" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-M_x00f6_ller-2000" NAME="Möller 2000" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ</AU>
<TI>New assessment of atypical antipsychotics</TI>
<TO>Aktuelle Bewertung neuer/atypischer Neuroleptika</TO>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<PG>329-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rust-1989" MODIFIED="2009-06-08 16:26:55 +0100" MODIFIED_BY="[Empty name]" NAME="Rust 1989" TYPE="BOOK">
<AU>Rust J, Golombok S</AU>
<SO>Modern Psychometrics</SO>
<YR>1989</YR>
<PB>Routledge</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2008-11-03 14:56:39 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson EN, Angus JWF</AU>
<TI>A rating scale for extrapyramidal side-effects</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tandon-2008" MODIFIED="2009-07-14 09:25:48 +0100" MODIFIED_BY="[Empty name]" NAME="Tandon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Tandon R, Keshavan MS, Nasralllah HA</AU>
<TI>Schizophrenia, "Just the Facts" What we know in 2008. 2. Epidemiology and etiology</TI>
<SO>Schizophrenia research</SO>
<YR>2008</YR>
<VL>102</VL>
<PG>1-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsuang-1978" MODIFIED="2009-07-14 09:25:48 +0100" MODIFIED_BY="[Empty name]" NAME="Tsuang 1978" TYPE="JOURNAL_ARTICLE">
<AU>Tsuang MT</AU>
<TI>Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>153-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2009-02-11 16:58:34 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>3-92</PG>
<IDENTIFIERS MODIFIED="2009-02-11 16:58:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001" MODIFIED="2012-08-08 09:52:08 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2001" TYPE="OTHER">
<AU>WHO</AU>
<TI>New understanding, new hope</TI>
<SO>The world health report 2001-Mental Health</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2007" MODIFIED="2009-07-03 14:46:03 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2007" TYPE="CONFERENCE_PROC">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y</AU>
<TI>The Leeds Outcomes Stakeholders Survey (LOSS) Study</TI>
<SO>Proceedings of the 15th Cochrane Colloquium, Sao Paulo, 23-27 October 2007</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-03-14 17:51:37 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Leucht-2009b" MODIFIED="2009-03-14 17:51:37 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2009b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Komossa K, Rummel-Kluge C, Hunger H, Schmid C, Schwarz S, Asenjo-Lobos C, Davis JM</AU>
<TI>A meta-analysis of head-to-head comparisons of second generation antipsychotics in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<NO>2</NO>
<PG>152-63</PG>
<IDENTIFIERS MODIFIED="2008-11-28 13:12:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-08-22 14:29:15 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-08-06 14:47:25 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-08-06 14:37:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addington-2004">
<CHAR_METHODS MODIFIED="2009-08-06 14:35:27 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: eight weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 14:37:44 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-III-R) schizophrenia (n=260) or schizoaffective disorder (n=36), acute exacerbation, PANSS total score of &#8805;60.<BR/>N=296.<BR/>Age: 18-64 years.<BR/>Gender: 215 M, 81 F.<BR/>History: duration of illness not reported, age at onset mean risperidone=24.6 years, mean ziprasidone=25.2 years.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 11:26:09 +0100" MODIFIED_BY="[Empty name]">
<P>1. Risperidone: flexible dose, allowed dose range: 6-10 mg/day, mean dose=7.4 mg/day. N=147.<BR/>2. Ziprasidone: flexible dose, allowed dose range: 80-160 mg/day, mean dose=114.2 mg/day. N=149.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-14 11:26:59 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS derived BPRS, BPRS positive subscore, PANSS negative subscore, depression MADRS.<BR/>General functioning: GAF.<BR/>Adverse effects: open interviews, EPS (akathisia, tremor, use of antiparkinson medication, AIMS, BAS, SAS), cardiac effects (ECG),<BR/>prolactin-associated side-effects, sedation, weight gain, laboratory (urine, blood chemistry).<BR/>
</P>
<P>Unable to use-<BR/>GAF total score (no usable data).<BR/>QTc abnormalities in ms (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 14:38:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breier-2005">
<CHAR_METHODS MODIFIED="2009-07-03 11:31:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 28 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 14:38:18 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, BPRS &#8805;42, CGI-S &#8805;4.<BR/>N=548.<BR/>Age: 18-75 years (mean olanzapine=40.1 years, mean ziprasidone=38.2 years).<BR/>Gender: 352 M, 196 F.<BR/>History: duration of illness not reported, age at onset mean olanzapine=23.9 years, mean ziprasidone=22.8 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 11:31:58 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose, allowed dose range: 10-20 mg/day, mean dose=15.27 mg/day. N=277.<BR/>2. Ziprasidone: flexible dose, allowed dose range: 80-160 mg/day, mean dose=115.96 mg/day. N=271.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-14 11:27:15 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, PANSS cognition subscore, depression MADRS, HAMD.<BR/>Quality of life: Heinrichs - Carpenter Scale.<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, dystonia, extrapyramidal symptoms, AIMS, BAS, SAS), cardiac effects (ECG), weight gain, laboratory (prolactin, glucose, lipids).<BR/>
<BR/>Unable to use-<BR/>Prolactin (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 14:39:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2006">
<CHAR_METHODS MODIFIED="2009-07-03 11:34:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 24 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 14:39:32 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia or schizoaffective disorder, dominant depressive symptoms, MADRS &#8805;16.<BR/>N=394.<BR/>Age: 18-60 years.<BR/>Gender: not reported.<BR/>History: duration of illness not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 11:33:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed dose: 10, 15 or 20 mg/day. N=202.<BR/>2. Ziprasidone: fixed dose: 80, 120 or 160 mg/day. N=192.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-14 11:27:26 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, depression MADRS, Calgary depression scale for schizophrenia.<BR/>General Functioning: GAF<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, AIMS, BAS, SAS), cardiac effects (ECG), weight gain, laboratory (prolactin, glucose, lipids).</P>
<P>Unable to use-<BR/>PANSS (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-14 10:01:56 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 14:40:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lieberman-2005">
<CHAR_METHODS MODIFIED="2009-07-03 11:34:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 78 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 14:40:26 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, more than one schizophrenic episode, responder.<BR/>N=1493.<BR/>Age: 18-65 years (mean=40.6 years).<BR/>Gender: 1080 M, 380 F.<BR/>History: duration of illness not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 11:34:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose, allowed dose range: 7.5-30 mg/day, mean dose=20.1 mg/day. N=336.<BR/>2. Perphenazine: flexible dose, allowed dose range: 8-32 mg/day, mean dose=20.8 mg/day. N=261.<BR/>3. Quetiapine: flexible dose, allowed dose range: 200-800 mg/day, mean dose=543.4 mg/day. N=337.<BR/>4. Risperidone: flexible dose, allowed dose range: 1.5-6.0 mg/day, mean dose=3.9 mg/day. N=341.<BR/>5. Ziprasidone: flexible dose, allowed dose range: 40-160 mg/day, mean dose=112.8 mg/day. N=185.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-06 14:40:56 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI-S<BR/>Mental State: PANSS total score<BR/>Service use: number of patients re-hospitalised.<BR/>Death: suicide attempt.<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, akathisia), cardiac effects (ECG), prolactin-associated side-effects, sedation, weight gain, laboratory (prolactin, lipids, glucose).</P>
<P>Unable to use-<BR/>Withdrawal due to 'extrapyramidal effects' (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-06 14:40:48 +0100" MODIFIED_BY="[Empty name]">
<P>33 patients were excluded before analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 14:42:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olie-2006">
<CHAR_METHODS MODIFIED="2009-07-03 11:36:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 14:42:07 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-III-R) chronic schizophrenia, PANSS negative subscore at least 6 points higher than PANSS positive subscore.<BR/>N=123.<BR/>Age: 18-64 years (mean=39 years).<BR/>Gender: 79 M, 44 F.<BR/>History: duration of illness not reported, age at onset not reported.<BR/>Setting: outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 11:36:47 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose, allowed dose range: 100-200 mg/day, mean dose=144.7 mg/day. N=63.<BR/>2. Ziprasidone: flexible dose, allowed dose range: 80-160 mg/day, mean dose=118.0 mg/day. N=60.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-14 11:27:51 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, BPRS total score, PANSS negative subscore<BR/>General Functioning: GAF<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, akathisia, parkinsonism, movement disorder burden score), cardiac effects (ECG), sedation, weight gain, laboratory (urine, blood chemistry).<BR/>
</P>
<P>Unable to use-<BR/>GAF (no data)<BR/>Laboratory (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 14:43:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2006">
<CHAR_METHODS MODIFIED="2009-07-03 11:38:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 18 weeks.<BR/>Design: parallel.<BR/>Location: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 14:43:18 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia, non-response to or intolerance of three previous antipsychotic treatment trials.<BR/>N=146.<BR/>Age: mean clozapine=38.3 years, mean ziprasidone=41.6 years.<BR/>Gender: 101 M, 45 F.<BR/>History: duration of illness not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 11:38:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose, allowed dose range: 250-600 mg/day, mean dose=345.7 mg/day. N=73.<BR/>2. Ziprasidone: flexible dose, allowed dose range: 80-160 mg/day, mean dose=130.4 mg/day. N=73.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-14 10:15:10 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, depression Calgary depression scale for schizophrenia.<BR/>Adverse effects: cardiac effects (ECG), laboratory.<BR/>
</P>
<P>Unable to use-<BR/>PANSS positive, negative subscore (no data).<BR/>CGI (no data).<BR/>Laboratory parameters (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 14:44:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simpson-2004">
<CHAR_METHODS MODIFIED="2009-08-06 14:43:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: six weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 14:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) acute schizophrenia (n=170) or schizoaffective disorder (n=99). CGI-S score &#8805;4, CGI-I score &#8805;3.<BR/>N=269.<BR/>Age: 18-55 years (mean olanzapine=37.6 years, mean ziprasidone=37.7 years).<BR/>Gender: 176 M, 93 F.<BR/>History: duration of illness mean olanzapine=14.0, mean risperidone=15.4, age at onset mean olanzapine=23.7 years, mean ziprasidone=22.2 years.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 11:41:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose, allowed dose range: 5-15 mg/day, mean dose=11.3 mg/day. N=133. <BR/>2. Ziprasidone: flexible dose, allowed dose range: 80-160 mg/day, mean dose=129.9 mg/day. N=136.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-14 11:29:20 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: BPRS total score, depression Calgary depression scale for schizophrenia.<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, ESRS) cardiac effects (ECG), weight gain, laboratory.<BR/>
</P>
<P>Unable to use-<BR/>Laboratory (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 14:45:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stroup-2006">
<CHAR_METHODS MODIFIED="2009-08-06 14:45:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: two step randomisation before and after the availability of ziprasidone.<BR/>Blinding: double, identical capsules.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 14:45:30 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) chronic schizophrenia.<BR/>N=444.<BR/>Age: 18-65 years (mean olanzapine=40.0 years, mean quetiapine=40.1 years, mean risperidone=41.8 years, mean ziprasidone=41.3 years).<BR/>Gender: 308 M, 136 F.<BR/>History: duration of illness not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 11:42:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose, allowed dose range: 7.5-30 mg/day, mean dose=20.5 mg/day. N=108.<BR/>2. Quetiapine: flexible dose, allowed dose range: 200-800 mg/day, mean dose=565.2 mg/day. N=95.<BR/>3. Risperidone: flexible dose, allowed dose range: 1.5-6.0 mg/day, mean dose=4.1 mg/day. N=104.<BR/>4. Ziprasidone: flexible dose, allowed dose range: 40-160 mg/day, mean dose=115.9 mg/day. N=137.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-14 10:23:55 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score.<BR/>Death: suicide.<BR/>Adverse effects: open interviews, EPS (akathisia), cardiac effects (ECG),<BR/>prolactin-associated side-effects, weight gain, laboratory (prolactin, glucose, cholesterol).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 14:47:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svestka-2005">
<CHAR_METHODS MODIFIED="2009-08-06 14:46:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blinding: double, no further details.<BR/>Duration: six weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 14:47:00 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (ICD-10) acute schizophrenia, schizoaffective disorder. N=48.<BR/>Age: not reported.<BR/>Gender: not reported.<BR/>History: duration of illness not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-06 14:47:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: dose: not reported, allowed dose range: not reported, mean dose: not reported. N=24.<BR/>2. Ziprasidone: dose: not reported, allowed dose range: not reported, mean dose: not reported. N=24.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-14 10:27:08 +0100" MODIFIED_BY="[Empty name]">
<P>Mental State: PANSS total score.<BR/>Adverse effects: EPS (akathisia, parkinsonoid, dystonia).</P>
<P>Unable to use-<BR/>EPS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-22 10:28:53 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Diagnostic tool<BR/>DSM III-R and DSM-IV - Diagnostic Statistical Manual version 3 Revised and version 4.<BR/>ICD 10 - The International Statistical Classification of Diseases and Related Health Problems.<BR/>BMI - Body Mass Index.</P>
<P>Rating Scales:</P>
<P>Global rating scales:<BR/>CGI - Clinical Global Impressions.<BR/>CGI-S - Clinical Global Impression-Severity.<BR/>CGI-I - Clinical Global Impression-Improvement.<BR/>
</P>
<P>Mental state:<BR/>BPRS - Brief Psychiatric Rating Scale.<BR/>MADRS - Montgomery-Asberg Depression Rating Scale.<BR/>MMSE - Wiing Mini Mental State Examination.<BR/>PANSS - Positive and Negative Syndrome Scale.<BR/>SANS - Scale for the Assessment of Negative Symptoms.</P>
<P>Side effects:<BR/>AIMS - Abnormal Involuntary Movement Scale.<BR/>BAS - Barnes Akathisia Scale.<BR/>BMI - Body mass index.<BR/>ESRS - Extrapyramidal Syndrome Rating Scale.<BR/>HAS - Hillside Akathisia Scale.<BR/>SAS - Simpson-Angus Index - for neurological side effects.<BR/>UKU - Udvalg for kliniske ndersogelser Side Effect Rating Scale -side effect rating scale.</P>
<P>Quality of Life:<BR/>QoL - Quality of Life Scale.<BR/>SWN -Subjective Well-being List.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-08-06 14:48:15 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-07-28 16:42:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ascher_x002d_Svanum-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 16:42:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-06 14:47:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baloescu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-06 14:47:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-03 11:47:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hagger-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 11:47:01 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-03 11:47:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harrigan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 11:47:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-03 11:47:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harrison-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 11:47:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised,<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: olanzapine versus ziprasidone.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-03 11:47:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swanson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 11:47:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-03 11:47:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 11:47:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-06 14:48:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tudor-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-06 14:48:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation unclear.<BR/>Participants: people with schizophrenia.<BR/>Intervention: inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-11 17:07:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uzun-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-11 17:07:53 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear, pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-08-22 14:29:15 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2012-08-12 22:17:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-A1281039">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:17:55 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12610000954022">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:08 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addington-2004a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:11 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addington-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:21 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Agid-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:23 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allison-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:33 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anon-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:35 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baldacara-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:37 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beuzen-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:45 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beuzen-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:48 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breier-2005a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:50 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caroff-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:18:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CATIE">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:18:58 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:19:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ChiCTR_x002d_TRC_x002d_10000934">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:19:04 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:19:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dunn-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:19:07 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:19:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eng-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:19:12 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:19:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUFEST">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:19:14 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:19:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fahnestock-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:19:17 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:19:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischhacker-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:19:23 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:19:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geng-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:19:26 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:19:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldstein-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:19:30 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:19:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gong-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:19:35 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:21:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gouzoulis_x002d_Mayfrank-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:21:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grootens-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:21:22 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:21:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grootens-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:21:25 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:21:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grootens-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:21:27 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:21:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harrison-2004a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:21:30 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:21:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harvey-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:21:41 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:21:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harvey-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:21:43 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:21:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harvey-2007a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:21:45 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:21:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harvey-2007b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:21:52 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:21:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harvey-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:21:54 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:22:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Houston-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:22:02 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:22:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:22:10 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:22:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-2008a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:22:13 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:22:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnsen-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:22:16 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:22:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnsen-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:22:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnsen-2010a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:22:46 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:22:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnsen-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:22:48 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:22:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kane-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:22:55 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:22:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keefe-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:22:57 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:23:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:23:44 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:23:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kjelby-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:23:42 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:23:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuwilsky-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:23:36 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:23:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:23:31 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:23:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2007a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:23:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liang-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:23:22 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:23:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:23:16 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:23:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2008a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:23:13 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:23:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loza-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:23:03 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:23:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:23:05 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:23:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:23:07 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lublin-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:00 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyer-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyer-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:05 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyer-2006a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:11 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyer-2006b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:14 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murray-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:20 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nai-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:22 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00077727">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:29 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00145444">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:31 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00148564">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:37 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00159770">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:42 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00224315">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:52 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:24:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00225498">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:24:55 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:25:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00239109">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:25:02 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:25:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00283179">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:25:05 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:25:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00418171">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:25:13 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:25:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00515723">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:25:26 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:25:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00634348">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:25:55 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:25:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00645372">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:25:57 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:26:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00645515">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:26:08 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:26:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00649844">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:26:11 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:26:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00932529">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:26:13 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:26:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newcomer-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:26:21 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:26:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newcomer-2009a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:26:23 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:26:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nie-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:26:26 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:26:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olfson-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:26:48 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:26:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parsons-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:26:50 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:26:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pfizer-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:26:54 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:27:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pfizer-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:27:36 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:27:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pfizer-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:27:39 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:27:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rappard-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:27:40 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:27:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ross-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:28:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roychowdhury-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:28:00 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:28:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2006a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:28:09 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:28:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2006b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:28:39 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:28:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2006c">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:28:41 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:28:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:28:44 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:29:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2007a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:29:06 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:29:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:29:07 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:29:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2009a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:29:09 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:29:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2009b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:29:14 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:29:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2009c">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:29:21 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:29:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Samochowiec-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:29:30 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:29:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schooler-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:29:32 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:29:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schooler-2011a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:29:34 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:30:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shang-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:30:58 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shang-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:00 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shuai-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:05 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simpson-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:07 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simpson-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:12 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sonmez-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:14 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sramek-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:19 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Street-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:21 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strom-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:27 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strom-2007a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:29 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strom-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:33 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strom-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:35 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strom-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:40 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:42 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svestka-2005a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:47 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swartz-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:49 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tao-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:53 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:31:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taylor-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:31:55 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Brunt-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:01 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Veelen-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:02 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:07 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:09 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2008a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:13 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2008b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:17 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warrington-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:23 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wei-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:25 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiden-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:29 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolf-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:31 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Woodruff-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:36 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2012">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:37 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:42 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yi-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:44 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yue-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:48 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:50 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2008a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:56 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2008b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:32:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:32:59 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:33:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:33:11 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:33:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:33:13 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:33:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zimbroff-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:33:21 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:33:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zink-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:33:23 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:33:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zou-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:33:28 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:33:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x4efb__x5217__x002c_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:33:30 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:33:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x4f55__x6587__x521a_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:33:37 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:33:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5170__x5e86__x699c_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:33:43 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:33:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5189__x660c__x534e_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:33:45 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:33:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5192__x96f7__x660e_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:33:53 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:33:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x51af__x9f99__x559c_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:33:55 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x56fd__x96c4_-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:00 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x5fe0_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:02 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x6653__x7ea2_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:04 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x6d2a__x79cb_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:10 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x743c__x534e_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:12 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5355__x7f8e__x8273_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:14 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5362__x6bbf__x519b_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:28 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5362__x6bbf__x519b_-2011a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:29 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5434__x8fdc__x82b3_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:31 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5468__x4e91_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:39 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5468__x6d77__x6653_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:42 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x55bb__x5fd7__x654f_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:48 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5b59__x4ed8__x6839_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:49 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5b59__x4ed8__x6839_-2009a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:51 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5b59__x5e73_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:56 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:34:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5b59__x6bc5_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:34:57 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5b59__x7231__x6c11_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5b63__x6797__x5f71_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:04 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5b8b__x65b0__x8679_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:09 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5bc7__x6842__x654f__x002c_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:10 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5c48__x5efa__x65b0_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:15 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5d14__x5f00__x8273_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:17 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5d14__x96bd__x002c_-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:22 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5e9e__x826f__x4fca_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:23 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x5c0f__x667a_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:28 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x5cf0_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:34 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x660e__x677e_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:36 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:52:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x7396__x9f99_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:52:27 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:52:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x8273__x7426_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:52:29 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:52:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x9999__x829d_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:52:31 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:52:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x9e3f__x71d5__x002c_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:52:41 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f6d__x4eae_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:41 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f6d__x6c5d__x6625_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f90__x56fd__x6d2a_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:49 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f90__x5a1f_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:51 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f90__x677e__x002c_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:57 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:35:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f90__x8389__x840d_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:35:59 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x65b9__x4f20__x8363_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:04 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6613__x5cf0_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:06 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6731__x5fd7__x9ad8_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:11 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x4ed5__x519b_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:13 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x4f5c__x73cd_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:17 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x542f__x658c_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:19 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x56fd__x80dc_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:23 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x57f9__x8f69_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:25 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x6625__x82b1_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:30 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x6811__x654f_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:31 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x6881_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:36 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x8f76__x7fa4_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:38 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x660e__x534e__x002c_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:43 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x8001__x864e_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:45 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x80dc__x826f_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:50 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x8bda__x002c_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:51 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x987a__x624d_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:56 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:36:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6797__x5353__x6bc5_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:36:58 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6797__x654f_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:18 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6bb5__x6b66__x521a_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:20 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6bb5__x6b66__x94a2_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:24 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6bb7__x6708__x73cd_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:26 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6e29__x5360__x7ea2_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6f58__x5929__x4f1f_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6f58__x6587__x71d5_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x718a__x8f89_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:39 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x738b__x4f53__x5bbe_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:43 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x738b__x5929__x9f99_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:45 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x738b__x5b66__x519b_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:50 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x738b__x65b9__x56fd_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:52 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x738b__x6c38__x5b66_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:56 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:37:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x738b__x79c0__x82b3_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:37:58 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:38:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x738b__x91d1__x5802_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:38:03 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:38:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x767d__x5251__x6587_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:38:04 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:38:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x767d__x9526__x6ce2_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:38:14 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:38:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x76ae__x73a5__x73a5_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:38:15 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:38:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x79e6__x6377_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:38:17 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:38:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x7a0b__x5e73_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:38:45 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:38:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x7a0b__x71d5_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:38:47 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:38:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x7ba1__x92ae__x53cb_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:38:50 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:38:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x80e1__x534e__x5ef7_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:38:59 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:39:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x83ab__x4e9a__x8389_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:39:00 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:39:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8463__x4f1f_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:39:02 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:39:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8463__x4f1f_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:39:45 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:39:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8463__x592a__x65b0_-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:39:47 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:39:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8521__x8fdb__x4f1f_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:39:50 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:40:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8983__x677e_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:40:08 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:40:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8bb8__x4e9a__x5e73_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:40:10 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:40:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8bb8__x5fd7__x5e73_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:40:12 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:40:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8c22__x709c__x9e9f_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:40:19 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:40:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8c22__x80b2__x5357_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:40:21 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:40:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8d75__x656c__x5e73_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:40:23 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:40:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8d75__x660e__x4e3d_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:40:28 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:40:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8d75__x9752__x971e_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:40:30 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:40:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9093__x5e7f_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:40:31 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:40:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x90a2__x9999__x7136_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:40:45 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:41:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x90d1__x5b66__x5b9d_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:41:17 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:41:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x90d1__x5e86__x6885_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:41:19 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:41:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x949f__x5c0f__x5175_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:41:21 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:41:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x963f__x6000__x7ea2_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:41:26 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:41:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9646__x7231__x76ca_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:41:28 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:41:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9648__x6069__x6c11_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:41:38 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:41:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9648__x6167_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:41:40 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:41:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9648__x6625__x6885_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:41:41 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:44:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x96f7__x5e86__x534e_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:44:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x989c__x5efa__x8f89_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:44:26 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:44:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9a6c__x5146__x5cf0_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:44:36 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:44:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9ad8__x661f__x6d77_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:44:38 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:44:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9ec4__x5cf0_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:44:39 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:44:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9ec4__x632f__x82f1_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:44:45 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-08-12 22:44:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9ec4__x667a__x8f89_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-12 22:44:47 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-08-06 14:49:21 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-08-06 14:48:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mortimer-2001">
<CHAR_STUDY_NAME MODIFIED="2009-01-13 13:50:44 +0000" MODIFIED_BY="[Empty name]">
<P>A1281014</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-03 11:47:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, double-dummy.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 14:48:41 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder.<BR/>N=unknown.<BR/>Age: unknown.<BR/>Gender: unknown.<BR/>History: duration of illness unknown, age at onset unknown.<BR/>Setting: unknown.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-06 14:48:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine:dose: unknown, allowed dose range: unknown, mean dose: unknown. N=unknown.<BR/>2. Ziprasidone: dose: unknown, allowed dose range: unknown, mean dose: unknown. N=unknown.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-13 15:25:25 +0000" MODIFIED_BY="[Empty name]">
<P>Unknown.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-01-13 13:50:44 +0000" MODIFIED_BY="[Empty name]">
<P>6 October 2000.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-13 13:50:44 +0000" MODIFIED_BY="[Empty name]">
<P>Prof Ann Mortimer<BR/>Coniston House<BR/>East Riding Campus<BR/>Willerby<BR/>HU10 6NS<BR/>UK<BR/>Telephone: 01482 466700<BR/>E-mail: A.M.Mortimer@medschool.hull.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-01-13 13:50:44 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-08-06 14:49:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reveley-2003">
<CHAR_STUDY_NAME MODIFIED="2009-01-13 13:51:17 +0000" MODIFIED_BY="[Empty name]">
<P>MREC/00/147</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-03 11:48:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, double-dummy.<BR/>Duration: unknown.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 14:49:09 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder.<BR/>N=unknown.<BR/>Age: 18-70 years.<BR/>Gender: unknown.<BR/>History: duration of illness unknown, age at onset unknown.<BR/>Setting: unknown.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-06 14:49:21 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine:dose: unknown, allowed dose range: unknown, mean dose: unknown. N=unknown.<BR/>2. Ziprasidone: dose: unknown, allowed dose range: unknown, mean dose: unknown. N=unknown.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-13 15:27:50 +0000" MODIFIED_BY="[Empty name]">
<P>Global state (CGI).<BR/>General Mental State (PANSS).<BR/>Quality of life (QLS).<BR/>Health of the nation outcome scale (HoNOS).<BR/>Drug attitude inventory (DAI).<BR/>Resource utilization questionnaire.<BR/>Treatment costs.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-01-13 13:51:17 +0000" MODIFIED_BY="[Empty name]">
<P>1 May 2001</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-13 13:51:17 +0000" MODIFIED_BY="[Empty name]">
<P>Professor Michael Reveley<BR/>Department of Psychiatry<BR/>Section of Neuropsychiatry &amp; Psychopharmacology<BR/>Leicester General Hospital<BR/>Leicester<BR/>LE5 4PW<BR/>United Kingdom<BR/>Telephone: 0116 225 7924<BR/>E-mail: reveleym@leicspart.nhs.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-01-13 13:51:17 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-08-06 14:46:45 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-08-06 14:46:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:32:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:33:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:35:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:36:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-06 14:17:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:44:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:40:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 14:46:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Random, 2 step randomisation before and after the availability of ziprasidone, Participants were re-randomised to a different medication than they had received in previous phase 1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:42:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-03-13 15:01:43 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:32:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:33:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>No further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:35:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:36:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>No further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-13 15:01:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:44:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:40:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:41:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:42:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-03-13 15:21:53 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-06 14:16:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-11 15:32:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-13 13:53:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-11 15:34:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-06 14:16:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-11 15:36:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-06 14:16:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-11 15:37:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-13 15:01:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-11 15:39:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-13 15:04:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-11 15:44:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-13 15:05:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-11 15:40:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-13 15:19:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-11 15:41:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-13 15:21:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-11 15:43:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-08-06 14:44:45 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-06 14:36:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>The attrition rate was 33%. The last observation carried forward method was used to account for people leaving the study early. Data on study completers were also available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-06 14:39:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>The overall attrition was high (48.9%). The last observation carried forward method was used for people leaving the study early. Additionally a mixed models analysis was performed but it is unclear whether any statistical method can account for such high numbers leaving the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-06 14:39:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>The overall attrition was very high (62.7%). The last observation carried forward method was used for people leaving the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-13 13:59:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>The attrition was extremely high (75%), and it is unclear whether any statistical method can account for such a high dropout rate. Efficacy outcomes were evaluated based on mixed models analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-06 14:42:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>The rate of leaving the study early was about 25%, the analysis was based on the 'least squares mean change' (last observation carried forward). It is unclear whether the degree of attrition and the method used to account for it led to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-06 14:43:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>The overall attrition was 38.4%. Data on reasons for dropout were not available. The last observation carried forward method was used to account for people leaving the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-06 14:44:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>The overall attrition was high (42.8%). The last observation carried forward method was used to account for people leaving the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-13 15:19:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>The attrition rate was extremely high (72.5%). Efficacy data analysis was based on mixed models, but it is unclear whether any statistical method can account for such high dropout rates.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-11 15:43:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Data on subjects leaving the study early were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-08-06 14:39:11 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:33:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>Reporting on secondary outcomes was incomplete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 14:39:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>Only adverse effects with an incidence of at least 10% were reported therefore important side-effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:35:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>Secondary outcomes were not fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 18:01:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>No evidence for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 11:37:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>Predefined laboratory data and data on the Global Assessment of Functioning Scale have not been presented. Treatment emergent adverse events had to occur with an incidence of 5% for reporting. Important side-effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 16:06:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>Data were only presented as an abstract. Primary and secondary outcome data were reported incompletely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-13 15:05:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>The study focused on acutely ill schizophrenic or schizoaffective patients but data on the positive symptom subscore were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:41:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Use of antiparkinson medication was permitted but data on this was not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:43:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Allowed study medication dose ranges were not indicated. A publication was not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-08-06 14:46:45 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:33:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of ziprasidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:34:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 15:35:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 14:41:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Dose ranges were quite different, the upper dose range of olanzapine was 30 mg whereas risperidone could only be titrated up to 6 mg /day. No wash-out period. An overlap in the administration of formerly given antipsychotics was permitted for the first four weeks after randomisation. Allocation to ziprasidone treatment was not possible from the start of the study because ziprasidone was only available at later stages.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-13 15:02:33 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturers of ziprasidone.</P>
<P>The dose of ziprasidone could be increased to the maximum daily dose, whereas amisulpride could only be increased up to 200 mg which might have led to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 16:09:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturers of ziprasidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 14:44:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of ziprasidone. The upper dose limit of olanzapine was 15 mg/day which is below the maximum dose for this medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 14:46:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Patients had a history of intolerance to atypical antipsychotic treatment but baseline data on this were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 18:06:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Insufficient information, although the first author kindly provided us some.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-07-03 11:49:28 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-07-03 11:49:28 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-12-13 17:07:58 +0000" MODIFIED_BY="[Empty name]">Suggested design of future study</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: randomised - clearly described generation of sequence and concealment of allocation.<BR/>Blindness: double - described and tested.<BR/>Duration: 6 months minimum.</P>
</TD>
</TR>
<TR>
<TH>
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia (operational criteria).<BR/>N=2700.*<BR/>Age: any.<BR/>Sex: both.<BR/>History: any.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1. Ziprasidone: dose ~ 120-160 mg/day. N=300.<BR/>2. Amisulpride: dose ~ 400-800 mg/day. N=300.<BR/>3. Aripiprazole: dose ~ 10-30 mg/day. N=300.<BR/>4. Clozapine: dose ~ 300-800 mg/day. N=300.<BR/>5. Olanzapine: dose ~ 10-20 mg/day. N=300.<BR/>6. Quetiapine: dose ~ 300-800 mg/day. N=300.<BR/>7. Risperidone: dose ~ 4-8 mg/day. N=300.<BR/>8. Sertindole: dose ~ 12-24 mg/day. N=300.<BR/>9. Zotepine: dose ~ 100-300 mg/day. N=300.</P>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Leaving study early: any reason, adverse events, inefficacy.<BR/>Service outcomes: hospitalised, time in hospital, attending out patient clinics.<BR/>Global impression: CGI**, relapse.<BR/>Mental state: PANSS.<BR/>Adverse events: UKU.<BR/>Employment, family satisfaction, patient satisfaction.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<BR/>** Primary outcome<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-08-06 14:55:33 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-07-30 09:43:25 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>ZIPRASIDONE versus AMISULPRIDE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1852937853061514" CI_START="0.9301491441762969" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.0738260073283669" LOG_CI_START="-0.03144740918849071" LOG_EFFECT_SIZE="0.021189299069938092" METHOD="MH" MODIFIED="2009-07-30 09:43:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.43011312142355596" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="0.7889981043424464">
<NAME>No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1852937853061514" CI_START="0.9301491441762969" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" LOG_CI_END="0.0738260073283669" LOG_CI_START="-0.03144740918849071" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="898" O_E="0.0" SE="0.06183812597381831" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.0038239538239538233" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.074602970918261" CI_END="2.6507860244153933" CI_START="0.9138943949809875" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5564506063499617" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" I2="34.950950775843424" I2_Q="33.78760469296636" ID="CMP-001.02" LOG_CI_END="0.4233746722196196" LOG_CI_START="-0.03910398624297796" LOG_EFFECT_SIZE="0.19213534298832086" METHOD="MH" MODIFIED="2009-07-30 09:18:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2149604817708921" P_Q="0.22084572492879562" P_Z="0.10341423221282649" Q="3.020582461525211" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1886169984551638" TOTALS="SUB" TOTAL_1="180" TOTAL_2="189" WEIGHT="300.0" Z="1.6285220756616368">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.77503327942887E-31" CI_END="2.701530259939674" CI_START="0.7823968031734921" DF="0" EFFECT_SIZE="1.4538461538461538" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="100.0" ID="CMP-001.02.01" LOG_CI_END="0.43160983645090306" LOG_CI_START="-0.10657293271808835" LOG_EFFECT_SIZE="0.16251845186640734" NO="1" P_CHI2="0.0" P_Z="0.23652179373849358" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.00000000000001" Z="1.183725420913077">
<NAME>Any reason</NAME>
<DICH_DATA CI_END="2.701530259939674" CI_START="0.7823968031734921" EFFECT_SIZE="1.4538461538461538" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.43160983645090306" LOG_CI_START="-0.10657293271808835" LOG_EFFECT_SIZE="0.16251845186640734" ORDER="895" O_E="0.0" SE="0.3161312226575381" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.09993894993894994" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.496645143988354E-32" CI_END="3.372669756766324" CI_START="0.18387695645440197" DF="0" EFFECT_SIZE="0.7875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="100.0" ID="CMP-001.02.02" LOG_CI_END="0.5279738182613507" LOG_CI_START="-0.7354726933380746" LOG_EFFECT_SIZE="-0.1037494375383619" NO="2" P_CHI2="0.0" P_Z="0.7475363149039617" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="0.32188962354102046">
<NAME>Adverse events</NAME>
<DICH_DATA CI_END="3.372669756766324" CI_START="0.18387695645440197" EFFECT_SIZE="0.7875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5279738182613507" LOG_CI_START="-0.7354726933380746" LOG_EFFECT_SIZE="-0.1037494375383619" ORDER="896" O_E="0.0" SE="0.7421547350746006" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.5507936507936506" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.98257374427306" CI_START="1.064007936876357" DF="0" EFFECT_SIZE="4.725" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="1.3218587581368448" LOG_CI_START="0.026944867553718586" LOG_EFFECT_SIZE="0.6744018128452817" NO="3" P_CHI2="1.0" P_Z="0.04119810044743251" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="2.0415307518093564">
<NAME>Inefficacy</NAME>
<DICH_DATA CI_END="20.98257374427306" CI_START="1.064007936876357" EFFECT_SIZE="4.725" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3218587581368448" LOG_CI_START="0.026944867553718586" LOG_EFFECT_SIZE="0.6744018128452817" ORDER="897" O_E="0.0" SE="0.7606388292556648" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.5785714285714285" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.512355382143777" CI_START="0.817281953593212" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.111764705882353" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.1796538562238319" LOG_CI_START="-0.08762809063389149" LOG_EFFECT_SIZE="0.046012882794970233" METHOD="MH" MODIFIED="2009-07-30 09:38:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4997901773416693" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="63" WEIGHT="99.99999999999999" Z="0.6748199357512902">
<NAME>Global State: No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.512355382143777" CI_START="0.817281953593212" DF="0" EFFECT_SIZE="1.111764705882353" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="34" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.1796538562238319" LOG_CI_START="-0.08762809063389149" LOG_EFFECT_SIZE="0.046012882794970233" NO="1" P_CHI2="1.0" P_Z="0.4997901773416693" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="63" WEIGHT="99.99999999999999" Z="0.6748199357512902">
<NAME>Short term</NAME>
<DICH_DATA CI_END="1.5123553821437772" CI_START="0.817281953593212" EFFECT_SIZE="1.111764705882353" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="34" LOG_CI_END="0.17965385622383195" LOG_CI_START="-0.08762809063389149" LOG_EFFECT_SIZE="0.046012882794970233" ORDER="899" O_E="0.0" SE="0.15700273865120185" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.024649859943977587" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.949487354480153" CI_START="-3.5494873544801546" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.6999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2009-07-03 12:07:26 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3971211690878793" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="63" UNITS="" WEIGHT="100.0" Z="0.846773896496401">
<NAME>Mental state: 1a. General mental state: PANSS total score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.949487354480153" CI_START="-3.5494873544801546" DF="0" EFFECT_SIZE="2.6999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="1.0" P_Z="0.3971211690878793" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="63" WEIGHT="100.0" Z="0.846773896496401">
<NAME>Short term</NAME>
<CONT_DATA CI_END="8.949487354480153" CI_START="-3.5494873544801546" EFFECT_SIZE="2.6999999999999993" ESTIMABLE="YES" MEAN_1="-11.9" MEAN_2="-14.6" ORDER="900" SD_1="17.6" SD_2="17.6" SE="3.1885725471362294" STUDY_ID="STD-Olie-2006" TOTAL_1="59" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.721861989528271" CI_START="-1.5218619895282717" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2009-07-03 12:07:19 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.25578454821994423" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="63" UNITS="" WEIGHT="100.0" Z="1.1364111552108564">
<NAME>Mental state: 1b. General mental state: BPRS total score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.721861989528271" CI_START="-1.5218619895282717" DF="0" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="1.0" P_Z="0.25578454821994423" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="63" WEIGHT="100.0" Z="1.1364111552108564">
<NAME>Short term</NAME>
<CONT_DATA CI_END="5.7218619895282705" CI_START="-1.5218619895282712" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="-7.3" ORDER="901" SD_1="10.2" SD_2="10.2" SE="1.8479227261812237" STUDY_ID="STD-Olie-2006" TOTAL_1="59" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1852937853061514" CI_START="0.9301491441762969" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.0738260073283669" LOG_CI_START="-0.03144740918849071" LOG_EFFECT_SIZE="0.021189299069938092" METHOD="MH" MODIFIED="2009-07-03 12:07:42 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.43011312142355596" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="0.7889981043424464">
<NAME>Mental state: 2a. Negative symptoms: no clinically important change (less than 50% PANSS negative subscore reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1852937853061514" CI_START="0.9301491441762969" DF="0" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.0738260073283669" LOG_CI_START="-0.03144740918849071" LOG_EFFECT_SIZE="0.021189299069938092" NO="1" P_CHI2="1.0" P_Z="0.43011312142355596" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="0.7889981043424464">
<NAME>Short term</NAME>
<DICH_DATA CI_END="1.1852937853061514" CI_START="0.9301491441762969" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" LOG_CI_END="0.0738260073283669" LOG_CI_START="-0.03144740918849071" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="902" O_E="0.0" SE="0.06183812597381831" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.0038239538239538233" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.001523954419146" CI_START="-1.4015239544191447" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2009-07-03 12:07:54 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.4763280538853417" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="63" UNITS="" WEIGHT="100.0" Z="0.7122208161690167">
<NAME>Mental state: 2b. Negative symptoms: PANSS negative subscore (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.001523954419146" CI_START="-1.4015239544191447" DF="0" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.4763280538853417" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="63" WEIGHT="100.0" Z="0.7122208161690167">
<NAME>Short term</NAME>
<CONT_DATA CI_END="3.001523954419146" CI_START="-1.4015239544191447" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="-6.1" MEAN_2="-6.9" ORDER="903" SD_1="6.2" SD_2="6.2" SE="1.1232471472866263" STUDY_ID="STD-Olie-2006" TOTAL_1="59" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.512355382143777" CI_START="0.817281953593212" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.111764705882353" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.1796538562238319" LOG_CI_START="-0.08762809063389149" LOG_EFFECT_SIZE="0.046012882794970233" METHOD="MH" MODIFIED="2009-07-03 12:08:04 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.4997901773416693" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="63" WEIGHT="99.99999999999999" Z="0.6748199357512902">
<NAME>Adverse effects: 1. At least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5123553821437772" CI_START="0.817281953593212" EFFECT_SIZE="1.111764705882353" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="34" LOG_CI_END="0.17965385622383195" LOG_CI_START="-0.08762809063389149" LOG_EFFECT_SIZE="0.046012882794970233" ORDER="904" O_E="0.0" SE="0.15700273865120185" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.024649859943977587" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-03 12:08:16 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="60" TOTAL_2="63" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 2. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="905" O_E="0.0" SE="0.0" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4965210819213723" CI_END="3.1703659084860876" CI_START="1.0689160791848409" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8408843245788789" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.5011093893046924" LOG_CI_START="0.02894361000053856" LOG_EFFECT_SIZE="0.2650264996526155" METHOD="MH" MODIFIED="2009-07-03 12:08:27 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.4731890336286986" P_Q="0.48726400533891856" P_Z="0.027788857348777226" Q="1.4378986993294036" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="180" TOTAL_2="189" WEIGHT="300.0" Z="2.20025430488996">
<NAME>Adverse effects: 3. Extrapyramidal side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.539216954562802E-32" CI_END="9.099047192171593" CI_START="0.27262469878540874" DF="0" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="100.0" ID="CMP-001.10.01" LOG_CI_END="0.9589959175027474" LOG_CI_START="-0.5644348012515088" LOG_EFFECT_SIZE="0.19728055812561932" NO="1" P_CHI2="0.0" P_Z="0.6117190921331659" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="0.5076211002130213">
<NAME>Akathisia</NAME>
<DICH_DATA CI_END="9.099047192171593" CI_START="0.27262469878540874" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9589959175027474" LOG_CI_START="-0.5644348012515088" LOG_EFFECT_SIZE="0.19728055812561932" ORDER="906" O_E="0.0" SE="0.8948707452999292" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.8007936507936506" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.3472915525650574E-32" CI_END="50.79617637949438" CI_START="0.7813580239480826" DF="0" EFFECT_SIZE="6.299999999999999" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="100.0" ID="CMP-001.10.02" LOG_CI_END="1.705831022524394" LOG_CI_START="-0.10714992361723058" LOG_EFFECT_SIZE="0.7993405494535817" NO="2" P_CHI2="0.0" P_Z="0.08393619190393033" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="1.7282902963163234">
<NAME>Parkinsonism</NAME>
<DICH_DATA CI_END="50.79617637949438" CI_START="0.7813580239480826" EFFECT_SIZE="6.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.705831022524394" LOG_CI_START="-0.10714992361723058" LOG_EFFECT_SIZE="0.7993405494535817" ORDER="907" O_E="0.0" SE="1.0649539821640108" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="1.1341269841269843" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.073624994642504" CI_START="0.936008092996753" DF="0" EFFECT_SIZE="1.6961538461538461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.4876508792039732" LOG_CI_START="-0.028720396209932046" LOG_EFFECT_SIZE="0.22946524149702055" NO="3" P_CHI2="1.0" P_Z="0.08151913398424433" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="1.7419389127617426">
<NAME>Use of antiparkinson medication</NAME>
<DICH_DATA CI_END="3.073624994642504" CI_START="0.936008092996753" EFFECT_SIZE="1.6961538461538461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" LOG_CI_END="0.4876508792039732" LOG_CI_START="-0.028720396209932046" LOG_EFFECT_SIZE="0.22946524149702055" ORDER="908" O_E="0.0" SE="0.30331904325716513" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.09200244200244201" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.775068371233377E-32" CI_END="1.6668542541357372" CI_START="0.07349172832361164" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="100.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.22189762778734315" LOG_CI_START="-1.1337615390867921" LOG_EFFECT_SIZE="-0.4559319556497244" METHOD="MH" MODIFIED="2009-07-03 12:08:39 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="1.0" P_Z="0.18738967893672748" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="1.3183405302895568">
<NAME>Adverse effects: 4. Sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6668542541357372" CI_START="0.07349172832361164" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.22189762778734315" LOG_CI_START="-1.1337615390867921" LOG_EFFECT_SIZE="-0.4559319556497244" ORDER="909" O_E="0.0" SE="0.7963209052429706" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.6341269841269841" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.770669918651923E-32" CI_END="1.2925066811324375" CI_START="0.17623835878261626" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="100.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.11143279669553613" LOG_CI_START="-0.7538995602000724" LOG_EFFECT_SIZE="-0.3212333817522681" METHOD="MH" MODIFIED="2009-07-03 12:08:49 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="1.0" P_Z="0.14562027466994273" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="1.4551769706732598">
<NAME>Adverse effects: 5. Weight gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2925066811324375" CI_START="0.17623835878261626" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.11143279669553613" LOG_CI_START="-0.7538995602000724" LOG_EFFECT_SIZE="-0.3212333817522681" ORDER="910" O_E="0.0" SE="0.5083005099047299" STUDY_ID="STD-Olie-2006" TOTAL_1="60" TOTAL_2="63" VAR="0.25836940836940836" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-07-03 11:54:41 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>ZIPRASIDONE versus CLOZAPINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5087353295215662" CI_START="0.6628067762667884" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.17861306017993295" LOG_CI_START="-0.17861306017993295" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="73" WEIGHT="100.0" Z="0.0">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5087353295215662" CI_START="0.6628067762667884" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.17861306017993295" LOG_CI_START="-0.17861306017993295" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="73" WEIGHT="100.0" Z="0.0">
<NAME>Any reason</NAME>
<DICH_DATA CI_END="1.5087353295215662" CI_START="0.6628067762667884" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" LOG_CI_END="0.17861306017993295" LOG_CI_START="-0.17861306017993295" LOG_EFFECT_SIZE="0.0" ORDER="911" O_E="0.0" SE="0.20983639139719978" STUDY_ID="STD-Sacchetti-2006" TOTAL_1="73" TOTAL_2="73" VAR="0.04403131115459882" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.718701546423268" CI_START="-7.718701546423268" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2009-07-03 11:54:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8920141818991236" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="73" UNITS="" WEIGHT="100.0" Z="0.13575599239943506">
<NAME>Mental state: general mental state: PANSS total score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.718701546423268" CI_START="-7.718701546423268" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="1.0" P_Z="0.8920141818991236" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="73" WEIGHT="100.0" Z="0.13575599239943506">
<NAME>Medium term</NAME>
<CONT_DATA CI_END="6.718701546423268" CI_START="-7.718701546423268" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-25.0" MEAN_2="-24.5" ORDER="912" SD_1="22.0" SD_2="22.5" SE="3.6830786705079603" STUDY_ID="STD-Sacchetti-2006" TOTAL_1="73" TOTAL_2="73" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="73" TOTAL_2="73" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="913" O_E="0.0" SE="0.0" STUDY_ID="STD-Sacchetti-2006" TOTAL_1="73" TOTAL_2="73" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-08-06 14:54:16 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>ZIPRASIDONE versus OLANZAPINE</NAME>
<DICH_OUTCOME CHI2="6.315063452420909" CI_END="1.5583534617633061" CI_START="0.9214348985750256" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1982993215319417" ESTIMABLE="YES" EVENTS_1="270" EVENTS_2="221" I2="84.16484636244398" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.19266597007792904" LOG_CI_START="-0.03553534323208999" LOG_EFFECT_SIZE="0.07856531342291952" METHOD="MH" MODIFIED="2009-07-30 09:27:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01197166481709211" P_Q="1.0" P_Z="0.17715856143419084" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.030304762152993603" TOTALS="YES" TOTAL_1="407" TOTAL_2="410" WEIGHT="100.0" Z="1.3495556402327065">
<NAME>No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6109872884665637" CI_START="1.1529389624063873" EFFECT_SIZE="1.3628536285362853" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="120" LOG_CI_END="0.20709211362182023" LOG_CI_START="0.06180631597486531" LOG_EFFECT_SIZE="0.13444921479834276" ORDER="929" O_E="0.0" SE="0.08534159671411845" STUDY_ID="STD-Breier-2005" TOTAL_1="271" TOTAL_2="277" VAR="0.007283188129715232" WEIGHT="47.803846064654515"/>
<DICH_DATA CI_END="1.207873289626995" CI_START="0.9391754040489688" EFFECT_SIZE="1.0650844496214327" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="101" LOG_CI_END="0.08202137757807652" LOG_CI_START="-0.027253289633175064" LOG_EFFECT_SIZE="0.02738404397245072" ORDER="930" O_E="0.0" SE="0.06418848043821569" STUDY_ID="STD-Simpson-2004" TOTAL_1="136" TOTAL_2="133" VAR="0.004120161020967199" WEIGHT="52.19615393534549"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.16270089077305" CI_END="1.3713540921386937" CI_START="1.2020527439972426" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.283915865408308" ESTIMABLE="YES" EVENTS_1="905" EVENTS_2="781" I2="22.91895305553245" I2_Q="52.518184653470556" ID="CMP-003.02" LOG_CI_END="0.1371496068002362" LOG_CI_START="0.07992352417620609" LOG_EFFECT_SIZE="0.10853656548822117" METHOD="MH" MODIFIED="2009-07-30 09:18:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19947087357411752" P_Q="0.12171549271570126" P_Z="1.048504115034542E-13" Q="4.212138869172753" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.005626884188275433" TOTALS="SUB" TOTAL_1="2763" TOTAL_2="3048" WEIGHT="300.0" Z="7.434643421608549">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2934514944439246" CI_END="1.3548107912333514" CI_START="1.1764877846856898" DF="4" EFFECT_SIZE="1.2625047906627491" ESTIMABLE="YES" EVENTS_1="610" EVENTS_2="535" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.13187864719493755" LOG_CI_START="0.07058742231430076" LOG_EFFECT_SIZE="0.10123303475461913" NO="1" P_CHI2="0.5099706623833966" P_Z="9.516579652846288E-11" STUDIES="5" TAU2="0.0" TOTAL_1="921" TOTAL_2="1016" WEIGHT="100.0" Z="6.474437492517078">
<NAME>Any reason</NAME>
<DICH_DATA CI_END="1.6972064688069652" CI_START="1.1942614928475568" EFFECT_SIZE="1.4236953083816553" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="112" LOG_CI_END="0.22973467838671568" LOG_CI_START="0.07709942936192998" LOG_EFFECT_SIZE="0.1534170538743228" ORDER="914" O_E="0.0" SE="0.08965870083382727" STUDY_ID="STD-Breier-2005" TOTAL_1="271" TOTAL_2="277" VAR="0.008038682635209737" WEIGHT="16.124524709633434"/>
<DICH_DATA CI_END="1.4793329962337096" CI_START="1.0870908214752653" EFFECT_SIZE="1.2681361607142858" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="112" LOG_CI_END="0.1700659442124764" LOG_CI_START="0.03626582892332098" LOG_EFFECT_SIZE="0.1031658865678987" ORDER="915" O_E="0.0" SE="0.07859485004210233" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" VAR="0.006177150453140553" WEIGHT="20.98377524841409"/>
<DICH_DATA CI_END="1.3773556378335543" CI_START="1.10921612429941" EFFECT_SIZE="1.236036036036036" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="216" LOG_CI_END="0.13904609102453366" LOG_CI_START="0.045016174143617235" LOG_EFFECT_SIZE="0.09203113258407546" ORDER="916" O_E="0.0" SE="0.055233638631445627" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="0.0030507548364691224" WEIGHT="42.48782472942333"/>
<DICH_DATA CI_END="1.7461899502061795" CI_START="0.9936414314643418" EFFECT_SIZE="1.3172268907563025" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="49" LOG_CI_END="0.24209148440927541" LOG_CI_START="-0.002770308188828892" LOG_EFFECT_SIZE="0.11966058811022329" ORDER="917" O_E="0.0" SE="0.1438330290575481" STUDY_ID="STD-Simpson-2004" TOTAL_1="136" TOTAL_2="133" VAR="0.020687940247869477" WEIGHT="6.265482944716518"/>
<DICH_DATA CI_END="1.3798706701816867" CI_START="0.9480568372911969" EFFECT_SIZE="1.143763884481117" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="46" LOG_CI_END="0.13983838360520556" LOG_CI_START="-0.0231656253391541" LOG_EFFECT_SIZE="0.058336379133025716" ORDER="918" O_E="0.0" SE="0.09574936173677438" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="68" VAR="0.009167940272999674" WEIGHT="14.138392367812628"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.50516815090438" CI_END="1.606976386339209" CI_START="0.7744325711159715" DF="4" EFFECT_SIZE="1.1155692961870753" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="123" I2="46.70339265459367" ID="CMP-003.02.02" LOG_CI_END="0.2060094950844854" LOG_CI_START="-0.11101638974089903" LOG_EFFECT_SIZE="0.047496552671793216" NO="2" P_CHI2="0.11148171414005126" P_Z="0.5570154545772608" STUDIES="5" TAU2="0.07549328984675631" TOTAL_1="921" TOTAL_2="1016" WEIGHT="100.0" Z="0.5872803268275617">
<NAME>Adverse events</NAME>
<DICH_DATA CI_END="2.0150822532469945" CI_START="0.8511300715012629" EFFECT_SIZE="1.3096171586715868" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="32" LOG_CI_END="0.30429277822016104" LOG_CI_START="-0.07000406504041627" LOG_EFFECT_SIZE="0.11714435658987236" ORDER="919" O_E="0.0" SE="0.21986381853051884" STUDY_ID="STD-Breier-2005" TOTAL_1="271" TOTAL_2="277" VAR="0.04834009869882092" WEIGHT="28.00444007311946"/>
<DICH_DATA CI_END="3.5054129921731585" CI_START="1.0068969735975337" EFFECT_SIZE="1.8787202380952381" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.5447391919619485" LOG_CI_START="0.002985035511799006" LOG_EFFECT_SIZE="0.27386211373687375" ORDER="920" O_E="0.0" SE="0.31822907322514254" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" VAR="0.10126974304573315" WEIGHT="19.618834616201497"/>
<DICH_DATA CI_END="1.2342067610915926" CI_START="0.5451046169813349" EFFECT_SIZE="0.8202266782911944" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="62" LOG_CI_END="0.09138792118769158" LOG_CI_START="-0.2635201395261004" LOG_EFFECT_SIZE="-0.08606610916920439" ORDER="921" O_E="0.0" SE="0.2084747516865156" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="0.04346172209075434" WEIGHT="29.152909592390127"/>
<DICH_DATA CI_END="10.499284543896312" CI_START="0.36435585325388925" EFFECT_SIZE="1.9558823529411764" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0211597058104775" LOG_CI_START="-0.4384742492887787" LOG_EFFECT_SIZE="0.29134272826084945" ORDER="922" O_E="0.0" SE="0.8573962105299091" STUDY_ID="STD-Simpson-2004" TOTAL_1="136" TOTAL_2="133" VAR="0.7351282618310482" WEIGHT="4.278056389443623"/>
<DICH_DATA CI_END="1.3795833215028366" CI_START="0.381460218387374" EFFECT_SIZE="0.725435148792813" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.13974793531620786" LOG_CI_START="-0.41855074692456434" LOG_EFFECT_SIZE="-0.13940140580417826" ORDER="923" O_E="0.0" SE="0.3279474095712778" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="68" VAR="0.10754950344451146" WEIGHT="18.945759328845288"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.748759592314058" CI_END="1.9426146543341043" CI_START="1.2687310614486933" DF="4" EFFECT_SIZE="1.5699221485089936" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="123" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.2883866605618424" LOG_CI_START="0.10336957252253763" LOG_EFFECT_SIZE="0.19587811654219003" NO="3" P_CHI2="0.7818425314544182" P_Z="3.3241881514015695E-5" STUDIES="5" TAU2="0.0" TOTAL_1="921" TOTAL_2="1016" WEIGHT="100.0" Z="4.15003887317342">
<NAME>Inefficacy</NAME>
<DICH_DATA CI_END="3.1728474648168237" CI_START="1.1269774322223487" EFFECT_SIZE="1.890959409594096" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" LOG_CI_END="0.5014491938209611" LOG_CI_START="0.05191521936515225" LOG_EFFECT_SIZE="0.27668220659305665" ORDER="924" O_E="0.0" SE="0.26405848182440367" STUDY_ID="STD-Breier-2005" TOTAL_1="271" TOTAL_2="277" VAR="0.06972688182340893" WEIGHT="16.939424156435607"/>
<DICH_DATA CI_END="2.392166103210952" CI_START="1.017301921197579" EFFECT_SIZE="1.559985632183908" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="29" LOG_CI_END="0.37879133217398037" LOG_CI_START="0.007449864673428777" LOG_EFFECT_SIZE="0.1931205984237046" ORDER="925" O_E="0.0" SE="0.2181278161797338" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" VAR="0.04757974419133974" WEIGHT="24.82428702353908"/>
<DICH_DATA CI_END="2.4045340520412735" CI_START="1.1527285362868833" EFFECT_SIZE="1.664864864864865" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="48" LOG_CI_END="0.381030931756637" LOG_CI_START="0.061727044438224056" LOG_EFFECT_SIZE="0.22137898809743048" ORDER="926" O_E="0.0" SE="0.18756068399056924" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="0.03517901017901018" WEIGHT="33.574941998144006"/>
<DICH_DATA CI_END="2.332983460084856" CI_START="0.48785518729395744" EFFECT_SIZE="1.0668449197860963" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3679116598313261" LOG_CI_START="-0.3117090728587899" LOG_EFFECT_SIZE="0.028101293486268084" ORDER="927" O_E="0.0" SE="0.3992125825590577" STUDY_ID="STD-Simpson-2004" TOTAL_1="136" TOTAL_2="133" VAR="0.15937068607347246" WEIGHT="7.411232613806171"/>
<DICH_DATA CI_END="2.321026181312648" CI_START="0.8321712630294302" EFFECT_SIZE="1.3897810218978102" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="15" LOG_CI_END="0.3656800393509984" LOG_CI_START="-0.0797872855669009" LOG_EFFECT_SIZE="0.14294637689204875" ORDER="928" O_E="0.0" SE="0.2616697117555958" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="68" VAR="0.06847103805025659" WEIGHT="17.250114208075132"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5304070539866117" CI_START="0.9157290180663186" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1838235294117647" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.1848069587837459" LOG_CI_START="-0.03823302346048151" LOG_EFFECT_SIZE="0.0732869676616322" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.19773950632435128" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="133" WEIGHT="100.0" Z="1.288018549030066">
<NAME>Global State: no clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5304070539866117" CI_START="0.9157290180663186" DF="0" EFFECT_SIZE="1.1838235294117647" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="57" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.1848069587837459" LOG_CI_START="-0.03823302346048151" LOG_EFFECT_SIZE="0.0732869676616322" NO="1" P_CHI2="1.0" P_Z="0.19773950632435128" STUDIES="1" TAU2="0.0" TOTAL_1="136" TOTAL_2="133" WEIGHT="100.0" Z="1.288018549030066">
<NAME>Short term</NAME>
<DICH_DATA CI_END="1.5304070539866117" CI_START="0.9157290180663186" EFFECT_SIZE="1.1838235294117647" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="57" LOG_CI_END="0.1848069587837459" LOG_CI_START="-0.03823302346048151" LOG_EFFECT_SIZE="0.0732869676616322" ORDER="931" O_E="0.0" SE="0.13101478963597743" STUDY_ID="STD-Simpson-2004" TOTAL_1="136" TOTAL_2="133" VAR="0.01716487510335942" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6109872884665637" CI_START="1.1529389624063873" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3628536285362853" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="120" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.20709211362182023" LOG_CI_START="0.06180631597486531" LOG_EFFECT_SIZE="0.13444921479834276" METHOD="MH" MODIFIED="2009-07-03 12:09:43 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="2.8612534388345673E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="271" TOTAL_2="277" WEIGHT="100.0" Z="3.627548225942709">
<NAME>Mental state: 1a. General mental state: no clinically important change (less than 30% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6109872884665637" CI_START="1.1529389624063873" DF="0" EFFECT_SIZE="1.3628536285362853" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="120" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.20709211362182023" LOG_CI_START="0.06180631597486531" LOG_EFFECT_SIZE="0.13444921479834276" NO="1" P_CHI2="1.0" P_Z="2.8612534388345673E-4" STUDIES="1" TAU2="0.0" TOTAL_1="271" TOTAL_2="277" WEIGHT="100.0" Z="3.627548225942709">
<NAME>Long term</NAME>
<DICH_DATA CI_END="1.6109872884665637" CI_START="1.1529389624063873" EFFECT_SIZE="1.3628536285362853" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="120" LOG_CI_END="0.20709211362182023" LOG_CI_START="0.06180631597486531" LOG_EFFECT_SIZE="0.13444921479834276" ORDER="932" O_E="0.0" SE="0.08534159671411845" STUDY_ID="STD-Breier-2005" TOTAL_1="271" TOTAL_2="277" VAR="0.007283188129715232" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.6588217876124228" CI_END="10.993510719627633" CI_START="5.64461554143744" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="8.319063130532536" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2009-07-03 12:10:07 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8828440293894123" P_Q="0.8365123330703385" P_Z="1.0834135464808267E-9" Q="0.3570281222498377" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="603" TOTAL_2="688" UNITS="" WEIGHT="100.00000000000001" Z="6.096610076578712">
<NAME>Mental state: 1b. General mental state: PANSS total score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="18.740983252808114" CI_START="-2.0009832528081173" DF="0" EFFECT_SIZE="8.369999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" NO="1" P_CHI2="1.0" P_Z="0.1136935342622551" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="6.650102159896472" Z="1.5818074478288595">
<NAME>Short term</NAME>
<CONT_DATA CI_END="18.74098325280811" CI_START="-2.0009832528081155" EFFECT_SIZE="8.369999999999997" ESTIMABLE="YES" MEAN_1="60.29" MEAN_2="51.92" ORDER="933" SD_1="18.33" SD_2="18.33" SE="5.291415217122919" STUDY_ID="STD-Svestka-2005" TOTAL_1="24" TOTAL_2="24" WEIGHT="6.650102159896472"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.067602174695258" CI_START="-0.06760217469525998" DF="0" EFFECT_SIZE="6.499999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" NO="2" P_CHI2="1.0" P_Z="0.05240527426518377" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="66" WEIGHT="16.582671861170375" Z="1.939789524492854">
<NAME>Medium term</NAME>
<CONT_DATA CI_END="13.067602174695258" CI_START="-0.06760217469525998" EFFECT_SIZE="6.499999999999999" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-8.2" ORDER="934" SD_1="22.31" SD_2="22.31" SE="3.350879009257143" STUDY_ID="STD-Stroup-2006" TOTAL_1="135" TOTAL_2="66" WEIGHT="16.582671861170375"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3017936653625852" CI_END="11.760023997138989" CI_START="5.655157608114122" DF="1" EFFECT_SIZE="8.707590802626555" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.03" NO="3" P_CHI2="0.5827602256060537" P_Z="2.2559082005320522E-8" STUDIES="2" TAU2="0.0" TOTAL_1="444" TOTAL_2="598" WEIGHT="76.76722597893317" Z="5.591134441842001">
<NAME>Long term</NAME>
<CONT_DATA CI_END="14.374783182495172" CI_START="5.025216817504835" EFFECT_SIZE="9.700000000000003" ESTIMABLE="YES" MEAN_1="-26.0" MEAN_2="-35.7" ORDER="935" SD_1="28.3" SD_2="26.5" SE="2.385137287914095" STUDY_ID="STD-Breier-2005" TOTAL_1="261" TOTAL_2="268" WEIGHT="32.729942095500206"/>
<CONT_DATA CI_END="12.000174298283659" CI_START="3.939825701716341" EFFECT_SIZE="7.97" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-11.27" ORDER="936" SD_1="22.31" SD_2="22.31" SE="2.056249160736197" STUDY_ID="STD-Lieberman-2005" TOTAL_1="183" TOTAL_2="330" WEIGHT="44.03728388343296"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.207873289626995" CI_START="0.9391754040489688" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0650844496214327" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="101" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.08202137757807652" LOG_CI_START="-0.027253289633175064" LOG_EFFECT_SIZE="0.02738404397245072" METHOD="MH" MODIFIED="2009-07-03 12:10:24 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.32593868229576006" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="133" WEIGHT="100.0" Z="0.982327218316858">
<NAME>Mental state: 1c. General mental state: no clinically important change (less than 40% BPRS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.207873289626995" CI_START="0.9391754040489688" DF="0" EFFECT_SIZE="1.0650844496214327" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="101" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.08202137757807652" LOG_CI_START="-0.027253289633175064" LOG_EFFECT_SIZE="0.02738404397245072" NO="1" P_CHI2="1.0" P_Z="0.32593868229576006" STUDIES="1" TAU2="0.0" TOTAL_1="136" TOTAL_2="133" WEIGHT="100.0" Z="0.982327218316858">
<NAME>Short term</NAME>
<DICH_DATA CI_END="1.207873289626995" CI_START="0.9391754040489688" EFFECT_SIZE="1.0650844496214327" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="101" LOG_CI_END="0.08202137757807652" LOG_CI_START="-0.027253289633175064" LOG_EFFECT_SIZE="0.02738404397245072" ORDER="937" O_E="0.0" SE="0.06418848043821569" STUDY_ID="STD-Simpson-2004" TOTAL_1="136" TOTAL_2="133" VAR="0.004120161020967199" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.8476686810170233" CI_START="-2.8476686810170233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2009-07-03 12:10:40 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.7697242128767854" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="126" UNITS="" WEIGHT="100.0" Z="0.2927356574523104">
<NAME>Mental state: 1d. General mental state: BPRS total score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.8476686810170233" CI_START="-2.8476686810170233" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" NO="1" P_CHI2="1.0" P_Z="0.7697242128767854" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0" Z="0.2927356574523104">
<NAME>Short term</NAME>
<CONT_DATA CI_END="3.8476686810170233" CI_START="-2.8476686810170233" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-11.45" MEAN_2="-11.95" ORDER="938" SD_1="13.53" SD_2="13.53" SE="1.708025610380092" STUDY_ID="STD-Simpson-2004" TOTAL_1="125" TOTAL_2="126" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.28307811812891015" CI_END="4.30162061340871" CI_START="1.9260748119775293" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="3.11384771269312" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2009-07-03 12:11:01 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.5946908359090073" P_Q="0.5946908359090073" P_Z="2.7736437609926155E-7" Q="0.28307811812891015" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="396" TOTAL_2="334" UNITS="" WEIGHT="100.0" Z="5.138212335492825">
<NAME>Mental state: 2. Positive symptoms: PANSS positive subscore (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.748968887282627" CI_START="1.4510311127173736" DF="0" EFFECT_SIZE="3.6" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.01" NO="1" P_CHI2="1.0" P_Z="0.001025721856229936" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="66" WEIGHT="30.549673241874178" Z="3.283374825061498">
<NAME>Medium term</NAME>
<CONT_DATA CI_END="5.748968887282627" CI_START="1.4510311127173736" EFFECT_SIZE="3.6" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-3.4" ORDER="939" SD_1="7.3" SD_2="7.3" SE="1.0964328448039957" STUDY_ID="STD-Stroup-2006" TOTAL_1="135" TOTAL_2="66" WEIGHT="30.549673241874178"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.3252671182853994" CI_START="1.4747328817146013" DF="0" EFFECT_SIZE="2.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.02" NO="2" P_CHI2="1.0" P_Z="6.664639957515337E-5" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="268" WEIGHT="69.45032675812583" Z="3.987951088076671">
<NAME>Long term</NAME>
<CONT_DATA CI_END="4.3252671182853994" CI_START="1.4747328817146013" EFFECT_SIZE="2.9000000000000004" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-10.5" ORDER="940" SD_1="8.7" SD_2="8.0" SE="0.727190463461433" STUDY_ID="STD-Breier-2005" TOTAL_1="261" TOTAL_2="268" WEIGHT="69.45032675812583"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.458722696458569" CI_END="3.813375246458418" CI_START="-2.4503667647031397" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6815042408776392" ESTIMABLE="YES" I2="86.59287869121607" I2_Q="86.59287869121607" ID="CMP-003.09" MODIFIED="2009-07-03 12:11:17 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.006313018721630481" P_Q="0.006313018721630481" P_Z="0.6697480192134999" Q="7.458722696458569" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="4.433555388990264" TOTALS="YES" TOTAL_1="396" TOTAL_2="334" UNITS="" WEIGHT="99.99999999999999" Z="0.42649386422726693">
<NAME>Mental state: 3. Negative symptoms: PANSS negative subscore (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3012240887082851E-32" CI_END="0.9075778615878662" CI_START="-2.907577861587866" DF="0" EFFECT_SIZE="-0.9999999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-003.09.01" NO="1" P_CHI2="0.0" P_Z="0.30420293018215727" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="66" WEIGHT="47.452992472573776" Z="1.027462115181281">
<NAME>Medium term</NAME>
<CONT_DATA CI_END="0.9075778615878661" CI_START="-2.907577861587866" EFFECT_SIZE="-0.9999999999999999" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-0.4" ORDER="941" SD_1="6.48" SD_2="6.48" SE="0.9732718951136841" STUDY_ID="STD-Stroup-2006" TOTAL_1="135" TOTAL_2="66" WEIGHT="47.452992472573776"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.47868843497643" CI_START="0.9213115650235706" DF="0" EFFECT_SIZE="2.2" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.02" NO="2" P_CHI2="1.0" P_Z="7.458560339923234E-4" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="268" WEIGHT="52.54700752742621" Z="3.372143399472916">
<NAME>Long term</NAME>
<CONT_DATA CI_END="3.47868843497643" CI_START="0.9213115650235706" EFFECT_SIZE="2.2" ESTIMABLE="YES" MEAN_1="-6.3" MEAN_2="-8.5" ORDER="942" SD_1="7.6" SD_2="7.4" SE="0.6524040467388996" STUDY_ID="STD-Breier-2005" TOTAL_1="261" TOTAL_2="268" WEIGHT="52.54700752742621"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.124417202563715E-30" CI_END="1.413612668852425" CI_START="1.0250176346064346" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.203734984984985" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="111" I2="100.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.15033042868040372" LOG_CI_START="0.0107313371443434" LOG_EFFECT_SIZE="0.08053088291237359" METHOD="MH" MODIFIED="2009-07-30 09:29:46 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="1.0" P_Z="0.02374075955665788" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="192" TOTAL_2="202" WEIGHT="100.0" Z="2.2612988152676157">
<NAME>General Functioning: 1. No clinically important change (less than 5 points improvement on GAF total score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.124417202563715E-30" CI_END="1.413612668852425" CI_START="1.0250176346064346" DF="0" EFFECT_SIZE="1.203734984984985" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="111" I2="100.0" ID="CMP-003.10.01" LOG_CI_END="0.15033042868040372" LOG_CI_START="0.0107313371443434" LOG_EFFECT_SIZE="0.08053088291237359" NO="1" P_CHI2="0.0" P_Z="0.02374075955665788" STUDIES="1" TAU2="0.0" TOTAL_1="192" TOTAL_2="202" WEIGHT="100.0" Z="2.2612988152676157">
<NAME>Medium term</NAME>
<DICH_DATA CI_END="1.413612668852425" CI_START="1.0250176346064346" EFFECT_SIZE="1.203734984984985" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="111" LOG_CI_END="0.15033042868040372" LOG_CI_START="0.0107313371443434" LOG_EFFECT_SIZE="0.08053088291237359" ORDER="943" O_E="0.0" SE="0.08200119739492967" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" VAR="0.00672419637420222" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.341927183864724" CI_START="0.6380728161352747" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.4899999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" MODIFIED="2009-07-03 12:11:44 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.016463527812802886" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="168" UNITS="" WEIGHT="100.0" Z="2.398474387685924">
<NAME>General Functioning: 2. GAF total score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.341927183864724" CI_START="0.6380728161352747" EFFECT_SIZE="3.4899999999999998" ESTIMABLE="YES" MEAN_1="-3.15" MEAN_2="-6.64" ORDER="944" SD_1="13.13" SD_2="13.13" SE="1.4550916273770145" STUDY_ID="STD-Kinon-2006" TOTAL_1="158" TOTAL_2="168" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.1391621265264625E-32" CI_END="8.612600398661876" CI_START="-1.2126003986618774" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.699999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.12" MODIFIED="2009-07-03 12:11:58 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="1.0" P_Z="0.1398964355656598" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="193" TOTAL_2="200" UNITS="" WEIGHT="100.0" Z="1.4761768013481222">
<NAME>General Functioning: 3. QLS total score (Heinrichs-Carpenter) (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.1391621265264625E-32" CI_END="8.612600398661876" CI_START="-1.2126003986618774" DF="0" EFFECT_SIZE="3.699999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-003.12.01" NO="1" P_CHI2="0.0" P_Z="0.1398964355656598" STUDIES="1" TAU2="0.0" TOTAL_1="193" TOTAL_2="200" WEIGHT="100.0" Z="1.4761768013481222">
<NAME>Long term</NAME>
<CONT_DATA CI_END="8.612600398661876" CI_START="-1.212600398661877" EFFECT_SIZE="3.6999999999999993" ESTIMABLE="YES" MEAN_1="-10.9" MEAN_2="-14.6" ORDER="945" SD_1="25.48" SD_2="24.16" SE="2.5064748318907086" STUDY_ID="STD-Breier-2005" TOTAL_1="193" TOTAL_2="200" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.6289560206306053" CI_START="1.1710439793693936" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.3999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.13" MODIFIED="2009-07-30 09:30:15 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="1.2941528442744733E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="261" TOTAL_2="268" UNITS="" WEIGHT="100.0" Z="3.827568671238896">
<NAME>Cognitive Functioning: PANSS cognition score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.6289560206306053" CI_START="1.1710439793693936" DF="0" EFFECT_SIZE="2.3999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-003.13.01" NO="1" P_CHI2="1.0" P_Z="1.2941528442744733E-4" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="268" WEIGHT="100.0" Z="3.827568671238896">
<NAME>Long term</NAME>
<CONT_DATA CI_END="3.6289560206306053" CI_START="1.1710439793693936" EFFECT_SIZE="2.3999999999999995" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-8.2" ORDER="946" SD_1="7.5" SD_2="6.9" SE="0.6270298996943077" STUDY_ID="STD-Breier-2005" TOTAL_1="261" TOTAL_2="268" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.04770209084770279" CI_END="2.2020850409252866" CI_START="1.071873990297166" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5363455600190619" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="0.34283408670268867" LOG_CI_START="0.030143732618653905" LOG_EFFECT_SIZE="0.18648890966067128" METHOD="MH" MODIFIED="2009-07-03 12:12:43 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.8271111689423017" P_Q="0.8273054430040396" P_Z="0.019395039325894477" Q="0.04759322991504116" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="444" WEIGHT="100.0" Z="2.3378498356417428">
<NAME>Service use: Number of patients re-hospitalised</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7867798764144585" CI_START="0.7495257892857095" DF="0" EFFECT_SIZE="1.4452554744525548" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" I2="0.0" ID="CMP-003.14.01" LOG_CI_END="0.4451026657947438" LOG_CI_START="-0.12521341958449517" LOG_EFFECT_SIZE="0.15994462310512433" NO="1" P_CHI2="1.0" P_Z="0.27161971953741015" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="108" WEIGHT="30.060605699906375" Z="1.0993402039446964">
<NAME>Medium term</NAME>
<DICH_DATA CI_END="2.7867798764144585" CI_START="0.7495257892857095" EFFECT_SIZE="1.4452554744525548" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.4451026657947438" LOG_CI_START="-0.12521341958449517" LOG_EFFECT_SIZE="0.15994462310512433" ORDER="947" O_E="0.0" SE="0.33500649166191815" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="108" VAR="0.11222934945562682" WEIGHT="30.060605699906375"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.425755742731701" CI_START="1.0255308191937378" DF="0" EFFECT_SIZE="1.5772403982930299" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="38" I2="0.0" ID="CMP-003.14.02" LOG_CI_END="0.38484706820229464" LOG_CI_START="0.010948716293520448" LOG_EFFECT_SIZE="0.19789789224790758" NO="2" P_CHI2="1.0" P_Z="0.038009741202993906" STUDIES="1" TAU2="0.0" TOTAL_1="185" TOTAL_2="336" WEIGHT="69.93939430009362" Z="2.074749671626916">
<NAME>Long term</NAME>
<DICH_DATA CI_END="2.425755742731701" CI_START="1.0255308191937378" EFFECT_SIZE="1.5772403982930299" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="38" LOG_CI_END="0.38484706820229464" LOG_CI_START="0.010948716293520448" LOG_EFFECT_SIZE="0.19789789224790758" ORDER="948" O_E="0.0" SE="0.21962974273790567" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="0.04823722389511863" WEIGHT="69.93939430009362"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.813199326459243" CI_END="1.1818575154652549" CI_START="0.9368797409511006" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0522634474931643" ESTIMABLE="YES" EVENTS_1="490" EVENTS_2="567" I2="61.60343702175164" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="0.07256512123459159" LOG_CI_START="-0.028316152114578053" LOG_EFFECT_SIZE="0.02212448456000675" METHOD="MH" MODIFIED="2009-07-03 12:12:54 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.05003434541524654" P_Q="1.0" P_Z="0.38996124763709217" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.007825182214759478" TOTALS="YES" TOTAL_1="729" TOTAL_2="854" WEIGHT="100.0" Z="0.8596876600484089">
<NAME>Adverse effects: 1. At least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1718212416908527" CI_START="0.9793679948449879" EFFECT_SIZE="1.0712815782003975" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="208" LOG_CI_END="0.06886136623124424" LOG_CI_START="-0.00905409256747195" LOG_EFFECT_SIZE="0.029903636831886144" ORDER="949" O_E="0.0" SE="0.04576792618610722" STUDY_ID="STD-Breier-2005" TOTAL_1="271" TOTAL_2="277" VAR="0.002094703067376959" WEIGHT="35.3988917006315"/>
<DICH_DATA CI_END="1.0454776149359477" CI_START="0.8090559530546608" EFFECT_SIZE="0.919700977573318" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="235" LOG_CI_END="0.019314738431670985" LOG_CI_START="-0.09202144221642146" LOG_EFFECT_SIZE="-0.03635335189237525" ORDER="950" O_E="0.0" SE="0.06539942363567208" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="0.004277084611878104" WEIGHT="29.015468739470702"/>
<DICH_DATA CI_END="1.3471906128704798" CI_START="1.040267157000791" EFFECT_SIZE="1.1838235294117647" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="95" LOG_CI_END="0.12942904803268618" LOG_CI_START="0.017144887290578226" LOG_EFFECT_SIZE="0.0732869676616322" ORDER="951" O_E="0.0" SE="0.06595627183547396" STUDY_ID="STD-Simpson-2004" TOTAL_1="136" TOTAL_2="133" VAR="0.004350229794434937" WEIGHT="28.841154986776505"/>
<DICH_DATA CI_END="1.5600002146324075" CI_START="0.6839949825947387" EFFECT_SIZE="1.0329725648124843" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="29" LOG_CI_END="0.19312465810681018" LOG_CI_START="-0.16494708401001612" LOG_EFFECT_SIZE="0.014088787048397033" ORDER="952" O_E="0.0" SE="0.2103331138031335" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="108" VAR="0.044240018762121906" WEIGHT="6.74448457312129"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8854229070886053" CI_END="24.68037622677253" CI_START="0.1006974348849768" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5764677535655958" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="65.34303524300356" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="1.392351775781215" LOG_CI_START="-0.9969815923012859" LOG_EFFECT_SIZE="0.19768509173996446" METHOD="MH" MODIFIED="2009-07-03 12:13:04 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.08938466641347809" P_Q="1.0" P_Z="0.7456949175368597" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.716420666895665" TOTALS="YES" TOTAL_1="513" TOTAL_2="671" WEIGHT="100.00000000000001" Z="0.3243211393324905">
<NAME>Adverse effects: 2a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0737893970566916" CI_START="0.13343680677613168" EFFECT_SIZE="0.5260416666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3167646496710184" LOG_CI_START="-0.8747243595128326" LOG_EFFECT_SIZE="-0.27897985492090704" ORDER="953" O_E="0.0" SE="0.6998865419603106" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" VAR="0.48984117161716173" WEIGHT="61.43695951340516"/>
<DICH_DATA CI_END="187.7018310603498" CI_START="0.4372254291797999" EFFECT_SIZE="9.059139784946236" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.273468509251752" LOG_CI_START="-0.35929458727287006" LOG_EFFECT_SIZE="0.9570869609894411" ORDER="954" O_E="0.0" SE="1.5464980752860746" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="2.391656296863533" WEIGHT="38.56304048659486"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="955" O_E="0.0" SE="0.0" STUDY_ID="STD-Simpson-2004" TOTAL_1="136" TOTAL_2="133" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.683044759623047" CI_END="4.962046211832247" CI_START="-0.5786091730136835" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1917185194092816" ESTIMABLE="YES" I2="18.54565459293944" I2_Q="0.0" ID="CMP-003.17" MODIFIED="2009-07-03 12:13:14 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.29778642374946696" P_Q="1.0" P_Z="0.12099590656931007" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.600810830105688" TOTALS="YES" TOTAL_1="649" TOTAL_2="723" UNITS="" WEIGHT="100.0" Z="1.5506069459005327">
<NAME>Adverse effects: 2b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.875354906648791" CI_START="-2.33535490664879" EFFECT_SIZE="0.7700000000000005" ESTIMABLE="YES" MEAN_1="5.58" MEAN_2="4.81" ORDER="956" SD_1="17.98" SD_2="18.46" SE="1.5843938618992153" STUDY_ID="STD-Breier-2005" TOTAL_1="259" TOTAL_2="270" WEIGHT="48.59666950223645"/>
<CONT_DATA CI_END="5.679193785646074" CI_START="-5.479193785646073" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.2" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="957" SD_1="26.8" SD_2="27.4" SE="2.84657974822703" STUDY_ID="STD-Lieberman-2005" TOTAL_1="148" TOTAL_2="231" WEIGHT="20.588421699518978"/>
<CONT_DATA CI_END="11.095635826497578" CI_START="0.02436417350242248" EFFECT_SIZE="5.5600000000000005" ESTIMABLE="YES" MEAN_1="6.08" MEAN_2="0.52" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="958" SD_1="23.16" SD_2="23.16" SE="2.824355891313293" STUDY_ID="STD-Simpson-2004" TOTAL_1="136" TOTAL_2="133" WEIGHT="20.859335779179826"/>
<CONT_DATA CI_END="14.822600094545269" CI_START="-2.022600094545271" EFFECT_SIZE="6.3999999999999995" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="-5.1" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="959" SD_1="25.7" SD_2="33.0" SE="4.297323910531859" STUDY_ID="STD-Stroup-2006" TOTAL_1="106" TOTAL_2="89" WEIGHT="9.955573019064742"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.151884179818215" CI_START="0.11848749920531965" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7013888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.6182452300120257" LOG_CI_START="-0.92632746663724" LOG_EFFECT_SIZE="-0.1540411183126071" METHOD="MH" MODIFIED="2009-07-03 12:13:23 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.6958440576423719" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="192" TOTAL_2="202" WEIGHT="100.0" Z="0.3909366579973164">
<NAME>Adverse effects: 3a. Cholesterol - abnormally high cholesterol value</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.151884179818215" CI_START="0.11848749920531965" EFFECT_SIZE="0.7013888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6182452300120257" LOG_CI_START="-0.92632746663724" LOG_EFFECT_SIZE="-0.1540411183126071" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="960" O_E="0.0" SE="0.9072896477699363" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" VAR="0.8231745049504949" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="23.330549943447267" CI_END="-5.945770709460744" CI_START="-25.716799891632505" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-15.831285300546623" ESTIMABLE="YES" I2="87.14132325525145" I2_Q="0.0" ID="CMP-003.19" MODIFIED="2009-07-03 12:13:33 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="3.445743122920675E-5" P_Q="1.0" P_Z="0.0016963557723927386" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="85.10809882466995" TOTALS="YES" TOTAL_1="671" TOTAL_2="831" UNITS="" WEIGHT="100.0" Z="3.1388096929247853">
<NAME>Adverse effects: 3b. Cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.346155677753892" CI_START="-10.43384432224611" EFFECT_SIZE="-7.390000000000001" ESTIMABLE="YES" MEAN_1="-5.95" MEAN_2="1.44" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="961" SD_1="14.59" SD_2="17.12" SE="1.5530103339936672" STUDY_ID="STD-Breier-2005" TOTAL_1="203" TOTAL_2="215" WEIGHT="29.06667602375527"/>
<CONT_DATA CI_END="-2.0365348576243347" CI_START="-16.823465142375664" EFFECT_SIZE="-9.43" ESTIMABLE="YES" MEAN_1="-11.7" MEAN_2="-2.27" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="962" SD_1="33.18" SD_2="33.92" SE="3.7722454089434163" STUDY_ID="STD-Kinon-2006" TOTAL_1="146" TOTAL_2="172" WEIGHT="25.60868371728685"/>
<CONT_DATA CI_END="-7.9119022443834375" CI_START="-29.88809775561656" EFFECT_SIZE="-18.9" ESTIMABLE="YES" MEAN_1="-9.2" MEAN_2="9.7" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="963" SD_1="70.7" SD_2="38.5" SE="5.606275340919156" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" WEIGHT="21.828970181497674"/>
<CONT_DATA CI_END="-20.966992672583295" CI_START="-39.8330073274167" EFFECT_SIZE="-30.4" ESTIMABLE="YES" MEAN_1="-12.5" MEAN_2="17.9" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="964" SD_1="41.0" SD_2="34.3" SE="4.812847277716866" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="108" WEIGHT="23.495670077460193"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5683968698817954" CI_END="10.451555965455121" CI_START="0.24464538660560547" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.599038758066511" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="1.019180950438277" LOG_CI_START="-0.6114629695243962" LOG_EFFECT_SIZE="0.20385899045694036" METHOD="MH" MODIFIED="2009-07-03 12:14:24 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.4508967791064452" P_Q="0.45524292237219666" P_Z="0.6240917913101673" Q="0.5575654696119874" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="444" WEIGHT="100.0" Z="0.4900595087975355">
<NAME>Adverse effects: 4. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.947766438030133" CI_START="0.08289904484076205" DF="0" EFFECT_SIZE="0.9081081081081082" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.20.01" LOG_CI_END="0.997725579988985" LOG_CI_START="-1.0814504733432866" LOG_EFFECT_SIZE="-0.04186244667715092" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9370927350770852" STUDIES="1" TAU2="0.0" TOTAL_1="185" TOTAL_2="336" WEIGHT="61.508585789098035" Z="0.07892442552947401">
<NAME>Suicide attempt</NAME>
<DICH_DATA CI_END="9.947766438030133" CI_START="0.08289904484076205" EFFECT_SIZE="0.9081081081081082" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.997725579988985" LOG_CI_START="-1.0814504733432866" LOG_EFFECT_SIZE="-0.04186244667715092" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="965" O_E="0.0" SE="1.221318305814829" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="1.4916184041184042" WEIGHT="61.508585789098035"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="81.40934758608616" CI_START="0.1915845827277492" DF="0" EFFECT_SIZE="3.9492753623188412" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.20.02" LOG_CI_END="1.9106742743238618" LOG_CI_START="-0.7176394425730499" LOG_EFFECT_SIZE="0.596517415875406" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3736485450269993" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="108" WEIGHT="38.49141421090196" Z="0.8896598939087408">
<NAME>Suicide</NAME>
<DICH_DATA CI_END="81.40934758608616" CI_START="0.1915845827277492" EFFECT_SIZE="3.949275362318841" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9106742743238618" LOG_CI_START="-0.7176394425730499" LOG_EFFECT_SIZE="0.596517415875406" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="966" O_E="0.0" SE="1.5438844876679731" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="108" VAR="2.3835793112618" WEIGHT="38.49141421090196"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.094071733303661" CI_END="1.960305129292249" CI_START="1.1355713839170498" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.49200080716134" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="140" I2="33.85188895506335" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="0.29232367628200506" LOG_CI_START="0.05521443989159146" LOG_EFFECT_SIZE="0.1737690580867982" METHOD="MH" MODIFIED="2009-08-06 14:53:56 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.14705584549812123" P_Q="0.45704270704242655" P_Z="0.004068799593162716" Q="2.602550074817949" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.056150519749284464" TOTALS="SUB" TOTAL_1="1785" TOTAL_2="2054" WEIGHT="400.0" Z="2.8727779707137806">
<NAME>Adverse effects: 5a. Extrapyramidal side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8850891915666204" CI_END="2.528934678864932" CI_START="0.7806960322850279" DF="1" EFFECT_SIZE="1.4051082768590695" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" I2="0.0" ID="CMP-003.21.01" LOG_CI_END="0.40293761187707294" LOG_CI_START="-0.10751802783538524" LOG_EFFECT_SIZE="0.14770979202084383" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.34681167591787543" P_Z="0.2566671765816383" STUDIES="2" TAU2="0.0" TOTAL_1="322" TOTAL_2="444" WEIGHT="100.0" Z="1.1343037474826831">
<NAME>Akathisia</NAME>
<DICH_DATA CI_END="3.4337700026610842" CI_START="0.8368304004469539" EFFECT_SIZE="1.6951351351351351" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.5357712023216012" LOG_CI_START="-0.07736255110282714" LOG_EFFECT_SIZE="0.22920432560938703" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="967" O_E="0.0" SE="0.36015780182253754" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="0.12971364221364223" WEIGHT="69.3115423225924"/>
<DICH_DATA CI_END="2.656890156061985" CI_START="0.3183657619565676" EFFECT_SIZE="0.9197080291970803" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4243735997236896" LOG_CI_START="-0.49707364380137736" LOG_EFFECT_SIZE="-0.036350022038843875" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="968" O_E="0.0" SE="0.5412626720840424" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="108" VAR="0.2929652801915576" WEIGHT="30.68845767740759"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="234.7093937691836" CI_START="0.752156160068697" DF="0" EFFECT_SIZE="13.286764705882351" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-003.21.02" LOG_CI_END="2.3705304717054503" LOG_CI_START="-0.12369198332402179" LOG_EFFECT_SIZE="1.1234192441907143" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07746813953711003" STUDIES="1" TAU2="0.0" TOTAL_1="271" TOTAL_2="277" WEIGHT="100.0" Z="1.76556926886218">
<NAME>Dystonia</NAME>
<DICH_DATA CI_END="234.7093937691836" CI_START="0.752156160068697" EFFECT_SIZE="13.286764705882353" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3705304717054503" LOG_CI_START="-0.12369198332402179" LOG_EFFECT_SIZE="1.1234192441907143" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="969" O_E="0.0" SE="1.4651186166845878" STUDY_ID="STD-Breier-2005" TOTAL_1="271" TOTAL_2="277" VAR="2.14657256095576" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7943524818796281" CI_END="4.728127967137635" CI_START="0.7652534349503324" DF="1" EFFECT_SIZE="1.9021609205681855" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="16" I2="44.26958972116362" ID="CMP-003.21.03" LOG_CI_END="0.6746892222449536" LOG_CI_START="-0.1161947123328794" LOG_EFFECT_SIZE="0.27924725495603714" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.18039689477313514" P_Z="0.16634073915731254" STUDIES="2" TAU2="0.21516336663978095" TOTAL_1="408" TOTAL_2="385" WEIGHT="100.0" Z="1.3840578587240078">
<NAME>Extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="5.0327022149394445" CI_START="1.3854173368274476" EFFECT_SIZE="2.640528905289053" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.7018012339467838" LOG_CI_START="0.14158061800659738" LOG_EFFECT_SIZE="0.42169092597669067" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="0.329076362940039" STUDY_ID="STD-Breier-2005" TOTAL_1="271" TOTAL_2="277" VAR="0.10829125264584426" WEIGHT="66.724811214814"/>
<DICH_DATA CI_END="3.58106797137533" CI_START="0.27115264073289813" EFFECT_SIZE="0.9854014598540146" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5540125643274794" LOG_CI_START="-0.5667861616502807" LOG_EFFECT_SIZE="-0.006386798661400644" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="971" O_E="0.0" SE="0.6583627196825076" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="108" VAR="0.4334414706677481" WEIGHT="33.275188785185996"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.280271148666415" CI_END="1.9898798032709806" CI_START="1.0289803883620792" DF="3" EFFECT_SIZE="1.4309253274589948" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="103" I2="43.18473586801163" ID="CMP-003.21.04" LOG_CI_END="0.29882684407167026" LOG_CI_START="0.012407097495867587" LOG_EFFECT_SIZE="0.15561697078376893" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.1523877573167879" P_Z="0.03319085675825203" STUDIES="4" TAU2="0.048629962704337684" TOTAL_1="784" TOTAL_2="948" WEIGHT="99.99999999999999" Z="2.1297669714869887">
<NAME>Use of antiparkinson medication</NAME>
<DICH_DATA CI_END="3.5583580717399643" CI_START="1.2948214865248437" EFFECT_SIZE="2.1464944649446496" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="20" LOG_CI_END="0.5512496482887277" LOG_CI_START="0.11220989755919651" LOG_EFFECT_SIZE="0.3317297729239621" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="972" O_E="0.0" SE="0.257894122860343" STUDY_ID="STD-Breier-2005" TOTAL_1="271" TOTAL_2="277" VAR="0.06650937860590571" WEIGHT="24.58427332444201"/>
<DICH_DATA CI_END="1.6844231764368371" CI_START="0.7649791411715794" EFFECT_SIZE="1.1351425438596492" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="38" LOG_CI_END="0.2264512083652911" LOG_CI_START="-0.11635040667329209" LOG_EFFECT_SIZE="0.05505040084599953" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="973" O_E="0.0" SE="0.20136336556902537" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" VAR="0.04054720499328495" WEIGHT="31.741499648936504"/>
<DICH_DATA CI_END="1.9080914872566719" CI_START="0.542140632355281" EFFECT_SIZE="1.017081081081081" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="0.28059919398348354" LOG_CI_START="-0.26588804199742216" LOG_EFFECT_SIZE="0.007355575993030665" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.32100930757063034" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="0.10304697554697555" WEIGHT="18.662145147452783"/>
<DICH_DATA CI_END="2.7353134495798903" CI_START="1.0104532079950477" EFFECT_SIZE="1.6625" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="20" LOG_CI_END="0.4370071009154528" LOG_CI_START="0.004516207034831625" LOG_EFFECT_SIZE="0.22076165397514222" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="975" O_E="0.0" SE="0.254047291929929" STUDY_ID="STD-Simpson-2004" TOTAL_1="136" TOTAL_2="133" VAR="0.06454002653693056" WEIGHT="25.012081879168687"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.2706985123210663" CI_END="0.1890351390882199" CI_START="-0.00985055149675608" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.08959229379573191" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.22" MODIFIED="2009-08-06 14:54:16 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.7741842846929644" P_Q="0.6273834609368674" P_Z="0.0774268889918198" Q="1.7431509157918028" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1493" TOTAL_2="1547" UNITS="" WEIGHT="400.0" Z="1.7658150127893688">
<NAME>Adverse effects: 5b. Extrapyramidal side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5719841399556892" CI_END="0.46227322950249405" CI_START="-0.1504429362780875" DF="1" EFFECT_SIZE="0.15591514661220326" ESTIMABLE="YES" I2="0.0" ID="CMP-003.22.01" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4494716696604615" P_Z="0.31852840477599864" STUDIES="2" TAU2="0.0" TOTAL_1="453" TOTAL_2="472" WEIGHT="100.0" Z="0.9974865657898575">
<NAME>Abnormal involuntary movement: AIMS (high=poor)</NAME>
<CONT_DATA CI_END="0.44408852306943297" CI_START="-0.28408852306943294" EFFECT_SIZE="0.08000000000000002" ESTIMABLE="YES" MEAN_1="-0.45" MEAN_2="-0.53" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="976" SD_1="2.14" SD_2="2.14" SE="0.185762863981847" STUDY_ID="STD-Breier-2005" TOTAL_1="261" TOTAL_2="270" WEIGHT="70.80186668761414"/>
<CONT_DATA CI_END="0.9069591903959133" CI_START="-0.22695919039591333" EFFECT_SIZE="0.34" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.68" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="977" SD_1="2.87" SD_2="2.87" SE="0.289270208467102" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" WEIGHT="29.19813331238587"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9555634565735744" CI_END="0.1736058646024361" CI_START="-0.043067739884729006" DF="1" EFFECT_SIZE="0.06526906235885355" ESTIMABLE="YES" I2="0.0" ID="CMP-003.22.02" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.328307382546943" P_Z="0.23767884743744283" STUDIES="2" TAU2="0.0" TOTAL_1="452" TOTAL_2="472" WEIGHT="100.00000000000001" Z="1.180808449934008">
<NAME>Akathisia: Barnes Akathisia Scale (high=poor)</NAME>
<CONT_DATA CI_END="0.25064317699986555" CI_START="-0.030643176999865573" EFFECT_SIZE="0.10999999999999999" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.21" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="978" SD_1="0.85" SD_2="0.8" SE="0.07175804152996738" STUDY_ID="STD-Breier-2005" TOTAL_1="260" TOTAL_2="270" WEIGHT="59.33551123532141"/>
<CONT_DATA CI_END="0.1698902103625385" CI_START="-0.1698902103625385" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="-0.12" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="979" SD_1="0.86" SD_2="0.86" SE="0.08668027152672743" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" WEIGHT="40.6644887646786"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5329410111225616" CI_START="-0.7329410111225614" DF="0" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" I2="0.0" ID="CMP-003.22.03" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4889426472797386" STUDIES="1" TAU2="0.0" TOTAL_1="136" TOTAL_2="133" WEIGHT="99.99999999999999" Z="0.6919915389409541">
<NAME>Extrapyramidal symptoms: ESRS total score (high=poor)</NAME>
<CONT_DATA CI_END="1.5329410111225616" CI_START="-0.7329410111225614" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.4" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="980" SD_1="4.74" SD_2="4.74" SE="0.5780417497765549" STUDY_ID="STD-Simpson-2004" TOTAL_1="136" TOTAL_2="133" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8120206742456766" CI_START="-0.1320206742456766" DF="1" EFFECT_SIZE="0.33999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-003.22.04" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.15801574298595344" STUDIES="2" TAU2="0.0" TOTAL_1="452" TOTAL_2="470" WEIGHT="100.00000000000001" Z="1.4117766256924118">
<NAME>Extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</NAME>
<CONT_DATA CI_END="0.9738661824843571" CI_START="-0.29386618248435714" EFFECT_SIZE="0.33999999999999997" ESTIMABLE="YES" MEAN_1="-0.82" MEAN_2="-1.16" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="981" SD_1="4.07" SD_2="3.31" SE="0.3234070561929773" STUDY_ID="STD-Breier-2005" TOTAL_1="260" TOTAL_2="268" WEIGHT="55.45323377944655"/>
<CONT_DATA CI_END="1.0472173873231254" CI_START="-0.3672173873231255" EFFECT_SIZE="0.33999999999999997" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="-0.37" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="982" SD_1="3.58" SD_2="3.58" SE="0.3608318279833537" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" WEIGHT="44.546766220553465"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.394640106301956" CI_START="0.1496867088006702" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0520833333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.23" LOG_CI_END="0.8689170419366177" LOG_CI_START="-0.8248167604504694" LOG_EFFECT_SIZE="0.02205014074307413" METHOD="MH" MODIFIED="2009-07-03 12:14:59 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.9592998614786126" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="192" TOTAL_2="202" WEIGHT="100.0" Z="0.05103220075026597">
<NAME>Adverse effects: 6a. Glucose - abnormally high fasting glucose value</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.394640106301956" CI_START="0.1496867088006702" EFFECT_SIZE="1.0520833333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8689170419366177" LOG_CI_START="-0.8248167604504694" LOG_EFFECT_SIZE="0.02205014074307413" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="983" O_E="0.0" SE="0.994907619639714" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" VAR="0.9898411716171617" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.122723469234303" CI_END="-2.7674564542944617" CI_START="-13.722864858068824" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.245160656181643" ESTIMABLE="YES" I2="41.43740106181425" I2_Q="0.0" ID="CMP-003.24" MODIFIED="2009-07-03 12:15:14 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.16302839274774872" P_Q="1.0" P_Z="0.0031758798955907504" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="12.950914302972771" TOTALS="YES" TOTAL_1="631" TOTAL_2="789" UNITS="" WEIGHT="100.0" Z="2.950180830738384">
<NAME>Adverse effects: 6b. Glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.382225302705808" CI_START="-10.077774697294192" EFFECT_SIZE="-5.2299999999999995" ESTIMABLE="YES" MEAN_1="-0.18" MEAN_2="5.05" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="984" SD_1="21.44" SD_2="30.27" SE="2.473399886698337" STUDY_ID="STD-Breier-2005" TOTAL_1="219" TOTAL_2="228" WEIGHT="40.96204940650633"/>
<CONT_DATA CI_END="7.443835877931082" CI_START="-12.86383587793108" EFFECT_SIZE="-2.71" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="2.85" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="985" SD_1="36.25" SD_2="37.84" SE="5.180623704324796" STUDY_ID="STD-Kinon-2006" TOTAL_1="90" TOTAL_2="117" WEIGHT="19.630414673113147"/>
<CONT_DATA CI_END="-3.2970343309453334" CI_START="-22.102965669054665" EFFECT_SIZE="-12.7" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="15.0" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="986" SD_1="53.0" SD_2="51.3" SE="4.797519619352222" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" WEIGHT="21.716780523765834"/>
<CONT_DATA CI_END="-4.951971370274162" CI_START="-26.84802862972584" EFFECT_SIZE="-15.9" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="14.8" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="987" SD_1="45.6" SD_2="41.6" SE="5.5858315336825015" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="108" WEIGHT="17.690755396614684"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.1856550740302714" CI_END="1.0594756157665413" CI_START="0.671976533662337" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.843767000885061" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="166" I2="0.0" I2_Q="0.0" ID="CMP-003.25" LOG_CI_END="0.02509096570948317" LOG_CI_START="-0.17264589283739873" LOG_EFFECT_SIZE="-0.07377746356395777" METHOD="MH" MODIFIED="2009-08-06 14:53:39 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.5272511390539687" P_Q="0.4676435787156983" P_Z="0.1435873678516852" Q="2.5425900736679266" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="784" TOTAL_2="1104" WEIGHT="400.0" Z="1.4625616338674612">
<NAME>Adverse effects: 7a. Prolactin-associated side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4072196165626583E-31" CI_END="1.3540514870833165" CI_START="0.5852801144352238" DF="0" EFFECT_SIZE="0.8902243589743589" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" I2="100.0" ID="CMP-003.25.01" LOG_CI_END="0.1316351784784048" LOG_CI_START="-0.2326362312894799" LOG_EFFECT_SIZE="-0.050500526405537594" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.5868292161325299" STUDIES="1" TAU2="0.0" TOTAL_1="192" TOTAL_2="202" WEIGHT="100.00000000000001" Z="0.5434366261038035">
<NAME>Abnormally high prolactin value</NAME>
<DICH_DATA CI_END="1.3540514870833162" CI_START="0.5852801144352238" EFFECT_SIZE="0.8902243589743589" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" LOG_CI_END="0.13163517847840472" LOG_CI_START="-0.2326362312894799" LOG_EFFECT_SIZE="-0.050500526405537594" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="988" O_E="0.0" SE="0.213974829270215" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" VAR="0.04578522756121766" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.789753746331083" CI_START="0.5117152205318911" DF="0" EFFECT_SIZE="1.1948051948051948" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-003.25.02" LOG_CI_END="0.4455658694637233" LOG_CI_START="-0.2909716651175765" LOG_EFFECT_SIZE="0.07729710217307338" MODIFIED="2009-07-03 12:21:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6807916665124557" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="92" WEIGHT="100.0" Z="0.4113830708021138">
<NAME>Amenorrhoea</NAME>
<DICH_DATA CI_END="2.789753746331083" CI_START="0.5117152205318911" EFFECT_SIZE="1.1948051948051948" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.4455658694637233" LOG_CI_START="-0.2909716651175765" LOG_EFFECT_SIZE="0.07729710217307338" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="989" O_E="0.0" SE="0.43264579373265233" STUDY_ID="STD-Lieberman-2005" TOTAL_1="56" TOTAL_2="92" VAR="0.18718238283455677" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.5638330049815234" CI_START="0.5310210950011803" DF="0" EFFECT_SIZE="1.5567567567567568" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-003.25.03" LOG_CI_END="0.6593297447860776" LOG_CI_START="-0.2748882260736436" LOG_EFFECT_SIZE="0.19222075935621707" MODIFIED="2009-08-06 14:53:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4199270152255503" STUDIES="2" TAU2="0.0" TOTAL_1="214" TOTAL_2="366" WEIGHT="100.0" Z="0.8065478874751744">
<NAME>Galactorrhoea</NAME>
<DICH_DATA CI_END="4.5638330049815234" CI_START="0.5310210950011803" EFFECT_SIZE="1.5567567567567568" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.6593297447860776" LOG_CI_START="-0.2748882260736436" LOG_EFFECT_SIZE="0.19222075935621707" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="990" O_E="0.0" SE="0.5487642605365383" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="0.30114221364221366" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="991" O_E="0.0" SE="0.0" STUDY_ID="STD-Stroup-2006" TOTAL_1="29" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6422761415759807" CI_END="1.0108726959308194" CI_START="0.5583786966357159" DF="1" EFFECT_SIZE="0.7512987278163616" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="109" I2="0.0" ID="CMP-003.25.04" LOG_CI_END="0.004696466237953969" LOG_CI_START="-0.25307115934987207" LOG_EFFECT_SIZE="-0.124187346555959" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4228880248963389" P_Z="0.058952982574800354" STUDIES="2" TAU2="0.0" TOTAL_1="322" TOTAL_2="444" WEIGHT="100.00000000000001" Z="1.8885438078595516">
<NAME>Sexual dysfunction</NAME>
<DICH_DATA CI_END="0.9874051453817763" CI_START="0.49418893363800964" EFFECT_SIZE="0.6985446985446986" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="91" LOG_CI_END="-0.005504613996080121" LOG_CI_START="-0.3061069839718952" LOG_EFFECT_SIZE="-0.1558057989839877" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="992" O_E="0.0" SE="0.17657532012952343" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="0.031178843678843677" WEIGHT="73.5312487712098"/>
<DICH_DATA CI_END="1.6374338903294825" CI_START="0.516578326590867" EFFECT_SIZE="0.9197080291970803" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.21416377483500362" LOG_CI_START="-0.28686381891269147" LOG_EFFECT_SIZE="-0.036350022038843875" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="993" O_E="0.0" SE="0.29430608869398406" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="108" VAR="0.0866160738423512" WEIGHT="26.468751228790207"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.2607983981283497" CI_END="3.724844970247748" CI_START="-3.326449081582278" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.19919794433273513" ESTIMABLE="YES" I2="11.535676880532877" I2_Q="0.0" ID="CMP-003.26" MODIFIED="2009-07-03 12:15:47 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.32290466507723536" P_Q="1.0" P_Z="0.911824629805991" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.3319265655906523" TOTALS="YES" TOTAL_1="467" TOTAL_2="612" UNITS="" WEIGHT="99.99999999999997" Z="0.11073734659675677">
<NAME>Adverse effects: 7b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.565003574062559" CI_START="-11.46500357406256" EFFECT_SIZE="-4.45" ESTIMABLE="YES" MEAN_1="-7.19" MEAN_2="-2.74" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="994" SD_1="34.51" SD_2="27.79" SE="3.5791492238612608" STUDY_ID="STD-Kinon-2006" TOTAL_1="145" TOTAL_2="168" WEIGHT="22.880389136069837"/>
<CONT_DATA CI_END="5.524502333062243" CI_START="-2.324502333062244" EFFECT_SIZE="1.5999999999999996" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-6.1" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="995" SD_1="21.8" SD_2="22.0" SE="2.0023339020605566" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" WEIGHT="60.581097928891104"/>
<CONT_DATA CI_END="9.869139460703845" CI_START="-6.869139460703845" EFFECT_SIZE="1.4999999999999996" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-5.1" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="996" SD_1="26.9" SD_2="37.4" SE="4.270047575730243" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="108" WEIGHT="16.53851293503904"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.695060327115386" CI_END="1.0430457425643769" CI_START="0.3923219317466995" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6396950215712383" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="134" I2="62.89507919585853" I2_Q="0.0" ID="CMP-003.27" LOG_CI_END="0.018303354742625302" LOG_CI_START="-0.40635741307787066" LOG_EFFECT_SIZE="-0.19402702916762266" METHOD="MH" MODIFIED="2009-07-03 12:16:01 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.10065974475156847" P_Q="1.0" P_Z="0.07329157820468395" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08118183826718225" TOTALS="YES" TOTAL_1="322" TOTAL_2="444" WEIGHT="100.0" Z="1.7910106984810514">
<NAME>Adverse effects: 8. Sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.06098993634266" CI_START="0.5820793365230974" EFFECT_SIZE="0.7858627858627859" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="104" LOG_CI_END="0.025711264569033106" LOG_CI_START="-0.2350178176422459" LOG_EFFECT_SIZE="-0.1046532765366064" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="997" O_E="0.0" SE="0.15315355352067725" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="0.023456010956010954" WEIGHT="59.466267614455504"/>
<DICH_DATA CI_END="0.8012705310577176" CI_START="0.2792091887473583" EFFECT_SIZE="0.472992700729927" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" LOG_CI_END="-0.09622082934727431" LOG_CI_START="-0.5540702932243525" LOG_EFFECT_SIZE="-0.32514556128581346" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="998" O_E="0.0" SE="0.26894304147279385" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="108" VAR="0.07233035955663691" WEIGHT="40.53373238554449"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.898710047652552" CI_END="0.29614956026157613" CI_START="0.140524257552758" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.20400048303946183" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="186" I2="0.0" I2_Q="0.0" ID="CMP-003.28" LOG_CI_END="-0.5284889078858193" LOG_CI_START="-0.8522487005846926" LOG_EFFECT_SIZE="-0.6903688042352559" METHOD="MH" MODIFIED="2009-07-03 12:16:10 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.8257392120615636" P_Q="0.4370428391933602" P_Z="6.343803484936629E-17" Q="0.6040348721481547" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="785" TOTAL_2="923" WEIGHT="100.0" Z="8.358653686250603">
<NAME>Adverse effects: 9a. Weight gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2929593339612439" CI_END="0.3273372766335768" CI_START="0.14488253032753573" DF="2" EFFECT_SIZE="0.21777385726757276" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="151" I2="0.0" ID="CMP-003.28.01" LOG_CI_END="-0.48500453513061204" LOG_CI_START="-0.8389839778120951" LOG_EFFECT_SIZE="-0.6619942564713536" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8637433067678882" P_Z="2.286994360782562E-13" STUDIES="3" TAU2="0.0" TOTAL_1="514" TOTAL_2="646" WEIGHT="83.65458408305213" Z="7.330848881095755">
<NAME>Weight gain of 7% or more of total body weight</NAME>
<DICH_DATA CI_END="0.442606697700062" CI_START="0.06946720079207938" EFFECT_SIZE="0.1753472222222222" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="30" LOG_CI_END="-0.35398201844271954" LOG_CI_START="-1.1582202008384195" LOG_EFFECT_SIZE="-0.7561011096405695" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="999" O_E="0.0" SE="0.47241348938244243" STUDY_ID="STD-Kinon-2006" TOTAL_1="192" TOTAL_2="202" VAR="0.22317450495049504" WEIGHT="16.206022986030465"/>
<DICH_DATA CI_END="0.4206518318387692" CI_START="0.13341330744200183" EFFECT_SIZE="0.23689776733254994" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="92" LOG_CI_END="-0.37607721549498424" LOG_CI_START="-0.8748008491272161" LOG_EFFECT_SIZE="-0.6254390323111002" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1000" O_E="0.0" SE="0.2929527311173746" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="336" VAR="0.08582130266912875" WEIGHT="42.143046593776546"/>
<DICH_DATA CI_END="0.4562413596784295" CI_START="0.10365629983478523" EFFECT_SIZE="0.21746790838157565" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="29" LOG_CI_END="-0.3408053471480973" LOG_CI_START="-0.9844042980048417" LOG_EFFECT_SIZE="-0.6626048225764696" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1001" O_E="0.0" SE="0.3780532095994395" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="108" VAR="0.14292422928843773" WEIGHT="25.305514503245128"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.3671243848912543" CI_START="0.05807799894092323" DF="0" EFFECT_SIZE="0.1460200316288877" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="35" I2="0.0" ID="CMP-003.28.02" LOG_CI_END="-0.43518676811928375" LOG_CI_START="-1.2359883555291444" LOG_EFFECT_SIZE="-0.8355875618242141" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.309911561660156E-5" STUDIES="1" TAU2="0.0" TOTAL_1="271" TOTAL_2="277" WEIGHT="16.34541591694787" Z="4.090205496225842">
<NAME>Weight gain - as "weight gain" reported adverse event</NAME>
<DICH_DATA CI_END="0.3671243848912545" CI_START="0.05807799894092323" EFFECT_SIZE="0.14602003162888771" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="35" LOG_CI_END="-0.4351867681192836" LOG_CI_START="-1.2359883555291444" LOG_EFFECT_SIZE="-0.835587561824214" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1002" O_E="0.0" SE="0.47039481647634096" STUDY_ID="STD-Breier-2005" TOTAL_1="271" TOTAL_2="277" VAR="0.2212712833678105" WEIGHT="16.34541591694787"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.759378564406" CI_END="-2.9589660854731017" CI_START="-4.688071974009748" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.823519029741425" ESTIMABLE="YES" I2="59.013783781391226" I2_Q="0.0" ID="CMP-003.29" MODIFIED="2009-07-03 12:16:19 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.04468201774516134" P_Q="1.0" P_Z="4.3971120329985476E-18" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.5483409230311257" TOTALS="YES" TOTAL_1="743" TOTAL_2="916" UNITS="" WEIGHT="100.0" Z="8.668016970133518">
<NAME>Adverse effects: 9b. Weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.1798138473902684" CI_START="-5.180186152609731" EFFECT_SIZE="-4.18" ESTIMABLE="YES" MEAN_1="-1.12" MEAN_2="3.06" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1003" SD_1="4.7" SD_2="6.87" SE="0.5103084344911806" STUDY_ID="STD-Breier-2005" TOTAL_1="260" TOTAL_2="269" WEIGHT="24.058563567615014"/>
<CONT_DATA CI_END="-3.2620455353673785" CI_START="-5.097954464632621" EFFECT_SIZE="-4.18" ESTIMABLE="YES" MEAN_1="-1.65" MEAN_2="2.53" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1004" SD_1="4.16" SD_2="4.91" SE="0.4683527206996296" STUDY_ID="STD-Kinon-2006" TOTAL_1="182" TOTAL_2="194" WEIGHT="25.34534367075486"/>
<CONT_DATA CI_END="-3.750946368979796" CI_START="-6.249053631020204" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="4.3" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1005" SD_1="6.3" SD_2="7.0" SE="0.6372839709671093" STUDY_ID="STD-Lieberman-2005" TOTAL_1="161" TOTAL_2="307" WEIGHT="20.385619438723054"/>
<CONT_DATA CI_END="-1.3237229393016543" CI_START="-3.916277060698346" EFFECT_SIZE="-2.62" ESTIMABLE="YES" MEAN_1="0.95" MEAN_2="3.57" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1006" SD_1="5.1" SD_2="5.1" SE="0.6613780002710324" STUDY_ID="STD-Simpson-2004" TOTAL_1="116" TOTAL_2="122" WEIGHT="19.738540159156425"/>
<CONT_DATA CI_END="0.12304227509318144" CI_START="-4.363042275093182" EFFECT_SIZE="-2.12" ESTIMABLE="YES" MEAN_1="-0.54" MEAN_2="1.58" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1007" SD_1="4.78" SD_2="2.93" SE="1.1444303532034326" STUDY_ID="STD-Svestka-2005" TOTAL_1="24" TOTAL_2="24" WEIGHT="10.471933163750654"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-07-03 12:22:20 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>ZIPRASIDONE versus QUETIAPINE</NAME>
<DICH_OUTCOME CHI2="1.3074171318444814" CI_END="1.0159966443746171" CI_START="0.8826092383513842" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9469572453173601" ESTIMABLE="YES" EVENTS_1="386" EVENTS_2="504" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.006892273566016843" LOG_CI_START="-0.054231531065089454" LOG_EFFECT_SIZE="-0.02366962874953629" METHOD="MH" MODIFIED="2008-12-04 14:28:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.934166622577949" P_Q="0.8037223552092412" P_Z="0.1290255168603334" Q="0.4370031095602127" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="966" TOTAL_2="1200" WEIGHT="300.0" Z="1.517955898082825">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3471231876464046" CI_END="1.0272031523445404" CI_START="0.8843352038297991" DF="1" EFFECT_SIZE="0.9530959600707692" ESTIMABLE="YES" EVENTS_1="253" EVENTS_2="330" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.011656343516579307" LOG_CI_START="-0.05338308614091291" LOG_EFFECT_SIZE="-0.020863371312166798" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5557463556280561" P_Z="0.20859586681683207" STUDIES="2" TAU2="0.0" TOTAL_1="322" TOTAL_2="400" WEIGHT="100.0" Z="1.2574358841482427">
<NAME>Any reason</NAME>
<DICH_DATA CI_END="1.0561899352630661" CI_START="0.8848088373342979" EFFECT_SIZE="0.9667089472143624" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="277" LOG_CI_END="0.02374202465546913" LOG_CI_START="-0.053150548351364346" LOG_EFFECT_SIZE="-0.01470426184794762" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1008" O_E="0.0" SE="0.045167078008588976" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.002040064935833962" WEIGHT="71.54588515302154"/>
<DICH_DATA CI_END="1.0583128784126703" CI_START="0.7992559442707153" EFFECT_SIZE="0.9197080291970803" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="53" LOG_CI_END="0.024614081007525466" LOG_CI_START="-0.09731412508521317" LOG_EFFECT_SIZE="-0.036350022038843875" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1009" O_E="0.0" SE="0.07162123181322883" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="63" VAR="0.00512960084644426" WEIGHT="28.45411484697846"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.43512352495854006" CI_END="1.3850029281262555" CI_START="0.6709316408522383" DF="1" EFFECT_SIZE="0.9639721402368968" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="60" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.14145069157211415" LOG_CI_START="-0.1733217264972052" LOG_EFFECT_SIZE="-0.01593551746254549" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5094855840345844" P_Z="0.8426942580256309" STUDIES="2" TAU2="0.0" TOTAL_1="322" TOTAL_2="400" WEIGHT="100.0" Z="0.19844839324340122">
<NAME>Adverse events</NAME>
<DICH_DATA CI_END="1.5974311229640143" CI_START="0.6782942038717427" EFFECT_SIZE="1.040926640926641" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="49" LOG_CI_END="0.2034221415963017" LOG_CI_START="-0.16858189403224097" LOG_EFFECT_SIZE="0.01742012378203037" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1010" O_E="0.0" SE="0.21851701197788084" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.04774968452374132" WEIGHT="71.59752965967938"/>
<DICH_DATA CI_END="1.5678265445885247" CI_START="0.4024053842784253" EFFECT_SIZE="0.794293297942933" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.19529801313477935" LOG_CI_START="-0.39533621695122156" LOG_EFFECT_SIZE="-0.10001910190822112" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1011" O_E="0.0" SE="0.34694147043910845" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="63" VAR="0.12036838391045077" WEIGHT="28.402470340320615"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.26068818683177E-4" CI_END="1.1219689198600813" CI_START="0.6801681290696401" DF="1" EFFECT_SIZE="0.8735716920181861" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="114" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.04998082650996635" LOG_CI_START="-0.16738372184973724" LOG_EFFECT_SIZE="-0.05870144766988541" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9770708282792578" P_Z="0.2897750107964706" STUDIES="2" TAU2="0.0" TOTAL_1="322" TOTAL_2="400" WEIGHT="100.0" Z="1.0586153458929675">
<NAME>Inefficacy</NAME>
<DICH_DATA CI_END="1.1893552773806084" CI_START="0.6381671417357089" EFFECT_SIZE="0.8712103407755581" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="92" LOG_CI_END="0.07531160395308108" LOG_CI_START="-0.19506556073516718" LOG_EFFECT_SIZE="-0.05987697839104302" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1012" O_E="0.0" SE="0.15882088492642749" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.025224073488813524" WEIGHT="64.63048385281105"/>
<DICH_DATA CI_END="1.3371835517664366" CI_START="0.5763710486446133" EFFECT_SIZE="0.8779031187790312" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="22" LOG_CI_END="0.12619102584678907" LOG_CI_START="-0.23929784210105084" LOG_EFFECT_SIZE="-0.056553408127130854" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1013" O_E="0.0" SE="0.21468997023163586" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="63" VAR="0.04609178331806069" WEIGHT="35.369516147188946"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.654218121272513" CI_END="6.359612316548716" CI_START="-6.1446181796429435" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10749706845288608" ESTIMABLE="YES" I2="62.32412129261745" I2_Q="62.32412129261745" ID="CMP-004.02" MODIFIED="2009-07-03 12:17:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1032755830430685" P_Q="0.1032755830430685" P_Z="0.973117131651759" Q="2.654218121272513" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="13.085073913627628" TOTALS="YES" TOTAL_1="318" TOTAL_2="392" UNITS="" WEIGHT="100.0" Z="0.03369905611952088">
<NAME>Mental state: 1. General mental state: PANSS total score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7019642341910619E-32" CI_END="2.9718012051119262" CI_START="-10.371801205111927" DF="0" EFFECT_SIZE="-3.7000000000000006" ESTIMABLE="YES" I2="100.0" ID="CMP-004.02.01" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.27706207590453114" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="63" WEIGHT="41.24232919054188" Z="1.0869428689274838">
<NAME>Medium term</NAME>
<CONT_DATA CI_END="2.9718012051119267" CI_START="-10.371801205111927" EFFECT_SIZE="-3.7" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="2.0" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1014" SD_1="22.31" SD_2="22.31" SE="3.404042756774228" STUDY_ID="STD-Stroup-2006" TOTAL_1="135" TOTAL_2="63" WEIGHT="41.24232919054188"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.812358606828371" CI_START="-1.2523586068283707" DF="0" EFFECT_SIZE="2.7800000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.02" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.17661732356095186" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="329" WEIGHT="58.75767080945811" Z="1.3512438769197157">
<NAME>Long term</NAME>
<CONT_DATA CI_END="6.812358606828371" CI_START="-1.2523586068283707" EFFECT_SIZE="2.7800000000000002" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-6.08" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1015" SD_1="22.31" SD_2="22.31" SE="2.0573636243497844" STUDY_ID="STD-Lieberman-2005" TOTAL_1="183" TOTAL_2="329" WEIGHT="58.75767080945811"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.1830635946802817" CI_START="-2.1830635946802817" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2009-07-03 12:17:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="63" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Mental state: 2. Positive symptoms: PANSS positive subscore (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.1830635946802817" CI_START="-2.1830635946802817" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="63" WEIGHT="100.0" Z="0.0">
<NAME>Medium term</NAME>
<CONT_DATA CI_END="2.1830635946802817" CI_START="-2.1830635946802817" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.2" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1016" SD_1="7.3" SD_2="7.3" SE="1.1138284233281879" STUDY_ID="STD-Stroup-2006" TOTAL_1="135" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3378427525381129" CI_START="-3.5378427525381126" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2009-07-03 12:17:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.10560558084083535" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="63" UNITS="" WEIGHT="100.0" Z="1.61826462500982">
<NAME>Mental state: 3. Negative symptoms: PANSS negative subscore (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3378427525381129" CI_START="-3.5378427525381126" DF="0" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.01" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10560558084083535" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="63" WEIGHT="100.0" Z="1.61826462500982">
<NAME>Medium term</NAME>
<CONT_DATA CI_END="0.3378427525381129" CI_START="-3.5378427525381126" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="0.2" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1017" SD_1="6.48" SD_2="6.48" SE="0.9887134497488571" STUDY_ID="STD-Stroup-2006" TOTAL_1="135" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.07922643432155069" CI_END="1.1704872677511786" CI_START="0.6285857565394732" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8577596544016253" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.06836669391860667" LOG_CI_START="-0.20163546411766528" LOG_EFFECT_SIZE="-0.06663438509952929" METHOD="MH" MODIFIED="2009-07-03 12:17:45 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.778348481607875" P_Q="0.7783667994900627" P_Z="0.3333406018369405" Q="0.07921298859334608" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="432" WEIGHT="99.99999999999997" Z="0.9674070450170621">
<NAME>Service use: Number of patients re-hospitalised</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3990073358785984" CI_START="0.46081249254981355" DF="0" EFFECT_SIZE="0.8029197080291971" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.1458199917779193" LOG_CI_START="-0.33647575577428274" LOG_EFFECT_SIZE="-0.09532788199818172" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.43846314257710706" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="95" WEIGHT="31.340621553921228" Z="0.7747910546057531">
<NAME>Medium term</NAME>
<DICH_DATA CI_END="1.3990073358785984" CI_START="0.46081249254981355" EFFECT_SIZE="0.8029197080291971" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" LOG_CI_END="0.1458199917779193" LOG_CI_START="-0.33647575577428274" LOG_EFFECT_SIZE="-0.09532788199818172" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1018" O_E="0.0" SE="0.2833029095146174" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="95" VAR="0.08026053853944748" WEIGHT="31.340621553921228"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2864355724621337" CI_START="0.6074889163326158" DF="0" EFFECT_SIZE="0.8840222575516693" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="68" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.10938804066309332" LOG_CI_START="-0.21646164138314142" LOG_EFFECT_SIZE="-0.05353680036002403" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5195491578799092" STUDIES="1" TAU2="0.0" TOTAL_1="185" TOTAL_2="337" WEIGHT="68.65937844607875" Z="0.6440405274863492">
<NAME>Long term</NAME>
<DICH_DATA CI_END="1.2864355724621337" CI_START="0.6074889163326158" EFFECT_SIZE="0.8840222575516693" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="68" LOG_CI_END="0.10938804066309332" LOG_CI_START="-0.21646164138314142" LOG_EFFECT_SIZE="-0.05353680036002403" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1019" O_E="0.0" SE="0.19140571621589825" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.036636148200120976" WEIGHT="68.65937844607875"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7749183520141483" CI_END="1.0966317605829894" CI_START="0.8531136266628567" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9672391112773655" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="252" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.04006081974023059" LOG_CI_START="-0.06899312106433594" LOG_EFFECT_SIZE="-0.014466150662052642" METHOD="MH" MODIFIED="2009-07-03 12:17:53 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3786998495209666" P_Q="1.0" P_Z="0.6030749576067946" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="432" WEIGHT="100.0" Z="0.5199836719952116">
<NAME>Adverse effects: 1. At least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1250278506949194" CI_START="0.8629817912734604" EFFECT_SIZE="0.9853316953316953" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="220" LOG_CI_END="0.051163273783741456" LOG_CI_START="-0.06399836770644282" LOG_EFFECT_SIZE="-0.006417546961350671" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1020" O_E="0.0" SE="0.06764651827065345" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.00457605143414185" WEIGHT="89.67410168242317"/>
<DICH_DATA CI_END="1.2170914646108995" CI_START="0.5571217275299789" EFFECT_SIZE="0.8234489051094891" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="32" LOG_CI_END="0.08532321675363674" LOG_CI_START="-0.25404990389494625" LOG_EFFECT_SIZE="-0.0843633435706548" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1021" O_E="0.0" SE="0.19934945099301835" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="95" VAR="0.03974020361121783" WEIGHT="10.325898317576826"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9782555134533517" CI_START="0.12379750186607058" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6072072072072072" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.47396195443783784" LOG_CI_START="-0.9072881189405131" LOG_EFFECT_SIZE="-0.2166630822513376" METHOD="MH" MODIFIED="2009-07-03 12:18:02 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.538633673547094" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="185" TOTAL_2="337" WEIGHT="100.0" Z="0.6148804567349925">
<NAME>Adverse effects: 2a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9782555134533517" CI_START="0.12379750186607058" EFFECT_SIZE="0.6072072072072072" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.47396195443783784" LOG_CI_START="-0.9072881189405131" LOG_EFFECT_SIZE="-0.2166630822513376" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1022" O_E="0.0" SE="0.8113531304005772" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.6582939022108161" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.5636698059626409" CI_END="1.3697634706811965" CI_START="-8.184207208251438" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.4072218687851206" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.08" MODIFIED="2009-07-03 12:18:15 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.4527855008857582" P_Q="1.0" P_Z="0.16212522230665982" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="254" TOTAL_2="295" UNITS="" WEIGHT="99.99999999999999" Z="1.3979595237573332">
<NAME>Adverse effects: 2b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1022405595492764" CI_START="-10.302240559549277" EFFECT_SIZE="-4.6000000000000005" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="5.9" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1023" SD_1="26.8" SD_2="27.8" SE="2.9093598681036092" STUDY_ID="STD-Lieberman-2005" TOTAL_1="148" TOTAL_2="214" WEIGHT="70.180546719628"/>
<CONT_DATA CI_END="8.147905242271312" CI_START="-9.347905242271311" EFFECT_SIZE="-0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.9" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1024" SD_1="25.7" SD_2="33.3" SE="4.463298974508548" STUDY_ID="STD-Stroup-2006" TOTAL_1="106" TOTAL_2="81" WEIGHT="29.81945328037199"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.13489167522883302" CI_END="-8.568655961625055" CI_START="-23.460636369209595" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.014646165417325" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.09" MODIFIED="2009-07-03 12:18:24 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.7134132361710872" P_Q="1.0" P_Z="2.4929095935043033E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="432" UNITS="" WEIGHT="100.0" Z="4.2154406399009705">
<NAME>Adverse effects: 3. Cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.5101914337629534" CI_START="-25.489808566237045" EFFECT_SIZE="-14.5" ESTIMABLE="YES" MEAN_1="-9.2" MEAN_2="5.3" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1025" SD_1="70.7" SD_2="38.6" SE="5.607148219519978" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" WEIGHT="45.90549409223834"/>
<CONT_DATA CI_END="-7.176145815204306" CI_START="-27.423854184795694" EFFECT_SIZE="-17.3" ESTIMABLE="YES" MEAN_1="-12.5" MEAN_2="4.8" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1026" SD_1="41.0" SD_2="37.0" SE="5.165326641025735" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="95" WEIGHT="54.094505907761665"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.09806521565282314" CI_END="18.83251648470017" CI_START="0.3175556721451866" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4454800000172296" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="1.2749083562565506" LOG_CI_START="-0.4981801255344025" LOG_EFFECT_SIZE="0.38836411536107407" METHOD="MH" MODIFIED="2009-07-03 12:18:33 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.7541639453632699" P_Q="0.7571171602486241" P_Z="0.3905657330226957" Q="0.09564712813442758" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="432" WEIGHT="100.0" Z="0.8585918715422651">
<NAME>Adverse effects: 4. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="28.95453223995233" CI_START="0.11460400412826177" DF="0" EFFECT_SIZE="1.8216216216216217" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.10.01" LOG_CI_END="1.4617165533050185" LOG_CI_START="-0.940800208368369" LOG_EFFECT_SIZE="0.2604581724683248" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6708646970299637" STUDIES="1" TAU2="0.0" TOTAL_1="185" TOTAL_2="337" WEIGHT="54.46631138048997" Z="0.424961561692894">
<NAME>Suicide attempt</NAME>
<DICH_DATA CI_END="28.95453223995233" CI_START="0.11460400412826177" EFFECT_SIZE="1.8216216216216217" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.4617165533050185" LOG_CI_START="-0.940800208368369" LOG_EFFECT_SIZE="0.2604581724683248" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1027" O_E="0.0" SE="1.4112502384567203" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="1.9916272355441496" WEIGHT="54.46631138048997"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0695563841774005E-32" CI_END="71.64344920235524" CI_START="0.16886817722269662" DF="0" EFFECT_SIZE="3.4782608695652177" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="100.0" ID="CMP-004.10.02" LOG_CI_END="1.85517648635469" LOG_CI_START="-0.7724521844059884" LOG_EFFECT_SIZE="0.5413621509743507" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.41931481868778187" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="95" WEIGHT="45.53368861951003" Z="0.8076105503870127">
<NAME>Suicide</NAME>
<DICH_DATA CI_END="71.64344920235524" CI_START="0.16886817722269662" EFFECT_SIZE="3.4782608695652173" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.85517648635469" LOG_CI_START="-0.7724521844059884" LOG_EFFECT_SIZE="0.5413621509743507" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1028" O_E="0.0" SE="1.5434820881765163" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="95" VAR="2.382336956521739" WEIGHT="45.53368861951003"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.114381684415874" CI_END="2.094215459627405" CI_START="0.8633693282832633" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3446491715904703" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="40" I2="50.935349560425756" I2_Q="60.14196848509935" ID="CMP-004.11" LOG_CI_END="0.32102136125569264" LOG_CI_START="-0.06380338397942326" LOG_EFFECT_SIZE="0.12860898863813466" METHOD="MH" MODIFIED="2009-07-03 12:18:50 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.10617606371743349" P_Q="0.08135737875853077" P_Z="0.19018040339039805" Q="5.017809269512754" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2088191677031378" TOTALS="SUB" TOTAL_1="644" TOTAL_2="864" WEIGHT="300.0" Z="1.3100456191550716">
<NAME>Adverse effects: 5. Extrapyramidal side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1025672573372005" CI_END="2.385498627160108" CI_START="0.6905551400216506" DF="1" EFFECT_SIZE="1.283478998075155" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" I2="9.302585094437658" ID="CMP-004.11.01" LOG_CI_END="0.37757917096119464" LOG_CI_START="-0.16080163779347567" LOG_EFFECT_SIZE="0.10838876658385953" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.29370389241925465" P_Z="0.430010299763531" STUDIES="2" TAU2="0.021398300767514096" TOTAL_1="322" TOTAL_2="432" WEIGHT="99.99999999999999" Z="0.7891740395593746">
<NAME>Akathisia</NAME>
<DICH_DATA CI_END="3.192123936627362" CI_START="0.7958893735096958" EFFECT_SIZE="1.593918918918919" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.5040797448179328" LOG_CI_START="-0.09914729383665677" LOG_EFFECT_SIZE="0.20246622549063806" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1029" O_E="0.0" SE="0.35433854852770524" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.12555580697272092" WEIGHT="68.05697080615643"/>
<DICH_DATA CI_END="2.331718237346947" CI_START="0.2806878319441628" EFFECT_SIZE="0.8090024330900243" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.3676760695181322" LOG_CI_START="-0.5517764139920237" LOG_EFFECT_SIZE="-0.09205017223694582" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1030" O_E="0.0" SE="0.5400909401770624" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="95" VAR="0.2916982236613432" WEIGHT="31.94302919384356"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5141123490034964" CI_START="0.1620286835132397" DF="0" EFFECT_SIZE="0.4953076120959332" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-004.11.02" LOG_CI_END="0.1801581015458157" LOG_CI_START="-0.7904080966374099" LOG_EFFECT_SIZE="-0.3051249975457971" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.21782194887367734" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="95" WEIGHT="100.0" Z="1.232340477325662">
<NAME>Extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="1.5141123490034967" CI_START="0.1620286835132397" EFFECT_SIZE="0.49530761209593327" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.18015810154581577" LOG_CI_START="-0.7904080966374099" LOG_EFFECT_SIZE="-0.305124997545797" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1031" O_E="0.0" SE="0.5701153891929918" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="95" VAR="0.3250315569946765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.002545620760524" CI_START="1.0744741908790065" DF="0" EFFECT_SIZE="2.3184275184275185" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" ID="CMP-004.11.03" LOG_CI_END="0.6991910578788065" LOG_CI_START="0.031195988097869137" LOG_EFFECT_SIZE="0.3651935229883378" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.03211083009375577" STUDIES="1" TAU2="0.0" TOTAL_1="185" TOTAL_2="337" WEIGHT="100.0" Z="2.143028249232951">
<NAME>Use of antiparkinson medication</NAME>
<DICH_DATA CI_END="5.002545620760524" CI_START="1.0744741908790065" EFFECT_SIZE="2.3184275184275185" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.6991910578788065" LOG_CI_START="0.031195988097869137" LOG_EFFECT_SIZE="0.3651935229883378" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1032" O_E="0.0" SE="0.39238361061824667" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.15396489788181184" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.23523705520635957" CI_END="3.9933163602680866" CI_START="-10.19197687271376" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.099330256222836" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.12" MODIFIED="2009-07-03 12:19:01 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.6276675540755526" P_Q="1.0" P_Z="0.3917428086188588" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="432" UNITS="" WEIGHT="100.0" Z="0.8564610655024352">
<NAME>Adverse effects: 6. Glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.574325385951404" CI_START="-13.574325385951404" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="6.8" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1033" SD_1="53.0" SD_2="45.9" SE="4.62984292442541" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" WEIGHT="61.092507117301"/>
<CONT_DATA CI_END="10.470817750497485" CI_START="-12.270817750497486" EFFECT_SIZE="-0.9000000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.2" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1034" SD_1="45.6" SD_2="41.9" SE="5.801544232541539" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="95" WEIGHT="38.907492882698996"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.5850302194583907" CI_END="1.4909962784279678" CI_START="0.7707545614378332" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0720038165441341" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="80" I2="44.21246467757389" I2_Q="44.03618225146237" ID="CMP-004.13" LOG_CI_END="0.17347655944211948" LOG_CI_START="-0.1130838963758057" LOG_EFFECT_SIZE="0.030196331533156876" METHOD="MH" MODIFIED="2009-07-03 12:22:20 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.1665408345707241" P_Q="0.16748383256175325" P_Z="0.6795606548495408" Q="3.5737376048692844" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1420763503957815" TOTALS="SUB" TOTAL_1="455" TOTAL_2="777" WEIGHT="300.0" Z="0.4130627312222229">
<NAME>Adverse effects: 7a. Prolactin-associated side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.792437135582766" CI_START="0.808101640438046" DF="0" EFFECT_SIZE="2.342857142857143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-004.13.01" LOG_CI_END="0.832025627686785" LOG_CI_START="-0.0925340116199028" LOG_EFFECT_SIZE="0.3697458080334411" MODIFIED="2009-07-03 12:22:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.11696510548735756" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="82" WEIGHT="100.0" Z="1.5676402827266769">
<NAME>Amenorrhoea</NAME>
<DICH_DATA CI_END="6.792437135582766" CI_START="0.808101640438046" EFFECT_SIZE="2.342857142857143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.832025627686785" LOG_CI_START="-0.0925340116199028" LOG_EFFECT_SIZE="0.3697458080334411" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1035" O_E="0.0" SE="0.5430909087727741" STUDY_ID="STD-Lieberman-2005" TOTAL_1="56" TOTAL_2="82" VAR="0.29494773519163764" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.56785959144433" CI_START="0.5959750381382376" DF="0" EFFECT_SIZE="1.8216216216216217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-004.13.02" LOG_CI_END="0.7456882748370957" LOG_CI_START="-0.22477192990044592" LOG_EFFECT_SIZE="0.2604581724683248" MODIFIED="2009-07-03 12:22:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.29277444320332235" STUDIES="2" TAU2="0.0" TOTAL_1="214" TOTAL_2="358" WEIGHT="100.0" Z="1.052054757165646">
<NAME>Galactorrhoea</NAME>
<DICH_DATA CI_END="5.56785959144433" CI_START="0.5959750381382376" EFFECT_SIZE="1.8216216216216217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.7456882748370957" LOG_CI_START="-0.22477192990044592" LOG_EFFECT_SIZE="0.2604581724683248" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1036" O_E="0.0" SE="0.5700531281183209" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.3249605688774828" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1037" O_E="0.0" SE="0.0" STUDY_ID="STD-Stroup-2006" TOTAL_1="29" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3311248631084838" CI_START="0.6414096015354778" DF="0" EFFECT_SIZE="0.9240109674892284" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="69" I2="0.0" ID="CMP-004.13.03" LOG_CI_END="0.12421879538120545" LOG_CI_START="-0.1928645432185151" LOG_EFFECT_SIZE="-0.034322873918654837" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6713361561441442" STUDIES="1" TAU2="0.0" TOTAL_1="185" TOTAL_2="337" WEIGHT="100.0" Z="0.42431492631276285">
<NAME>Sexual dysfunction</NAME>
<DICH_DATA CI_END="1.3311248631084838" CI_START="0.6414096015354778" EFFECT_SIZE="0.9240109674892284" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="69" LOG_CI_END="0.12421879538120545" LOG_CI_START="-0.1928645432185151" LOG_EFFECT_SIZE="-0.034322873918654837" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1038" O_E="0.0" SE="0.1862563226813159" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.03469141773876647" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.455324578487429E-4" CI_END="8.160825601485232" CI_START="1.3716474107929115" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="4.766236506139072" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.14" MODIFIED="2009-07-03 12:19:31 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.9782169161828815" P_Q="1.0" P_Z="0.005924623182205565" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="432" UNITS="" WEIGHT="100.0" Z="2.7519242039160545">
<NAME>Adverse effects: 7b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.970983806398547" CI_START="0.6290161936014558" EFFECT_SIZE="4.800000000000001" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-9.3" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1039" SD_1="21.8" SD_2="25.7" SE="2.128092066639353" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" WEIGHT="66.23650613907044"/>
<CONT_DATA CI_END="10.542026479850566" CI_START="-1.142026479850565" EFFECT_SIZE="4.700000000000001" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-8.3" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1040" SD_1="26.9" SD_2="18.5" SE="2.980680525729924" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="95" WEIGHT="33.763493860929565"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.0737625909490736" CI_END="0.9741580022183338" CI_START="0.552738803727231" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7337948819578064" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="125" I2="6.869543749319534" I2_Q="0.0" ID="CMP-004.15" LOG_CI_END="-0.0113705976117049" LOG_CI_START="-0.2574800457256904" LOG_EFFECT_SIZE="-0.1344253216686977" METHOD="MH" MODIFIED="2009-07-03 12:19:42 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.30009752824050706" P_Q="1.0" P_Z="0.03226838628591679" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.003936809455959538" TOTALS="YES" TOTAL_1="322" TOTAL_2="432" WEIGHT="100.0" Z="2.141070089749937">
<NAME>Adverse effects: 8. Sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0751811867908851" CI_START="0.5890949048104682" EFFECT_SIZE="0.7958541065337181" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="103" LOG_CI_END="0.03148165661712787" LOG_CI_START="-0.22981473354013535" LOG_EFFECT_SIZE="-0.09916653846150374" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1041" O_E="0.0" SE="0.15348679301636797" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.023558195630449384" WEIGHT="76.01126718961142"/>
<DICH_DATA CI_END="0.9985138154571166" CI_START="0.3223677935201495" EFFECT_SIZE="0.5673523556735236" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="-6.459218445729501E-4" LOG_CI_START="-0.49164835332834533" LOG_EFFECT_SIZE="-0.24614713758645915" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1042" O_E="0.0" SE="0.28841725875480234" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="95" VAR="0.08318451514763461" WEIGHT="23.988732810388587"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.004469705029441615" CI_END="0.7399292357722174" CI_START="0.2754336959832329" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.451443733121627" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-004.16" LOG_CI_END="-0.13080981267871303" LOG_CI_START="-0.559982930148817" LOG_EFFECT_SIZE="-0.345396371413765" METHOD="MH" MODIFIED="2009-07-03 12:19:51 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.9466964589133811" P_Q="1.0" P_Z="0.0016064209610781493" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="432" WEIGHT="100.0" Z="3.1547383599065077">
<NAME>Adverse effects: 9a. Weight gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8171653401451591" CI_START="0.243543609943351" EFFECT_SIZE="0.44611141753998895" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="49" LOG_CI_END="-0.08769006213616634" LOG_CI_START="-0.6134232608889617" LOG_EFFECT_SIZE="-0.35055666151256404" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1043" O_E="0.0" SE="0.30881828336869716" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="337" VAR="0.09536873214278893" WEIGHT="66.63988157694057"/>
<DICH_DATA CI_END="1.087520272028289" CI_START="0.1965106974070624" EFFECT_SIZE="0.46228710462287104" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.03643736121101169" LOG_CI_START="-0.7066138030574922" LOG_EFFECT_SIZE="-0.33508822092324025" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1044" O_E="0.0" SE="0.436471932053903" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="95" VAR="0.19050774747086693" WEIGHT="33.360118423059426"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.05066202867806946" CI_START="-2.450662028678069" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.17" MODIFIED="2009-07-03 12:20:02 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.06003051313925749" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="305" UNITS="" WEIGHT="100.0" Z="1.88056943244215">
<NAME>Adverse effects: 9b. Weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.05066202867806946" CI_START="-2.450662028678069" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="0.5" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1045" SD_1="6.3" SD_2="7.0" SE="0.6381045970962385" STUDY_ID="STD-Lieberman-2005" TOTAL_1="161" TOTAL_2="305" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-08-06 14:55:33 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>ZIPRASIDONE versus RISPERIDONE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0725025810748816" CI_START="0.8934109874535282" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9788695469798657" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="128" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.030398346027139134" LOG_CI_START="-0.048948710739158005" LOG_EFFECT_SIZE="-0.009275182356009463" METHOD="MH" MODIFIED="2009-08-06 14:55:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6467976678069429" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="0.4582154426058435">
<NAME>No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0725025810748816" CI_START="0.8934109874535282" EFFECT_SIZE="0.9788695469798657" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="128" LOG_CI_END="0.030398346027139134" LOG_CI_START="-0.048948710739158005" LOG_EFFECT_SIZE="-0.009275182356009463" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1055" O_E="0.0" SE="0.04660885391878851" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.002172385263622967" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.559408965019696" CI_END="1.203468387477948" CI_START="1.0245373768342685" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1104045860899636" ESTIMABLE="YES" EVENTS_1="470" EVENTS_2="514" I2="16.31281777697731" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.0804346867803864" LOG_CI_START="0.010527806814104873" LOG_EFFECT_SIZE="0.04548124679724557" METHOD="MH" MODIFIED="2009-07-30 09:24:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2973204476757767" P_Q="0.9088955533087486" P_Z="0.010763160369702507" Q="0.19105032322173252" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.004397415307128512" TOTALS="SUB" TOTAL_1="1413" TOTAL_2="1674" WEIGHT="300.0" Z="2.550295642934576">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9919105185422825" CI_END="1.2020873854061311" CI_START="1.0168688800220511" DF="2" EFFECT_SIZE="1.1056062831254934" ESTIMABLE="YES" EVENTS_1="308" EVENTS_2="341" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.07993603973013964" LOG_CI_START="0.007264956507706525" LOG_EFFECT_SIZE="0.04360049811892314" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.36937053882301085" P_Z="0.018680772713028593" STUDIES="3" TAU2="0.0" TOTAL_1="471" TOTAL_2="558" WEIGHT="99.99999999999997" Z="2.3518407110991313">
<NAME>Any reason</NAME>
<DICH_DATA CI_END="1.7509101426777038" CI_START="0.9094665742139647" EFFECT_SIZE="1.2619010457312314" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="43" LOG_CI_END="0.24326385851029295" LOG_CI_START="-0.04121325800917421" LOG_EFFECT_SIZE="0.10102530025055936" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1046" O_E="0.0" SE="0.16710326642797269" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.027923501650898026" WEIGHT="6.525722365954316"/>
<DICH_DATA CI_END="1.1793153951213984" CI_START="0.9725881198019469" EFFECT_SIZE="1.0709753231492363" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="253" LOG_CI_END="0.07162996798148041" LOG_CI_START="-0.012071039657796186" LOG_EFFECT_SIZE="0.02977946416184213" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1047" O_E="0.0" SE="0.04916638621398107" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="0.0024173335333423475" WEIGHT="75.3810000753508"/>
<DICH_DATA CI_END="1.4651883926313058" CI_START="0.9886627675947256" EFFECT_SIZE="1.2035685320356853" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="45" LOG_CI_END="0.1658934694819006" LOG_CI_START="-0.004951820787347402" LOG_EFFECT_SIZE="0.0804708243472766" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1048" O_E="0.0" SE="0.10035536920198233" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="70" VAR="0.010071200127666184" WEIGHT="18.093277558694872"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8598877228247237" CI_END="1.9811152646321466" CI_START="0.7576751755819211" DF="2" EFFECT_SIZE="1.225170133482769" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="52" I2="30.067184664697564" ID="CMP-005.02.02" LOG_CI_END="0.29690974426011146" LOG_CI_START="-0.12051694171243227" LOG_EFFECT_SIZE="0.0881964012738396" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23932270450431026" P_Z="0.40754265778888177" STUDIES="3" TAU2="0.05785992662330701" TOTAL_1="471" TOTAL_2="558" WEIGHT="100.00000000000001" Z="0.8282257741142032">
<NAME>Adverse events</NAME>
<DICH_DATA CI_END="1.5751213691093258" CI_START="0.25024120284276763" EFFECT_SIZE="0.6278218425869433" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.1973140234612706" LOG_CI_START="-0.6016411810774028" LOG_EFFECT_SIZE="-0.20216357880806612" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1049" O_E="0.0" SE="0.46931024203806293" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.22025210328182523" WEIGHT="21.618016748465447"/>
<DICH_DATA CI_END="2.421615804840775" CI_START="0.9515208023576114" EFFECT_SIZE="1.5179650238473767" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" LOG_CI_END="0.3841052424103339" LOG_CI_START="-0.021581712631437863" LOG_EFFECT_SIZE="0.181261764889448" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1050" O_E="0.0" SE="0.23830252557435172" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="0.05678809369511456" WEIGHT="52.440770488147976"/>
<DICH_DATA CI_END="3.140502318844827" CI_START="0.6124447966059315" EFFECT_SIZE="1.3868613138686132" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.4969991184091386" LOG_CI_START="-0.21293305081629402" LOG_EFFECT_SIZE="0.1420330337964222" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1051" O_E="0.0" SE="0.41701767042393334" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="70" VAR="0.17390373744580429" WEIGHT="25.941212763386584"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.9164891533394464" CI_END="1.656062726950898" CI_START="0.7855491078308342" DF="2" EFFECT_SIZE="1.1405781856883712" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="121" I2="48.93385576480728" ID="CMP-005.02.03" LOG_CI_END="0.21907678260146457" LOG_CI_START="-0.10482666028243016" LOG_EFFECT_SIZE="0.057125061159517244" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14110606800679426" P_Z="0.4893543901955405" STUDIES="3" TAU2="0.05337264509412288" TOTAL_1="471" TOTAL_2="558" WEIGHT="100.0" Z="0.6913360444114547">
<NAME>Inefficacy</NAME>
<DICH_DATA CI_END="3.518619831766622" CI_START="0.9297638492044163" EFFECT_SIZE="1.808724832214765" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.5463723461517622" LOG_CI_START="-0.03162734393079527" LOG_EFFECT_SIZE="0.2573725011104835" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1052" O_E="0.0" SE="0.3395198790991041" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.11527374830347026" WEIGHT="21.464920022689576"/>
<DICH_DATA CI_END="1.2178540602583328" CI_START="0.652217760883905" EFFECT_SIZE="0.8912384912384912" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="91" LOG_CI_END="0.08559524837738322" LOG_CI_START="-0.18560737886822776" LOG_EFFECT_SIZE="-0.050006065245422275" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1053" O_E="0.0" SE="0.1593057657187279" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="0.02537832699123022" WEIGHT="45.96744967758513"/>
<DICH_DATA CI_END="1.909685050451289" CI_START="0.7442978559896076" EFFECT_SIZE="1.1922141119221412" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="18" LOG_CI_END="0.28096174833172455" LOG_CI_START="-0.1282532320268355" LOG_EFFECT_SIZE="0.0763542581524445" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1054" O_E="0.0" SE="0.24037490510944018" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="70" VAR="0.05778009500637237" WEIGHT="32.567630299725295"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5970766472804356" CI_START="0.9587288348138944" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.237401888294847" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.20332575940220413" LOG_CI_START="-0.018304210552735997" LOG_EFFECT_SIZE="0.09251077442473406" METHOD="MH" MODIFIED="2009-07-30 09:35:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.10179337966958006" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="1.6362208242075915">
<NAME>Global State: No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5970766472804356" CI_START="0.9587288348138944" DF="0" EFFECT_SIZE="1.237401888294847" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="59" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.20332575940220413" LOG_CI_START="-0.018304210552735997" LOG_EFFECT_SIZE="0.09251077442473406" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10179337966958006" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="1.6362208242075915">
<NAME>Short term</NAME>
<DICH_DATA CI_END="1.5970766472804356" CI_START="0.9587288348138944" EFFECT_SIZE="1.237401888294847" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="59" LOG_CI_END="0.20332575940220413" LOG_CI_START="-0.018304210552735997" LOG_EFFECT_SIZE="0.09251077442473406" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1056" O_E="0.0" SE="0.13018654143757666" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.016948535571477866" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0725025810748816" CI_START="0.8934109874535282" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9788695469798657" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="128" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.030398346027139134" LOG_CI_START="-0.048948710739158005" LOG_EFFECT_SIZE="-0.009275182356009463" METHOD="MH" MODIFIED="2009-07-30 09:32:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6467976678069429" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="0.4582154426058435">
<NAME>Mental State 1a. General Mental State (less than 50% PANSS total reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0725025810748816" CI_START="0.8934109874535282" DF="0" EFFECT_SIZE="0.9788695469798657" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="128" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.030398346027139134" LOG_CI_START="-0.048948710739158005" LOG_EFFECT_SIZE="-0.009275182356009463" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6467976678069429" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="0.4582154426058435">
<NAME>Short term</NAME>
<DICH_DATA CI_END="1.0725025810748816" CI_START="0.8934109874535282" EFFECT_SIZE="0.9788695469798657" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="128" LOG_CI_END="0.030398346027139134" LOG_CI_START="-0.048948710739158005" LOG_EFFECT_SIZE="-0.009275182356009463" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1057" O_E="0.0" SE="0.04660885391878851" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.002172385263622967" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.611510073537001" CI_END="7.54714992696524" CI_START="0.26705518909613346" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="3.9071025580306866" ESTIMABLE="YES" I2="64.3589697997392" I2_Q="64.35896979973919" ID="CMP-005.05" MODIFIED="2009-07-30 09:33:26 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.06046115452146317" P_Q="0.060461154521462945" P_Z="0.03539952564556726" Q="5.6115100735370005" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="6.480131997560582" TOTALS="YES" TOTAL_1="467" TOTAL_2="549" UNITS="" WEIGHT="99.99999999999999" Z="2.103758418914726">
<NAME>Mental State 1b. General Mental State: PANSS total score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.163278620044045" CI_START="-0.16327862004404503" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.01" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07713436743343303" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="147" WEIGHT="47.903505572401855" Z="1.7675607329890581">
<NAME>Short term</NAME>
<CONT_DATA CI_END="3.163278620044045" CI_START="-0.16327862004404503" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="-25.8" MEAN_2="-27.3" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1058" SD_1="7.3" SD_2="7.3" SE="0.8486271345615402" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" WEIGHT="47.903505572401855"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.23692355042586E-32" CI_END="12.770998742118666" CI_START="-0.17099874211866783" DF="0" EFFECT_SIZE="6.299999999999999" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-005.05.02" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.056369099295503544" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="69" WEIGHT="19.84505494690022" Z="1.9081711486408912">
<NAME>Medium term</NAME>
<CONT_DATA CI_END="12.770998742118667" CI_START="-0.17099874211866695" EFFECT_SIZE="6.3" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-8.0" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1059" SD_1="22.31" SD_2="22.31" SE="3.301590637971452" STUDY_ID="STD-Stroup-2006" TOTAL_1="135" TOTAL_2="69" WEIGHT="19.84505494690022"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.033693120600976" CI_START="1.9863068793990255" DF="0" EFFECT_SIZE="6.010000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.03" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.003416930702312155" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="333" WEIGHT="32.25143948069791" Z="2.9275054518388246">
<NAME>Long term</NAME>
<CONT_DATA CI_END="10.033693120600976" CI_START="1.9863068793990255" EFFECT_SIZE="6.010000000000001" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-9.31" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1060" SD_1="22.31" SD_2="22.31" SE="2.0529423766657717" STUDY_ID="STD-Lieberman-2005" TOTAL_1="183" TOTAL_2="333" WEIGHT="32.25143948069791"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.32503600615079" CI_START="-2.925036006150788" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7000000000000011" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.06" MODIFIED="2009-07-30 09:33:44 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.7050799579849456" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="147" UNITS="" WEIGHT="100.0" Z="0.3784720446500775">
<NAME>Mental State 1c. General Mental State: BPRS total score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.32503600615079" CI_START="-2.925036006150788" DF="0" EFFECT_SIZE="0.7000000000000011" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.01" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7050799579849456" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="0.3784720446500775">
<NAME>Short term</NAME>
<CONT_DATA CI_END="4.32503600615079" CI_START="-2.925036006150788" EFFECT_SIZE="0.7000000000000011" ESTIMABLE="YES" MEAN_1="-15.2" MEAN_2="-15.9" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1061" SD_1="15.91" SD_2="15.91" SE="1.849542152174535" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.6173595166950365" CI_START="0.3826404833049635" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2009-07-30 09:34:15 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.02065891451782499" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="69" UNITS="" WEIGHT="100.0" Z="2.3141605961175413">
<NAME>Mental State 2a. Positive Symptoms: PANSS positive subscore (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.6173595166950365" CI_START="0.3826404833049635" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" I2="0.0" ID="CMP-005.07.01" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02065891451782499" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="69" WEIGHT="100.0" Z="2.3141605961175413">
<NAME>Medium term</NAME>
<CONT_DATA CI_END="4.6173595166950365" CI_START="0.3826404833049635" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-2.3" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1062" SD_1="7.3" SD_2="7.3" SE="1.080305318565289" STUDY_ID="STD-Stroup-2006" TOTAL_1="135" TOTAL_2="69" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.153919128702248" CI_START="-0.153919128702248" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.08" MODIFIED="2009-07-30 09:34:28 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.13396997561019597" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="147" UNITS="" WEIGHT="100.0" Z="1.4986287283182487">
<NAME>Mental State 2b. Positive Symptoms: BPRS positive subscore (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.153919128702248" CI_START="-0.153919128702248" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-005.08.01" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.13396997561019597" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="1.4986287283182487">
<NAME>Short term</NAME>
<CONT_DATA CI_END="1.153919128702248" CI_START="-0.153919128702248" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="-6.0" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1063" SD_1="2.87" SD_2="2.87" SE="0.3336383392043316" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.006724677019308771" CI_END="1.1992117166121175" CI_START="-1.1228915085476252" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.038160104032246046" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.09" MODIFIED="2009-07-30 09:34:44 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9346434309841969" P_Q="0.9346434309841969" P_Z="0.9486375303788259" Q="0.006724677019308771" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="284" TOTAL_2="216" UNITS="" WEIGHT="100.0" Z="0.06441783357357751">
<NAME>Mental State 3. Negative Symptoms: PANSS negative subscore (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4764445832719744" CI_START="-1.4764445832719744" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.09.01" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="147" WEIGHT="61.83989596775399" Z="0.0">
<NAME>Short term</NAME>
<CONT_DATA CI_END="1.4764445832719744" CI_START="-1.4764445832719744" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-6.4" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1064" SD_1="6.48" SD_2="6.48" SE="0.7533018947888741" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" WEIGHT="61.83989596775399"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9795191326279231" CI_START="-1.779519132627923" DF="0" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-005.09.02" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9169470885657844" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="69" WEIGHT="38.16010403224601" Z="0.10428007624480289">
<NAME>Medium term</NAME>
<CONT_DATA CI_END="1.9795191326279233" CI_START="-1.7795191326279232" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.5" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1065" SD_1="6.48" SD_2="6.48" SE="0.9589559540141198" STUDY_ID="STD-Stroup-2006" TOTAL_1="135" TOTAL_2="69" WEIGHT="38.16010403224601"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.1341239906643562" CI_END="1.5928412113709285" CI_START="0.821431267104035" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1438573226377264" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-005.10" LOG_CI_END="0.20217248360866083" LOG_CI_START="-0.08542877010629502" LOG_EFFECT_SIZE="0.05837185675118289" METHOD="MH" MODIFIED="2009-07-30 09:35:07 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.7141939829696422" P_Q="0.7142377934020963" P_Z="0.4262687858964187" Q="0.13408098682659278" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="445" WEIGHT="99.99999999999999" Z="0.7955927553531409">
<NAME>Service use: Number of patients re-hospitalised</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8855886586046768" CI_START="0.5778085757323591" DF="0" EFFECT_SIZE="1.0437956204379562" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" I2="0.0" ID="CMP-005.10.01" LOG_CI_END="0.27544695733965574" LOG_CI_START="-0.2382160167223457" LOG_EFFECT_SIZE="0.01861547030865502" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8870320892934934" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="104" WEIGHT="31.349096293781944" Z="0.14206066312980767">
<NAME>Medium term</NAME>
<DICH_DATA CI_END="1.8855886586046768" CI_START="0.5778085757323591" EFFECT_SIZE="1.0437956204379562" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.27544695733965574" LOG_CI_START="-0.2382160167223457" LOG_EFFECT_SIZE="0.01861547030865502" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1066" O_E="0.0" SE="0.301728173636749" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="104" VAR="0.09103989076616814" WEIGHT="31.349096293781944"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7786136548964468" CI_START="0.7997812282598129" DF="0" EFFECT_SIZE="1.1926868044515104" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="51" I2="0.0" ID="CMP-005.10.02" LOG_CI_END="0.25008162218824376" LOG_CI_START="-0.09702879344937368" LOG_EFFECT_SIZE="0.07652641436943507" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3874697959153266" STUDIES="1" TAU2="0.0" TOTAL_1="185" TOTAL_2="341" WEIGHT="68.65090370621805" Z="0.8642150121284141">
<NAME>Long term</NAME>
<DICH_DATA CI_END="1.7786136548964468" CI_START="0.7997812282598129" EFFECT_SIZE="1.1926868044515104" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="51" LOG_CI_END="0.25008162218824376" LOG_CI_START="-0.09702879344937368" LOG_EFFECT_SIZE="0.07652641436943507" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1067" O_E="0.0" SE="0.20389437636980504" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="0.04157291671523171" WEIGHT="68.65090370621805"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.909190506813291" CI_END="1.0171601247138276" CI_START="0.8582586074124275" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9343374294934035" ESTIMABLE="YES" EVENTS_1="270" EVENTS_2="380" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="0.007389326379613008" LOG_CI_START="-0.0663818323729657" LOG_EFFECT_SIZE="-0.029496252996676357" METHOD="MH" MODIFIED="2009-07-30 09:35:00 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.6347048408066132" P_Q="1.0" P_Z="0.11703935997182294" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="471" TOTAL_2="592" WEIGHT="100.00000000000001" Z="1.567322366353542">
<NAME>Adverse effects: 1. At least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0266872932691384" CI_START="0.8133194742722365" EFFECT_SIZE="0.9137968973484432" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="122" LOG_CI_END="0.01143818703693248" LOG_CI_START="-0.08973882874778538" LOG_EFFECT_SIZE="-0.039150320855426454" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1068" O_E="0.0" SE="0.05943187990624877" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.0035321483491907767" WEIGHT="53.16299981597705"/>
<DICH_DATA CI_END="1.0763366762893487" CI_START="0.8304913530884057" EFFECT_SIZE="0.9454566635601118" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="232" LOG_CI_END="0.031948139159465254" LOG_CI_START="-0.08066488497723523" LOG_EFFECT_SIZE="-0.024358372908885" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1069" O_E="0.0" SE="0.06614944782135768" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="0.004375749447070522" WEIGHT="42.913700683604645"/>
<DICH_DATA CI_END="1.7035111253556687" CI_START="0.7226051747929926" EFFECT_SIZE="1.1094890510948905" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.2313449742201854" LOG_CI_START="-0.14109893264345388" LOG_EFFECT_SIZE="0.04512302078836577" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1070" O_E="0.0" SE="0.21877539451877434" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="104" VAR="0.04786267324684536" WEIGHT="3.923299500418304"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5093068555158693" CI_START="0.11052879603128314" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5266409266409268" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.12" LOG_CI_END="0.3995537731155771" LOG_CI_START="-0.9565245606371604" LOG_EFFECT_SIZE="-0.2784853937607916" METHOD="MH" MODIFIED="2009-07-30 09:35:36 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.42081984657334215" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="334" TOTAL_2="488" WEIGHT="100.0" Z="0.8049997236975696">
<NAME>Adverse effects: 2a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1071" O_E="0.0" SE="0.0" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.5093068555158693" CI_START="0.11052879603128314" EFFECT_SIZE="0.5266409266409267" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.3995537731155771" LOG_CI_START="-0.9565245606371604" LOG_EFFECT_SIZE="-0.27848539376079173" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1072" O_E="0.0" SE="0.7965671259423711" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="0.6345191861320894" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.9561880374657304" CI_END="6.393796042652385" CI_START="-1.9196794078932151" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.2370583173795846" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.13" MODIFIED="2009-07-30 09:35:31 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.6199639503332441" P_Q="1.0" P_Z="0.29151387290077113" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="367" TOTAL_2="426" UNITS="" WEIGHT="100.0" Z="1.0548064427355732">
<NAME>Adverse effects: 2b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.45340527560155" CI_START="-9.05340527560146" EFFECT_SIZE="0.7000000000000455" ESTIMABLE="YES" MEAN_1="409.6" MEAN_2="408.9" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1073" SD_1="45.3" SD_2="28.5" SE="4.9763186224518" STUDY_ID="STD-Addington-2004" TOTAL_1="113" TOTAL_2="123" WEIGHT="18.163214216147924"/>
<CONT_DATA CI_END="6.677694229014373" CI_START="-4.4776942290143715" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="0.2" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1074" SD_1="26.8" SD_2="26.6" SE="2.845814654254115" STUDY_ID="STD-Lieberman-2005" TOTAL_1="148" TOTAL_2="218" WEIGHT="55.53871677854407"/>
<CONT_DATA CI_END="13.805703110549338" CI_START="-2.4057031105493385" EFFECT_SIZE="5.7" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="-4.4" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1075" SD_1="25.7" SD_2="30.4" SE="4.135638804838298" STUDY_ID="STD-Stroup-2006" TOTAL_1="106" TOTAL_2="85" WEIGHT="26.298069005308008"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1348631023496153" CI_END="-1.1143605024078447" CI_START="-16.036424661943276" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.57539258217556" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.14" MODIFIED="2009-07-30 09:35:44 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.7134422499886184" P_Q="1.0" P_Z="0.024278124668238508" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="445" UNITS="" WEIGHT="99.99999999999999" Z="2.2526991486785435">
<NAME>Adverse effects: 3 Cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.7476167141966066" CI_START="-17.947616714196606" EFFECT_SIZE="-7.1" ESTIMABLE="YES" MEAN_1="-9.2" MEAN_2="-2.1" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1076" SD_1="70.7" SD_2="35.1" SE="5.534600023143906" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" WEIGHT="47.30740777944423"/>
<CONT_DATA CI_END="0.3783671086426921" CI_START="-20.178367108642693" EFFECT_SIZE="-9.9" ESTIMABLE="YES" MEAN_1="-12.5" MEAN_2="-2.6" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1077" SD_1="41.0" SD_2="39.8" SE="5.244161214041248" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="104" WEIGHT="52.69259222055575"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.08378416800824603" CI_END="6.416677912513066" CI_START="0.21837867413603537" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1837506557094644" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.15" LOG_CI_END="0.8073102402684553" LOG_CI_START="-0.6607897751122401" LOG_EFFECT_SIZE="0.07326023257810764" METHOD="MH" MODIFIED="2009-07-30 09:35:54 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.7722332614033067" P_Q="0.7722592002880116" P_Z="0.8449155443292935" Q="0.0837645439711975" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="445" WEIGHT="100.0" Z="0.1956098574317977">
<NAME>Adverse effects: 4. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.096152194002547" CI_START="0.08412971566980057" DF="0" EFFECT_SIZE="0.9216216216216216" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-005.15.01" LOG_CI_END="1.0041558887024853" LOG_CI_START="-1.0750505788514797" LOG_EFFECT_SIZE="-0.03544734507449727" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9467179319297545" STUDIES="1" TAU2="0.0" TOTAL_1="185" TOTAL_2="341" WEIGHT="49.85584157504884" Z="0.06682887993832648">
<NAME>Suicide attempt</NAME>
<DICH_DATA CI_END="10.096152194002547" CI_START="0.08412971566980057" EFFECT_SIZE="0.9216216216216216" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="1.0041558887024853" LOG_CI_START="-1.0750505788514797" LOG_EFFECT_SIZE="-0.03544734507449727" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1078" O_E="0.0" SE="1.2213361712792046" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="1.4916620432749466" WEIGHT="49.85584157504884"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.5178287338865" CI_START="0.1395508791489068" DF="0" EFFECT_SIZE="1.5182481751824817" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-005.15.02" LOG_CI_END="1.2179529587915257" LOG_CI_START="-0.8552674231788162" LOG_EFFECT_SIZE="0.18134276780635475" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7316942610122653" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="104" WEIGHT="50.14415842495116" Z="0.34287266018432333">
<NAME>Suicide</NAME>
<DICH_DATA CI_END="16.5178287338865" CI_START="0.1395508791489068" EFFECT_SIZE="1.5182481751824817" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2179529587915257" LOG_CI_START="-0.8552674231788162" LOG_EFFECT_SIZE="0.18134276780635475" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1079" O_E="0.0" SE="1.2178199149757827" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="104" VAR="1.4830853453116226" WEIGHT="50.14415842495116"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.85164377575052" CI_END="0.9625197932877405" CI_START="0.5788829129657755" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7464491018988658" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="160" I2="32.215979856337285" I2_Q="35.057109665780295" ID="CMP-005.16" LOG_CI_END="-0.016590330882050367" LOG_CI_START="-0.23740926942472454" LOG_EFFECT_SIZE="-0.12699980015338744" METHOD="MH" MODIFIED="2009-07-30 09:36:17 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.18209508927237883" P_Q="0.20188053297480935" P_Z="0.02416650312161526" Q="4.619443305588819" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04911224609755859" TOTALS="SUB" TOTAL_1="1091" TOTAL_2="1331" WEIGHT="400.0" Z="2.254471794739834">
<NAME>Adverse effects: 5a. Extrapyramidal side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9863861456955556" CI_END="1.8066878271901325" CI_START="0.5285827698266303" DF="2" EFFECT_SIZE="0.9772328565435245" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="53" I2="49.829245665034925" ID="CMP-005.16.01" LOG_CI_END="0.2568831184486641" LOG_CI_START="-0.27688699763861846" LOG_EFFECT_SIZE="-0.010001939594977121" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13625984270899538" P_Z="0.9414458426878888" STUDIES="3" TAU2="0.1438738846876364" TOTAL_1="471" TOTAL_2="592" WEIGHT="100.0" Z="0.07345274975452076">
<NAME>Akathisia</NAME>
<DICH_DATA CI_END="1.058957749130029" CI_START="0.36867882304936217" EFFECT_SIZE="0.6248322147651006" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" LOG_CI_END="0.024878632736630726" LOG_CI_START="-0.4333518075984936" LOG_EFFECT_SIZE="-0.20423658743093143" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1080" O_E="0.0" SE="0.26916682893011395" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.07245078179629322" WEIGHT="45.44411730682745"/>
<DICH_DATA CI_END="2.4941973610045403" CI_START="0.6674681788905499" EFFECT_SIZE="1.2902702702702702" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.3969308153830938" LOG_CI_START="-0.1755694341756124" LOG_EFFECT_SIZE="0.11068069060374072" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="0.3362894805127242" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="0.11309061470351793" WEIGHT="38.25697146239505"/>
<DICH_DATA CI_END="6.685715948084412" CI_START="0.4692790795741343" EFFECT_SIZE="1.7712895377128954" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8251479210450505" LOG_CI_START="-0.3285688061711145" LOG_EFFECT_SIZE="0.24828955743696798" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1082" O_E="0.0" SE="0.6776989165566807" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="104" VAR="0.45927582150209884" WEIGHT="16.29891123077749"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8698726672263117" CI_START="0.1150131176587441" DF="0" EFFECT_SIZE="0.31630170316301703" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="0.0" ID="CMP-005.16.02" LOG_CI_END="-0.060544315160930694" LOG_CI_START="-0.9392526239775342" LOG_EFFECT_SIZE="-0.49989846956923245" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.025743932660729683" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="104" WEIGHT="100.0" Z="2.230052877505861">
<NAME>Extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="0.8698726672263117" CI_START="0.1150131176587441" EFFECT_SIZE="0.31630170316301703" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.060544315160930694" LOG_CI_START="-0.9392526239775342" LOG_EFFECT_SIZE="-0.49989846956923245" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1083" O_E="0.0" SE="0.5161576102751523" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="104" VAR="0.266418678644956" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1112263791521224" CI_START="0.5292413588030674" DF="0" EFFECT_SIZE="1.0570469798657718" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" I2="0.0" ID="CMP-005.16.03" LOG_CI_END="0.3245348036276015" LOG_CI_START="-0.276346224200911" LOG_EFFECT_SIZE="0.024094289713345266" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8751011536852313" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="0.1571823302256367">
<NAME>Tremor</NAME>
<DICH_DATA CI_END="2.1112263791521224" CI_START="0.5292413588030674" EFFECT_SIZE="1.0570469798657718" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.3245348036276015" LOG_CI_START="-0.276346224200911" LOG_EFFECT_SIZE="0.024094289713345266" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1084" O_E="0.0" SE="0.3529604901555266" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.12458110761082959" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2889449232049158" CI_END="0.9666413812200809" CI_START="0.5095699404833481" DF="1" EFFECT_SIZE="0.7018343045883823" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="81" I2="0.0" ID="CMP-005.16.04" LOG_CI_END="-0.014734616965756467" LOG_CI_START="-0.2927961989365417" LOG_EFFECT_SIZE="-0.15376540795114907" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5908975164031494" P_Z="0.030182824987268753" STUDIES="2" TAU2="0.0" TOTAL_1="334" TOTAL_2="488" WEIGHT="100.0" Z="2.167682852958991">
<NAME>Use of antiparkinson medication</NAME>
<DICH_DATA CI_END="0.9696527947998229" CI_START="0.4552831724624831" EFFECT_SIZE="0.6644295302013423" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="49" LOG_CI_END="-0.013383746451273082" LOG_CI_START="-0.34171840117817504" LOG_EFFECT_SIZE="-0.1775510738147241" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1085" O_E="0.0" SE="0.19286540146933534" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.037197063083927895" WEIGHT="71.72136249505992"/>
<DICH_DATA CI_END="1.4723347361233448" CI_START="0.44168724464290443" EFFECT_SIZE="0.8064189189189189" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="32" LOG_CI_END="0.1680065583198048" LOG_CI_START="-0.35488514242417285" LOG_EFFECT_SIZE="-0.09343929205218403" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1086" O_E="0.0" SE="0.3071491733726756" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="0.09434061470351793" WEIGHT="28.278637504940082"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="120.65571624683724" CI_END="-0.31580298713423305" CI_START="-0.37214590719789675" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3439744471660649" ESTIMABLE="YES" I2="98.34239100954952" I2_Q="98.34239100954952" ID="CMP-005.17" MODIFIED="2009-07-30 09:36:30 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.1102230246251565E-16" P_Q="5.551115123125783E-16" P_Z="0.0" Q="120.65571624683727" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.041467880825051116" TOTALS="SUB" TOTAL_1="447" TOTAL_2="441" UNITS="" WEIGHT="300.0" Z="23.931224270442048">
<NAME>Adverse effects: 5b. Extrapyramidal side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.9724887109283464E-30" CI_END="-0.17126611432774136" CI_START="-0.24873388567225857" DF="0" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-005.17.01" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="2.251967048332722E-26" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="10.626159230087156">
<NAME>Abnormal involuntary movement: AIMS (high=poor)</NAME>
<CONT_DATA CI_END="-0.17126611432774141" CI_START="-0.24873388567225857" EFFECT_SIZE="-0.21" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="-0.04" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1087" SD_1="0.17" SD_2="0.17" SE="0.01976254970896738" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5110074778883222" CI_START="-0.6089925221116779" DF="0" EFFECT_SIZE="-0.56" ESTIMABLE="YES" I2="0.0" ID="CMP-005.17.02" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="22.403007316922995">
<NAME>Akathisia: Barnes Akathisia Scale (high=poor)</NAME>
<CONT_DATA CI_END="-0.5110074778883222" CI_START="-0.6089925221116779" EFFECT_SIZE="-0.56" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="0.28" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1088" SD_1="0.22" SD_2="0.21" SE="0.0249966440700567" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2648106925185568" CI_START="-0.4151893074814431" DF="0" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-005.17.03" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="7.802985575062357E-19" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="8.862799473290588">
<NAME>Extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</NAME>
<CONT_DATA CI_END="-0.2648106925185568" CI_START="-0.4151893074814431" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" MEAN_1="-0.57" MEAN_2="-0.23" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1089" SD_1="0.33" SD_2="0.33" SE="0.03836259649387785" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04254478263700791" CI_END="1.908421003456362" CI_START="-11.796249968074633" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.943914482309136" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.18" MODIFIED="2009-07-30 09:36:38 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.8365849206725411" P_Q="1.0" P_Z="0.1573322553643021" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="445" UNITS="" WEIGHT="100.0" Z="1.414100980330125">
<NAME>Adverse effects: 6. Glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.182936060750707" CI_START="-12.982936060750708" EFFECT_SIZE="-4.4" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="6.7" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1090" SD_1="53.0" SD_2="36.9" SE="4.37912947811889" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" WEIGHT="63.73903451272428"/>
<CONT_DATA CI_END="5.479388789884151" CI_START="-17.279388789884152" EFFECT_SIZE="-5.9" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="4.8" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1091" SD_1="45.6" SD_2="43.9" SE="5.805917292176447" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="104" WEIGHT="36.260965487275726"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.9015742109975324" CI_END="0.8901672996418708" CI_START="0.5355544763296088" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6904586026732118" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="162" I2="0.0" I2_Q="0.0" ID="CMP-005.19" LOG_CI_END="-0.050528363598695884" LOG_CI_START="-0.27119634637083023" LOG_EFFECT_SIZE="-0.16086235498476303" METHOD="MH" MODIFIED="2009-07-30 09:36:51 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.9680695721302696" P_Q="0.9231622655473649" P_Z="0.004269311563713143" Q="1.4104909157019268" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="934" TOTAL_2="1142" WEIGHT="600.0" Z="2.8575456962780237">
<NAME>Adverse effects: 7a. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5378608118853723" CI_START="0.14812085361553898" DF="0" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-005.19.01" LOG_CI_END="0.1869170302862331" LOG_CI_START="-0.8293837937907693" LOG_EFFECT_SIZE="-0.3212333817522681" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2153400571401619" STUDIES="1" TAU2="0.0" TOTAL_1="110" TOTAL_2="105" WEIGHT="100.0" Z="1.2390147561638662">
<NAME>Abnormal ejaculation</NAME>
<DICH_DATA CI_END="1.5378608118853723" CI_START="0.14812085361553898" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.1869170302862331" LOG_CI_START="-0.8293837937907693" LOG_EFFECT_SIZE="-0.3212333817522681" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1092" O_E="0.0" SE="0.5969801348330457" STUDY_ID="STD-Addington-2004" TOTAL_1="110" TOTAL_2="105" VAR="0.35638528138528136" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1282487912376167" CI_END="1.680064297153947" CI_START="0.4179211725611491" DF="1" EFFECT_SIZE="0.8379346281451199" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" I2="0.0" ID="CMP-005.19.02" LOG_CI_END="0.22532590277635187" LOG_CI_START="-0.3789056262395976" LOG_EFFECT_SIZE="-0.07678986173162286" MODIFIED="2009-07-03 12:22:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7202547844754176" P_Z="0.6183634039698396" STUDIES="2" TAU2="0.0" TOTAL_1="95" TOTAL_2="130" WEIGHT="100.0" Z="0.4981711683165695">
<NAME>Amenorrhoea</NAME>
<DICH_DATA CI_END="5.022443149516334" CI_START="0.2309161655162097" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7009150295435153" LOG_CI_START="-0.6365456628007128" LOG_EFFECT_SIZE="0.032184683371401235" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1093" O_E="0.0" SE="0.7856310312202014" STUDY_ID="STD-Addington-2004" TOTAL_1="39" TOTAL_2="42" VAR="0.6172161172161171" WEIGHT="20.41008024475994"/>
<DICH_DATA CI_END="1.7135998082786228" CI_START="0.36026319318724653" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.23390940489794565" LOG_CI_START="-0.4433801059379717" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1094" O_E="0.0" SE="0.3978432113021671" STUDY_ID="STD-Lieberman-2005" TOTAL_1="56" TOTAL_2="88" VAR="0.1582792207792208" WEIGHT="79.58991975524006"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.42151382857584" CI_START="0.25930107255041024" DF="0" EFFECT_SIZE="0.6071244192049561" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" ID="CMP-005.19.03" LOG_CI_END="0.1527510888910181" LOG_CI_START="-0.5861956868490004" LOG_EFFECT_SIZE="-0.21672229897899115" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.25028492999502683" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="1.1496576332447233">
<NAME>Decreased libido</NAME>
<DICH_DATA CI_END="1.42151382857584" CI_START="0.25930107255041024" EFFECT_SIZE="0.6071244192049561" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.1527510888910181" LOG_CI_START="-0.5861956868490004" LOG_EFFECT_SIZE="-0.21672229897899115" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1095" O_E="0.0" SE="0.4340609939152197" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.1884089464386684" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.628523357684079" CI_START="0.3466421639852515" DF="0" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-005.19.04" LOG_CI_END="0.4197118406157086" LOG_CI_START="-0.46011861279228256" LOG_EFFECT_SIZE="-0.02020338608828695" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9282772097809617" STUDIES="1" TAU2="0.0" TOTAL_1="110" TOTAL_2="105" WEIGHT="100.0" Z="0.09001259036992623">
<NAME>Erectile dysfunction</NAME>
<DICH_DATA CI_END="2.628523357684079" CI_START="0.3466421639852515" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4197118406157086" LOG_CI_START="-0.46011861279228256" LOG_EFFECT_SIZE="-0.02020338608828695" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1096" O_E="0.0" SE="0.5168167635628387" STUDY_ID="STD-Addington-2004" TOTAL_1="110" TOTAL_2="105" VAR="0.26709956709956706" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1216415941017048" CI_END="1.2773698482588471" CI_START="0.2451149813249317" DF="2" EFFECT_SIZE="0.5595556151992385" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" I2="0.0" ID="CMP-005.19.05" LOG_CI_END="0.10631666061690208" LOG_CI_START="-0.6106301440399906" LOG_EFFECT_SIZE="-0.2521567417115442" MODIFIED="2009-07-03 12:22:51 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.570740557156266" P_Z="0.16799514071079336" STUDIES="3" TAU2="0.0" TOTAL_1="136" TOTAL_2="167" WEIGHT="100.0" Z="1.3786744818539562">
<NAME>Galactorrhoea</NAME>
<DICH_DATA CI_END="4.343000382233543" CI_START="0.010643563419680646" EFFECT_SIZE="0.215" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.637789867585096" LOG_CI_START="-1.9729129477538854" LOG_EFFECT_SIZE="-0.6675615400843947" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1097" O_E="0.0" SE="1.533539756917476" STUDY_ID="STD-Addington-2004" TOTAL_1="39" TOTAL_2="42" VAR="2.3517441860465116" WEIGHT="7.5415218206106"/>
<DICH_DATA CI_END="1.6494557683602062" CI_START="0.2749761618004078" EFFECT_SIZE="0.673469387755102" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.21734067404041305" LOG_CI_START="-0.5607049543416653" LOG_EFFECT_SIZE="-0.1716821401506262" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1099" O_E="0.0" SE="0.45702785349960773" STUDY_ID="STD-Lieberman-2005" TOTAL_1="56" TOTAL_2="88" VAR="0.20887445887445888" WEIGHT="84.91095651969445"/>
<DICH_DATA CI_END="3.6508733493861105" CI_START="0.008968748307262266" EFFECT_SIZE="0.18095238095238095" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5623967673192747" LOG_CI_START="-2.047268163553493" LOG_EFFECT_SIZE="-0.7424356981171091" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1098" O_E="0.0" SE="1.5329300984444112" STUDY_ID="STD-Stroup-2006" TOTAL_1="41" TOTAL_2="37" VAR="2.349874686716792" WEIGHT="7.547521659694954"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.25482491894509296" CI_END="0.9703100139739905" CI_START="0.4958036936424581" DF="1" EFFECT_SIZE="0.693601678852185" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="97" I2="0.0" ID="CMP-005.19.06" LOG_CI_END="-0.013089486509411597" LOG_CI_START="-0.30469024214552204" LOG_EFFECT_SIZE="-0.15888986432746682" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6136980459208793" P_Z="0.0326856730992374" STUDIES="2" TAU2="0.0" TOTAL_1="334" TOTAL_2="488" WEIGHT="99.99999999999999" Z="2.1359232139913282">
<NAME>Sexual dysfunction</NAME>
<DICH_DATA CI_END="1.9355380401777156" CI_START="0.12571885882323705" EFFECT_SIZE="0.49328859060402686" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2868017111635902" LOG_CI_START="-0.9005995698197485" LOG_EFFECT_SIZE="-0.3068989293280791" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1100" O_E="0.0" SE="0.6974853901807488" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.4864858695155915" WEIGHT="6.030901895555848"/>
<DICH_DATA CI_END="1.0023413217179165" CI_START="0.5014215218126685" EFFECT_SIZE="0.7089397089397089" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="91" LOG_CI_END="0.001015634602190983" LOG_CI_START="-0.2997970293648591" LOG_EFFECT_SIZE="-0.14939069738133406" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1101" O_E="0.0" SE="0.1766988478609469" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="0.031222482835386058" WEIGHT="93.96909810444414"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.7538061671553615" CI_END="-16.59755069031768" CI_START="-27.343246145609346" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-21.970398417963512" ESTIMABLE="YES" I2="42.98115614327095" I2_Q="0.0" ID="CMP-005.20" MODIFIED="2009-07-30 09:37:01 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.1853990736761344" P_Q="1.0" P_Z="1.1050201328832392E-15" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="6.982288815474372" TOTALS="YES" TOTAL_1="322" TOTAL_2="445" UNITS="" WEIGHT="100.0" Z="8.014593341931906">
<NAME>Adverse effects: 7b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-15.597451737414964" CI_START="-24.202548262585033" EFFECT_SIZE="-19.9" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="15.4" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1103" SD_1="21.8" SD_2="27.7" SE="2.195218022638674" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" WEIGHT="63.67722073748226"/>
<CONT_DATA CI_END="-18.343780211790524" CI_START="-32.85621978820948" EFFECT_SIZE="-25.6" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="22.0" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1102" SD_1="26.9" SD_2="29.6" SE="3.7022209823474386" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="104" WEIGHT="36.322779262517734"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.3627454847858145" CI_END="1.1982525837349718" CI_START="0.62845877552119" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8677858903780256" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="145" I2="40.52478818130396" I2_Q="0.0" ID="CMP-005.21" LOG_CI_END="0.07854837411334034" LOG_CI_START="-0.20172320509155747" LOG_EFFECT_SIZE="-0.06158741548910856" METHOD="MH" MODIFIED="2009-07-30 09:37:14 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.18611853556896174" P_Q="1.0" P_Z="0.38903292260366285" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03366098342503067" TOTALS="YES" TOTAL_1="471" TOTAL_2="592" WEIGHT="100.0" Z="0.8613725059244085">
<NAME>Adverse effects: 8. Sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8797796787947716" CI_START="0.7360916207766214" EFFECT_SIZE="1.1763035622096025" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" LOG_CI_END="0.27410695038557475" LOG_CI_START="-0.13306812598686119" LOG_EFFECT_SIZE="0.0705194121993568" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1104" O_E="0.0" SE="0.23917665541030328" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.05720547249325896" WEIGHT="29.828384706110707"/>
<DICH_DATA CI_END="1.1727776075108771" CI_START="0.6365495236751331" EFFECT_SIZE="0.8640202702702703" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="96" LOG_CI_END="0.06921566515235344" LOG_CI_START="-0.19616780250183502" LOG_EFFECT_SIZE="-0.0634760686747408" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1105" O_E="0.0" SE="0.15588756256942177" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="0.02430093216383539" WEIGHT="46.76173270802381"/>
<DICH_DATA CI_END="1.0417931804545353" CI_START="0.3387921759729038" EFFECT_SIZE="0.5940971120279276" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.01778151022793393" LOG_CI_START="-0.47006662777176034" LOG_EFFECT_SIZE="-0.22614255877191325" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1106" O_E="0.0" SE="0.2865644111482503" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="104" VAR="0.08211916173674344" WEIGHT="23.409882585865482"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.13552837069872475" CI_END="0.7404590155698315" CI_START="0.32708959723809183" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.492134576283815" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-005.22" LOG_CI_END="-0.1304989746909878" LOG_CI_START="-0.4853332679628679" LOG_EFFECT_SIZE="-0.30791612132692786" METHOD="MH" MODIFIED="2009-07-30 09:37:23 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.9344808231170824" P_Q="1.0" P_Z="6.698937820270362E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="471" TOTAL_2="592" WEIGHT="100.00000000000001" Z="3.401613200884328">
<NAME>Adverse effects: 9a. Weight gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.017580832849195" CI_START="0.23912953719733548" EFFECT_SIZE="0.49328859060402686" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" LOG_CI_END="0.007568918011271556" LOG_CI_START="-0.6213667766674298" LOG_EFFECT_SIZE="-0.3068989293280791" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1107" O_E="0.0" SE="0.36943994033616817" STUDY_ID="STD-Addington-2004" TOTAL_1="149" TOTAL_2="147" VAR="0.1364858695155915" WEIGHT="31.830149987902843"/>
<DICH_DATA CI_END="0.9751577756420601" CI_START="0.2844161965796782" EFFECT_SIZE="0.5266409266409267" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="42" LOG_CI_END="-0.010925111945317666" LOG_CI_START="-0.5460456755762657" LOG_EFFECT_SIZE="-0.27848539376079173" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1108" O_E="0.0" SE="0.31433246796632963" STUDY_ID="STD-Lieberman-2005" TOTAL_1="185" TOTAL_2="341" VAR="0.09880490041780364" WEIGHT="43.96913189062638"/>
<DICH_DATA CI_END="0.9952243862243187" CI_START="0.18907253097084903" EFFECT_SIZE="0.4337851929092805" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="-0.002078990899940075" LOG_CI_START="-0.7233715621879016" LOG_EFFECT_SIZE="-0.36272527654392084" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1109" O_E="0.0" SE="0.42369082683036" STUDY_ID="STD-Stroup-2006" TOTAL_1="137" TOTAL_2="104" VAR="0.17951391674019412" WEIGHT="24.200718121470786"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1476548497559822" CI_START="-2.3476548497559824" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.23" MODIFIED="2009-07-30 09:37:56 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.08398638469723757" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="300" UNITS="" WEIGHT="100.0" Z="1.7280102613440929">
<NAME>Adverse effects: 9b. Weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1476548497559822" CI_START="-2.3476548497559824" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="0.4" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1110" SD_1="6.3" SD_2="6.9" SE="0.6365702939428094" STUDY_ID="STD-Lieberman-2005" TOTAL_1="161" TOTAL_2="300" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2009-07-30 09:19:12 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>ZIPRASIDONE versus OLANZAPINE - sensitivity analysis (skewed data excluded)</NAME>
<CONT_OUTCOME CHI2="0.6587225201387525" CI_END="11.083505100741771" CI_START="5.547363832923879" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="8.315434466832825" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2009-07-30 09:19:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7193831479912258" P_Q="0.5502170664829134" P_Z="3.912798524344886E-9" Q="0.35692885477616737" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="579" TOTAL_2="664" UNITS="" WEIGHT="100.0" Z="5.887838218846361">
<NAME>Mental State: 1. General Mental State: PANSS total score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.067602174695258" CI_START="-0.06760217469525998" DF="0" EFFECT_SIZE="6.499999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.01" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05240527426518377" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="66" WEIGHT="17.76399572453135" Z="1.939789524492854">
<NAME>Medium term</NAME>
<CONT_DATA CI_END="13.067602174695258" CI_START="-0.06760217469525998" EFFECT_SIZE="6.499999999999999" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-8.2" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1111" SD_1="22.31" SD_2="22.31" SE="3.350879009257143" STUDY_ID="STD-Stroup-2006" TOTAL_1="135" TOTAL_2="66" WEIGHT="17.76399572453135"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3017936653625852" CI_END="11.760023997138989" CI_START="5.655157608114122" DF="1" EFFECT_SIZE="8.707590802626555" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.02" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5827602256060537" P_Z="2.2559082005320522E-8" STUDIES="2" TAU2="0.0" TOTAL_1="444" TOTAL_2="598" WEIGHT="82.23600427546864" Z="5.591134441842001">
<NAME>Long term</NAME>
<CONT_DATA CI_END="14.374783182495172" CI_START="5.025216817504835" EFFECT_SIZE="9.700000000000003" ESTIMABLE="YES" MEAN_1="-26.0" MEAN_2="-35.7" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1112" SD_1="28.3" SD_2="26.5" SE="2.385137287914095" STUDY_ID="STD-Breier-2005" TOTAL_1="261" TOTAL_2="268" WEIGHT="35.0615724845917"/>
<CONT_DATA CI_END="12.000174298283659" CI_START="3.939825701716341" EFFECT_SIZE="7.97" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-11.27" MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1113" SD_1="22.31" SD_2="22.31" SE="2.056249160736197" STUDY_ID="STD-Lieberman-2005" TOTAL_1="183" TOTAL_2="330" WEIGHT="47.17443179087695"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-08-06 14:46:46 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-08-06 14:46:46 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApsAAAEACAMAAADLBU1LAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-08-06 14:46:46 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUYAAAKgCAIAAABoQEOlAAAdkUlEQVR42u3dv64lRxHH8SshIYIN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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]"/>
<EXTENSIONS MODIFIED="2008-12-04 11:12:07 +0000" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>